Fernandez-Martinez, A.
Rediti, M.
Tang, G.
Pascual, T.
Hoadley, K.A.
Venet, D.
Rashid, N.U.
Spears, P.A.
Islam, M.N.
El-Abed, S.
Bliss, J.
Lambertini, M.
Di Cosimo, S.
Huobe, J.
Goerlitz, D.
Hu, R.
Lucas, P.C.
Swain, S.M.
Sotiriou, C.
Perou, C.M.
Carey, L.A.
(2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. Jama oncol,
Vol.10
(5),
pp. 603-611.
show abstract
full text
IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). OBJECTIVE: To define the quantitative association between pCR and EFS by intrinsic subtype and by other gene expression signatures in a pooled analysis of 3 phase 3 trials: CALGB 40601, NeoALTTO, and NSABP B-41. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective pooled analysis, 1289 patients with EBC received chemotherapy plus either trastuzumab, lapatinib, or the combination, with a combined median follow-up of 5.5 years. Gene expression profiling by RNA sequencing was obtained from 758 samples, and intrinsic subtypes and 618 gene expression signatures were calculated. Data analyses were performed from June 1, 2020, to January 1, 2023. MAIN OUTCOMES AND MEASURES: The association of clinical variables and gene expression biomarkers with pCR and EFS were studied by logistic regression and Cox analyses. RESULTS: In the pooled analysis, of 758 women, median age was 49 years, 12% were Asian, 6% Black, and 75% were White. Overall, pCR results were associated with EFS in the ERBB2-enriched (hazard ratio [HR], 0.45; 95% CI, 0.29-0.70; P < .001) and basal-like (HR, 0.19; 95% CI, 0.04-0.86; P = .03) subtypes but not in luminal A or B tumors. Dual trastuzumab plus lapatinib blockade over trastuzumab alone had a trend toward EFS benefit in the intention-to-treat population; however, in the ERBB2-enriched subtype there was a significant and independent EFS benefit of trastuzumab plus lapatinib vs trastuzumab alone (HR, 0.47; 95% CI, 0.27-0.83; P = .009). Overall, 275 of 618 gene expression signatures (44.5%) were significantly associated with pCR and 9 of 618 (1.5%) with EFS. The ERBB2/HER2 amplicon and multiple immune signatures were significantly associated with pCR. Luminal-related signatures were associated with lower pCR rates but better EFS, especially among patients with residual disease and independent of hormone receptor status. There was significant adjusted HR for pCR ranging from 0.45 to 0.81 (higher pCR) and 1.21-1.94 (lower pCR rate); significant adjusted HR for EFS ranged from 0.71 to 0.94. CONCLUSIONS AND RELEVANCE: In patients with ERBB2/HER2-positive EBC, the association between pCR and EFS differed by tumor intrinsic subtype, and the benefit of dual ERBB2/HER2 blockade was limited to ERBB2-enriched tumors. Immune-activated signatures were concordantly associated with higher pCR rates and better EFS, whereas luminal signatures were associated with lower pCR rates..
Browne, I.
Pascual, J.
Cutts, R.
Kingston, B.
Hrebien, S.
Kilburn, L.
Pearson, A.
Moretti, L.
Wardley, A.
Macpherson, I.
Baird, R.
Roylance, R.
Faull, I.
Banks, K.C.
Garcia-Murillas, I.
Bliss, J.
Ring, A.
Turner, N.
(2024). Abstract PS06-04: The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial. Cancer research,
Vol.84
(9_Supplement).
show abstract
Abstract
Background:
Early changes in ctDNA levels, ctDNA dynamics, may help identify which patients are responding to therapy earlier than imaging. Few studies have assessed ctDNA dynamics during PARP inhibitor therapy. Here we report paired baseline and early on treatment ctDNA analysis from cohort E of plasmaMATCH, that recruited patients with TNBC to treatment with olaparib (PARP inhibitor) plus ceralasertib (ATR inhibitor).
Methods:
The plasmaMATCH trial assessed the ability of ctDNA testing to allocate patients to mutation matched treatment cohorts (A-D). Patients with TNBC, and without mutations matching cohorts B-D, were enrolled on cohort E. Samples were collected for ctDNA analysis pre-treatment at cycle 1-day1 (C1D1) and cycle 2-day 1 (C2D1). A minimum of 14 days of treatment in the first cycle was required for inclusion in this analysis. Samples were sequenced using error-corrected gene targeted panels (Guardant360, or GuardantOMNI, Guardant Health). Circulating DNA ratio (CDR) was calculated as the ratio of C2D1 ctDNA level to C1D1, pre-specified using the weighted mean of variant allele fractions (AF) of clonal mutations at C1D1, excluding variants with AF < 0.3%, and variants in genes frequently mutated in clonal haematopoesis (GNAS, JAK2, IDH1, IDH2 and ATM). The optimal cut-point for predicting progression free survival (PFS) was assessed as the cut-point with the highest Harrell’s C-index.
Results:
Of the 75 patients that were enrolled into cohort E, 53 patients had samples sent for paired C1D1-C2D1 ctDNA sequencing, 2 failed sequencing, and all 51 (68%) patients had detectable ctDNA at C1D1. The ctDNA analysis set was representative of the overall enrolled population. The optimal ctDNA dynamics C-index cut-point for predicting PFS was 0 (undetectable ctDNA at C2D1). Median PFS with ctDNA CDR >0 (detectable ctDNA at C2D1) was 4.3 months (95% CI 2.4-5.8), and with undetectable ctDNA was 12 months (95% CI 8-NA) (HR 4.02, 95% CI 1.22-13.23, p=0.01). Splitting patients by median CDR was not predictive (HR=0.98; 95%CI: 0.52-1.82, p=0.94). Confirmed objective response rate was 85.7% (42.1-99.6) in patients with undetectable ctDNA at C2D1, and with detectable ctDNA was 11.4% (3.8-24.6) (OR 4.02, 95% CI 1.22-13.23, p=0.01). Of the 7 patients with undetectable ctDNA at C2D1, one had a BRCA2 germline mutation, and all other patients were wildtype for BRCA1/2 mutations in tumour and germline. All patients with undetectable ctDNA and BRCA1/2 wildtype had a confirmed response.In cohorts A-D (mutation targeted therapies, in predominantly ER positive cancer), the optimal ctDNA dynamics C-index CDR cut-point was 0.165 (HR 3.44, 95%CI: 2.06-5.75, p< 0.001), with median CDR cut-point also highly predictive (HR=2.14, 95%CI:1.36-3.36, p=0.001). Undetectable ctDNA was also strongly predictive (HR=4.41; 95%CI: 1.97-9.87, p< 0.001) in cohort A-D.In cohort E, a significant association was found between baseline ctDNA and PFS, with an optimal C-index cutpoint of 6.81% (HR=3.02, 95% CI: 1.39-6.56, p=0.001). Median PFS for baseline ctDNA ≤ 6.81% was 10.2 months (95% CI 3.7-17.2), and for baseline ctDNA >6.81% was 4.4 months (95% CI 2.2-5.5).
Conclusions:
‘Clearance’ of ctDNA to become undetectable at C2D1 identified sporadic TNBC patients who benefited from olaparib and ceralasertib. Although ‘clearance’ of ctDNA was associated with good outcome on olaparib plus ceralasertib, median CDR was not predictive of treatment benefit. This contrasts the results of ctDNA dynamic assessment of cohort A-D, where median CDR was highly predictive of treatment benefit. ctDNA dynamic assessment may differ between mutation targeted therapies (cohorts A-D) that induce cell-cycle arrest, and PARP inhibitors (cohort E) that inhibit DNA repair mechanisms. Implementing ctDNA dynamics into clinical trials and care may require distinct analysis for different therapies.
Citation Format: Iseult Browne, Javier Pascual, Rosalind Cutts, Belinda Kingston, Sarah Hrebien, Lucy Kilburn, Alex Pearson, Laura Moretti, Andrew Wardley, Iain Macpherson, Richard Baird, Rebecca Roylance, Iris Faull, Kimberly C Banks, Isaac Garcia-Murillas, Judith Bliss, Alistair Ring, Nicholas Turner. The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PS06-04..
Penault-Llorca, F.
Dalenc, F.
Chabaud, S.
Cottu, P.
Allouache, D.
Cameron, D.
Grenier, J.
Venat Bouvet, L.
Jegannathen, A.
Campone, M.
Debled, M.
Hardy-Bessard, A.-.
Giacchetti, S.
Barthelemy, P.
Kaluzinski, L.
Mailliez, A.
Mouret-Reynier, M.-.
Legouffe, E.
Cayre, A.
Martinez, M.
Delbaldo, C.
Mollon-Grange, D.
Macaskill, E.J.
Sephton, M.
Stefani, L.
Belgadi, B.
Winter, M.
Orfeuvre, H.
Lacroix-Triki, M.
Bonnefoi, H.
Bliss, J.
Canon, J.-.
Lemonnier, J.
Andre, F.
Bachelot, T.
(2024). Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. Esmo open,
Vol.9
(5),
p. 103443.
show abstract
full text
BACKGROUND: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PATIENTS AND METHODS: Patients were classified into low or high risk according to the EPclin score, consisting of a 12-gene molecular score combined with tumor size and nodal status. Association of the EPclin score with disease-free survival (DFS) and distant metastasis-free survival (DMFS) was evaluated using Kaplan-Meier estimates. The independent prognostic added value of EPclin score was tested in a multivariate Cox model after adjusting on tumor characteristics. RESULTS: EndoPredict test results were available for 768 patients: 663 patients classified as EPclin high risk (EPCH) and 105 patients as EPclin low risk (EPCL). Median follow-up was 70 months (range 1-172 months). For the 429 EPCH randomized patients, there was no significant difference in DFS between treatment arms. The 60-month relapse rate for patients in the EPCL and EPCH groups was 0% and 7%, respectively. Hazard ratio (HR) supposing continuous EPclin score was 1.87 [95% confidence interval (CI) 1.4-2.5, P < 0.0001]. This prognostic effect remained significant when assessed in a Cox model adjusting on tumor size, number of positive nodes and tumor grade (HR 1.52, 95% CI 1.09-2.13, P = 0.0141). The 60-month DMFS for patients in the EPCL and EPCH groups was 100% and 94%, respectively (adjusted HR 8.10, 95% CI 1.1-59.1, P < 0.0001). CONCLUSIONS: The results confirm the value of EPclin score as an independent prognostic parameter in node-positive, hormone receptor-positive, HER2-negative early breast cancer patients receiving standard adjuvant treatment. EPclin score can be used to identify patients at higher risk of recurrence who may warrant additional systemic treatments..
Sydes, M.R.
Murray, M.L.
Ahmed, S.
Apostolidou, S.
Bliss, J.M.
Bloomfield, C.
Cannings-John, R.
Carpenter, J.
Clayton, T.
Clout, M.
Cosgriff, R.
Farrin, A.J.
Gentry-Maharaj, A.
Gilbert, D.C.
Harper, C.
James, N.D.
Langley, R.E.
Lessels, S.
Lugg-Widger, F.
Mackenzie, I.S.
Mafham, M.
Menon, U.
Mintz, H.
Pinches, H.
Robling, M.
Wright-Hughes, A.
Yorke-Edwards, V.
Love, S.B.
(2024). Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials. Contemp clin trials,
Vol.141,
p. 107514.
show abstract
full text
BACKGROUND: Better use of healthcare systems data, collected as part of interactions between patients and the healthcare system, could transform planning and conduct of randomised controlled trials. Multiple challenges to widespread use include whether healthcare systems data captures sufficiently well the data traditionally captured on case report forms. "Data Utility Comparison Studies" (DUCkS) assess the utility of healthcare systems data for RCTs by comparison to data collected by the trial. Despite their importance, there are few published UK examples of DUCkS. METHODS-AND-RESULTS: Building from ongoing and selected recent examples of UK-led DUCkS in the literature, we set out experience-based considerations for the conduct of future DUCkS. Developed through informal iterative discussions in many forums, considerations are offered for planning, protocol development, data, analysis and reporting, with comparisons at "patient-level" or "trial-level", depending on the item of interest and trial status. DISCUSSION: DUCkS could be a valuable tool in assessing where healthcare systems data can be used for trials and in which trial teams can play a leading role. There is a pressing need for trials to be more efficient in their delivery and research waste must be reduced. Trials have been making inconsistent use of healthcare systems data, not least because of an absence of evidence of utility. DUCkS can also help to identify challenges in using healthcare systems data, such as linkage (access and timing) and data quality. We encourage trial teams to incorporate and report DUCkS in trials and funders and data providers to support them..
Giacchetti, S.
Laas, E.
Bachelot, T.
Lemonnier, J.
André, F.
Cameron, D.
Bliss, J.
Chabaud, S.
Hardy-Bessard, A.-.
Lacroix-Triki, M.
Canon, J.-.
Debled, M.
Campone, M.
Cottu, P.
Dalenc, F.
Ballesta, A.
Penault-Llorca, F.
Asselain, B.
Dumas, E.
Reyal, F.
Gougis, P.
Lévi, F.
Hamy, A.-.
(2024). Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial. Ebiomedicine,
Vol.104,
p. 105141.
show abstract
full text
BACKGROUND: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III trial (NCT01805271). METHODS: 1278 patients with high-risk hormonal receptor positive (HR+)/HER2 negative (HER2-) primary BC were randomly assigned to adjuvant ET with placebo or everolimus. Patients prospectively reported in a diary the daily timing of ET intake among four 6-h slots (06:00-11:59 (morning), 12:00-17:59 (afternoon), 18:00-23:59 (evening), or 24:00-05:59 (nighttime). The association between ET timing and disease-free survival (DFS) was a prespecified secondary endpoint of the trial and the results of this observational study are reported here. FINDINGS: ET timing was recorded by 855 patients (67.2%). Patients declaring morning (n = 465, 54.4%) or afternoon (n = 45, 5.4%) ET intake were older than those declaring evening (n = 339, 39.6%) or nighttime (n = 5, 0.6%) intake. With a median follow-up of 46.7 months, 118 patients had a local (n = 30) or metastasis relapse (n = 84), and 41 patients died. ET intake timing was not associated with DFS in the whole population (HR = 0.77, 95% CI [0.53-1.12]). The association between ET intake timing and DFS according to the stratification factors revealed interactions with ET agent (tamoxifen versus Aromatase inhibitors (AI) with an increased DFS in the group of evening/nighttime versus morning/afternoon tamoxifen intake (HR = 0.43, 95% CI [0.22-0.85]), while no association was found for AI intake (HR = 1.07, 95% CI [0.68-1.69]). The interaction between ET intake timing and ET agent remained in multivariable analysis (HR = 0.38 [0.16-0.91]). INTERPRETATION: Tamoxifen intake in the evening/nighttime could be recommended in patients with high-risk HR+/HER2- BC while awaiting for results from further ET timing studies. FUNDING: UNIRAD was Supported by a grant from the French Ministry of Health PHRC 2012 and received funding from La Ligue contre le Cancer, Cancer Research-UK, Myriad Genetics, and Novartis..
Villacampa, G.
Dennett, S.
Mello, E.
Holton, J.
Lai, X.
Kilburn, L.
Bliss, J.
Rekowski, J.
Yap, C.
(2024). Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023. Esmo open,
Vol.9
(7),
p. 103603.
show abstract
full text
BACKGROUND: In a competitive landscape with many ongoing adjuvant randomised controlled trials (RCTs), the prevalence of trials that failed to recruit their targeted sample size and were inadequately powered is unclear. The aims of the study are (i) to determine the percentage of trials with accrual and statistical power failure and (ii) to evaluate their potential impact on the drug development process. MATERIALS AND METHODS: A systematic review was carried out to identify adjuvant phase III oncology RCTs reported between 2013 and 2023 across all solid tumours. No restrictions were applied regarding the type of intervention or journal of publication. The percentage of trials with accrual failure and power failure was estimated as well as their association with the efficacy endpoints. Logistic regression models were used to estimate the odds ratio (OR) and its 95% confidence interval (CI). RESULTS: A total of 282 RCTs met the inclusion criteria with a median sample size of 661 patients and a median accrual period of 4.3 years. Most of these studies were superiority trials (83.0%). Accrual failure was observed in 22.0% of the studies, finishing recruitment without achieving the targeted sample size. Overall, 39.7% of the studies experienced power failure, having less power than specified in the protocol at the date of the read-out. Among superiority RCTs evaluating intermediate survival endpoints, only 31.1% presented statistically significant results. Trials with power failure were less likely to present statistically significant results (37.9% versus 21.9%, P = 0.04). The association was consistent across all cancer types. In the subset of non-inferiority trials, 35.0% formally demonstrated non-inferiority of the experimental arm. CONCLUSIONS: Nearly 40% of adjuvant phase III RCTs experienced power failure, and the reduction in power significantly impacted the final study results. There is a need for procedural refinements in the design and implementation of future adjuvant RCTs to mitigate these fallacies..
Kingston, B.
Pearson, A.
Herrera-Abreu, M.T.
Sim, L.-.
Cutts, R.J.
Shah, H.
Moretti, L.
Kilburn, L.S.
Johnson, H.
Macpherson, I.R.
Ring, A.
Bliss, J.M.
Hou, Y.
Toy, W.
Katzenellenbogen, J.A.
Chandarlapaty, S.
Turner, N.C.
(2024). ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer. Cancer discov,
Vol.14
(2),
pp. 274-289.
show abstract
full text
UNLABELLED: Fulvestrant is used to treat patients with hormone receptor-positive advanced breast cancer, but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant in patients with activating ESR1 mutations in circulating tumor DNA (ctDNA). Baseline ESR1 mutations Y537S are associated with poor outcomes and Y537C with good outcomes. Sequencing of baseline and EOT ctDNA samples (n = 69) revealed 3/69 (4%) patients acquired novel ESR1 F404 mutations (F404L, F404I, and F404V), in cis with activating mutations. In silico modeling revealed that ESR1 F404 contributes to fulvestrant binding to estrogen receptor-alpha (ERα) through a pi-stacking bond, with mutations disrupting this bond. In vitro analysis demonstrated that single F404L, E380Q, and D538G models were less sensitive to fulvestrant, whereas compound mutations D538G + F404L and E380Q + F404L were resistant. Several oral ERα degraders were active against compound mutant models. We have identified a resistance mechanism specific to fulvestrant that can be targeted by treatments in clinical development. SIGNIFICANCE: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding domain may cause drug-specific resistance, emphasizing the potential of similar drug-specific mutations to impact the efficacy of oral ER degraders in development. This article is featured in Selected Articles from This Issue, p. 201..
Coakley, M.
Villacampa, G.
Sritharan, P.
Swift, C.
Dunne, K.
Kilburn, L.
Goddard, K.
Pipinikas, C.
Rojas, P.
Emmett, W.
Hall, P.
Harper-Wynne, C.
Hickish, T.
Macpherson, I.
Okines, A.
Wardley, A.
Wheatley, D.
Waters, S.
Palmieri, C.
Winter, M.
Cutts, R.J.
Garcia-Murillas, I.
Bliss, J.
Turner, N.C.
(2024). Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clin cancer res,
Vol.30
(4),
pp. 895-903.
show abstract
PURPOSE: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown. EXPERIMENTAL DESIGN: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays for ctDNA molecular residual disease (MRD) detection in early-stage triple-negative breast cancer. We compared tumor-informed dPCR assays with tumor-informed personalized multimutation sequencing assays in 141 patients from cTRAK-TN. RESULTS: MRD was first detected by personalized sequencing in 47.9% of patients, 0% first detected by dPCR, and 52.1% with both assays simultaneously (P < 0.001; Fisher exact test). The median lead time from ctDNA detection to relapse was 6.1 months with personalized sequencing and 3.9 months with dPCR (P = 0.004, mixed-effects Cox model). Detection of MRD at the first time point was associated with a shorter time to relapse compared with detection at subsequent time points (median lead time 4.2 vs. 7.1 months; P = 0.02). CONCLUSIONS: Personalized multimutation sequencing assays have potential clinically important improvements in clinical outcome in the early detection of MRD..
Larkin, J.
Marais, R.
Porta, N.
Gonzalez de Castro, D.
Parsons, L.
Messiou, C.
Stamp, G.
Thompson, L.
Edmonds, K.
Sarker, S.
Banerji, J.
Lorigan, P.
Evans, T.R.
Corrie, P.
Marshall, E.
Middleton, M.R.
Nathan, P.
Nicholson, S.
Ottensmeier, C.
Plummer, R.
Bliss, J.
Valpione, S.
Turajlic, S.
(2024). Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell rep med,
Vol.5
(3),
p. 101435.
show abstract
full text
Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49)..
Cheang, M.C.
Rimawi, M.
Johnston, S.
Jacobs, S.A.
Bliss, J.
Pogue-Geile, K.
Kilburn, L.
Zhu, Z.
Schuster, E.F.
Xiao, H.
Swaim, L.
Deng, S.
Lu, D.R.
Gauthier, E.
Tursi, J.
Slamon, D.J.
Rugo, H.S.
Finn, R.S.
Liu, Y.
(2024). Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. Npj breast cancer,
Vol.10
(1),
p. 54.
show abstract
full text
Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used.Trial number: NCT01740427..
Glynn, D.
Bliss, J.
Brunt, A.M.
Coles, C.E.
Wheatley, D.
Haviland, J.S.
Kirby, A.M.
Longo, F.
Faria, R.
Yarnold, J.R.
Griffin, S.
(2023). Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast cancer res treat,
Vol.197
(2),
pp. 405-416.
show abstract
full text
PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. METHODS: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. RESULTS: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. CONCLUSIONS: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system..
Ring, A.
Kilburn, L.S.
Pearson, A.
Moretti, L.
Afshari-Mehr, A.
Wardley, A.M.
Gurel, B.
Macpherson, I.R.
Riisnaes, R.
Baird, R.D.
Martin, S.
Roylance, R.
Johnson, H.
Ferreira, A.
Winter, M.C.
Dunne, K.
Copson, E.
Hickish, T.
Burcombe, R.
Randle, K.
Serra, V.
Llop-Guevara, A.
Bliss, J.M.
Turner, N.C.
(2023). Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clin cancer res,
Vol.29
(23),
pp. 4751-4759.
show abstract
full text
PURPOSE: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. PATIENTS AND METHODS: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1-7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. RESULTS: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4-25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. CONCLUSIONS: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy..
Turner, N.C.
Swift, C.
Jenkins, B.
Kilburn, L.
Coakley, M.
Beaney, M.
Fox, L.
Goddard, K.
Garcia-Murillas, I.
Proszek, P.
Hall, P.
Harper-Wynne, C.
Hickish, T.
Kernaghan, S.
Macpherson, I.R.
Okines, A.F.
Palmieri, C.
Perry, S.
Randle, K.
Snowdon, C.
Stobart, H.
Wardley, A.M.
Wheatley, D.
Waters, S.
Winter, M.C.
Hubank, M.
Allen, S.D.
Bliss, J.M.
c-TRAK TN investigators,
(2023). Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann oncol,
Vol.34
(2),
pp. 200-211.
show abstract
full text
BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA surveillance in TNBC and the activity of pembrolizumab in patients with ctDNA detected [ctDNA positive (ctDNA+)]. PATIENTS AND METHODS: c-TRAK TN, a multicentre phase II trial, with integrated prospective ctDNA surveillance by digital PCR, enrolled patients with early-stage TNBC and residual disease following neoadjuvant chemotherapy, or stage II/III with adjuvant chemotherapy. ctDNA surveillance comprised three-monthly blood sampling to 12 months (18 months if samples were missed due to coronavirus disease), and ctDNA+ patients were randomised 2 : 1 to intervention : observation. ctDNA results were blinded unless patients were allocated to intervention, when staging scans were done and those free of recurrence were offered pembrolizumab. A protocol amendment (16 September 2020) closed the observation group; all subsequent ctDNA+ patients were allocated to intervention. Co-primary endpoints were (i) ctDNA detection rate and (ii) sustained ctDNA clearance rate on pembrolizumab (NCT03145961). RESULTS: Two hundred and eight patients registered between 30 January 2018 and 06 December 2019, 185 had tumour sequenced, 171 (92.4%) had trackable mutations, and 161 entered ctDNA surveillance. Rate of ctDNA detection by 12 months was 27.3% (44/161, 95% confidence interval 20.6% to 34.9%). Seven patients relapsed without prior ctDNA detection. Forty-five patients entered the therapeutic component (intervention n = 31; observation n = 14; one observation patient was re-allocated to intervention following protocol amendment). Of patients allocated to intervention, 72% (23/32) had metastases on staging at the time of ctDNA+, and 4 patients declined pembrolizumab. Of the five patients who commenced pembrolizumab, none achieved sustained ctDNA clearance. CONCLUSIONS: c-TRAK TN is the first prospective study to assess whether ctDNA assays have clinical utility in guiding therapy in TNBC. Patients had a high rate of metastatic disease on ctDNA detection. Findings have implications for future trial design, emphasising the importance of commencing ctDNA testing early, with more sensitive and/or frequent ctDNA testing regimes..
Nuciforo, P.
Townend, J.
Piccart, M.J.
Fielding, S.
Gkolfi, P.
El-Abed, S.
de Azambuja, E.
Werutsky, G.
Bliss, J.
Moebus, V.
Colleoni, M.
Aspitia, A.M.
Gomez, H.
Gombos, A.
Coccia-Portugal, M.A.
Tseng, L.-.
Kunz, G.
Lerzo, G.
Sohn, J.
Semiglazov, V.
Saura, C.
Kroep, J.
Ferro, A.
Cameron, D.
Gelber, R.
Huober, J.
Di Cosimo, S.
(2023). Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur j cancer,
Vol.181,
pp. 92-101.
show abstract
BACKGROUND: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR. METHODS: Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population. RESULTS: A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%-71%) in the lapatinib group, 64% (95% CI, 55%-72%) in the trastuzumab group and 67% (95% CI, 58%-74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%-83%), 75% (95% CI, 66%-82%) and 80% (95% CI, 73%-86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and OS (hazard ratio 0.37, 95% CI, 0.20-0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns. CONCLUSIONS: Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR..
Kirby, A.M.
Haviland, J.S.
Mackenzie, M.
Fleming, H.
Anandadas, C.
Wickers, S.
Miles, E.
Iles, N.
Bliss, J.M.
Coles, C.E.
PARABLE Trial Management Group,
(2023). Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting. Clin oncol (r coll radiol),
Vol.35
(6),
pp. 347-350.
full text
Schuster, E.F.
Lopez-Knowles, E.
Alataki, A.
Zabaglo, L.
Folkerd, E.
Evans, D.
Sidhu, K.
Cheang, M.C.
Tovey, H.
Salto-Tellez, M.
Maxwell, P.
Robertson, J.
Smith, I.
Bliss, J.M.
Dowsett, M.
(2023). Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers. Nat commun,
Vol.14
(1),
p. 4017.
show abstract
full text
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale molecular analysis to identify features that impact on the response of ER + HER2- BC to AI. We compare the 15% of poorest responders (PRs, n = 177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant AI to good responders (GRs, n = 190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories. In this work, low ESR1 levels are associated with poor response, high proliferation, high expression of growth factor pathways and non-luminal subtypes. PRs having high ESR1 expression have similar proportions of luminal subtypes to GRs but lower plasma estradiol levels, lower expression of estrogen response genes, higher levels of tumor infiltrating lymphocytes and immune markers, and more TP53 mutations..
Goodwin, P.J.
Chen, B.E.
Gelmon, K.A.
Whelan, T.J.
Ennis, M.
Lemieux, J.
Ligibel, J.A.
Hershman, D.L.
Mayer, I.A.
Hobday, T.J.
Bliss, J.M.
Rastogi, P.
Rabaglio-Poretti, M.
Thompson, A.M.
Rea, D.W.
Stos, P.M.
Shepherd, L.E.
Stambolic, V.
Parulekar, W.R.
(2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA 32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. J clin oncol,
Vol.41
(35),
pp. 5356-5362.
show abstract
full text
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin (v placebo) did not affect invasive disease-free or overall survival. Here, we report metformin effects on the risk of new cancer. Between 2010 and 2013, 3,649 patients with breast cancer younger than 75 years without diabetes with high-risk T1-3, N0-3 M0 breast cancer (any estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) were randomly assigned to metformin 850 mg orally twice a day or placebo twice a day for 5 years. New primary invasive cancers (outside the ipsilateral breast) developing as a first event were identified. Time to events was described by the competing risks method; two-sided likelihood ratio tests adjusting for age, BMI, smoking, and alcohol intake were used to compare metformin versus placebo arms. A total of 184 patients developed new invasive cancers: 102 metformin and 82 placebo, hazard ratio (HR), 1.25; 95% CI, 0.94 to 1.68; P = .13. These included 48 contralateral invasive breast cancers (27 metformin v 21 placebo), HR, 1.29; 95% CI, 0.72 to 2.27; P = .40 and 136 new nonbreast primary cancers (75 metformin v 61 placebo), HR, 1.24; 95% CI, 0.88 to 1.74; P = .21. Metformin did not reduce the risk of new cancer development in these nondiabetic patients with breast cancer..
Brunt, A.M.
Haviland, J.S.
Wheatley, D.A.
Sydenham, M.A.
Bloomfield, D.J.
Chan, C.
Cleator, S.
Coles, C.E.
Donovan, E.
Fleming, H.
Glynn, D.
Goodman, A.
Griffin, S.
Hopwood, P.
Kirby, A.M.
Kirwan, C.C.
Nabi, Z.
Patel, J.
Sawyer, E.
Somaiah, N.
Syndikus, I.
Venables, K.
Yarnold, J.R.
Bliss, J.M.
FAST-Forward Trial Management Group,
(2023). One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. Health technol assess,
Vol.27
(25),
pp. 1-176.
show abstract
full text
BACKGROUND: FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard 15-fraction regimen after primary surgery for early breast cancer. Published acute toxicity and 5-year results are presented here with other aspects of the trial. DESIGN: Multicentre phase III non-inferiority trial. Patients with invasive carcinoma of the breast (pT1-3pN0-1M0) after breast conservation surgery or mastectomy randomised (1 : 1 : 1) to 40 Gy in 15 fractions (3 weeks), 27 Gy or 26 Gy in 5 fractions (1 week) whole breast/chest wall (Main Trial). Primary endpoint was ipsilateral breast tumour relapse; assuming 2% 5-year incidence for 40 Gy, non-inferiority pre-defined as < 1.6% excess for 5-fraction schedules (critical hazard ratio = 1.81). Normal tissue effects were assessed independently by clinicians, patients and photographs. SUB-STUDIES: Two acute skin toxicity sub-studies were undertaken to confirm safety of the test schedules. Primary endpoint was proportion of patients with grade ≥ 3 acute breast skin toxicity at any time from the start of radiotherapy to 4 weeks after completion. Nodal Sub-Study patients had breast/chest wall plus axillary radiotherapy testing the same three schedules, reduced to the 40 and 26 Gy groups on amendment, with the primary endpoint of 5-year patient-reported arm/hand swelling. LIMITATIONS: A sequential hypofractionated or simultaneous integrated boost has not been studied. PARTICIPANTS: Ninety-seven UK centres recruited 4096 patients (1361:40 Gy, 1367:27 Gy, 1368:26 Gy) into the Main Trial from November 2011 to June 2014. The Nodal Sub-Study recruited an additional 469 patients from 50 UK centres. One hundred and ninety and 162 Main Trial patients were included in the acute toxicity sub-studies. RESULTS: Acute toxicity sub-studies evaluable patients: (1) acute grade 3 Radiation Therapy Oncology Group toxicity reported in 40 Gy/15 fractions 6/44 (13.6%); 27 Gy/5 fractions 5/51 (9.8%); 26 Gy/5 fractions 3/52 (5.8%). (2) Grade 3 common toxicity criteria for adverse effects toxicity reported for one patient. At 71-month median follow-up in the Main Trial, 79 ipsilateral breast tumour relapse events (40 Gy: 31, 27 Gy: 27, 26 Gy: 21); hazard ratios (95% confidence interval) versus 40 Gy were 27 Gy: 0.86 (0.51 to 1.44), 26 Gy: 0.67 (0.38 to 1.16). With 2.1% (1.4 to 3.1) 5-year incidence ipsilateral breast tumour relapse after 40 Gy, estimated absolute differences versus 40 Gy (non-inferiority test) were -0.3% (-1.0-0.9) for 27 Gy (p = 0.0022) and -0.7% (-1.3-0.3) for 26 Gy (p = 0.00019). Five-year prevalence of any clinician-assessed moderate/marked breast normal tissue effects was 40 Gy: 98/986 (9.9%), 27 Gy: 155/1005 (15.4%), 26 Gy: 121/1020 (11.9%). Across all clinician assessments from 1 to 5 years, odds ratios versus 40 Gy were 1.55 (1.32 to 1.83; p < 0.0001) for 27 Gy and 1.12 (0.94-1.34; p = 0.20) for 26 Gy. Patient and photographic assessments showed higher normal tissue effects risk for 27 Gy versus 40 Gy but not for 26 Gy. Nodal Sub-Study reported no arm/hand swelling in 80% and 77% in 40 Gy and 26 Gy at baseline, and 73% and 76% at 24 months. The prevalence of moderate/marked arm/hand swelling at 24 months was 10% versus 7% for 40 Gy compared with 26 Gy. INTERPRETATION: Five-year local tumour incidence and normal tissue effects prevalence show 26 Gy in 5 fractions in 1 week is a safe and effective alternative to 40 Gy in 15 fractions for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer. FUTURE WORK: Ten-year Main Trial follow-up is essential. Inclusion in hypofractionation meta-analysis ongoing. A future hypofractionated boost trial is strongly supported. TRIAL REGISTRATION: FAST-Forward was sponsored by The Institute of Cancer Research and was registered as ISRCTN19906132. FUNDING: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 09/01/47) and is published in full in Health Technology Assessment; Vol. 27, No. 25. See the NIHR Funding and Awards website for further award information..
Taylor, C.
Dodwell, D.
McGale, P.
Hills, R.K.
Berry, R.
Bradley, R.
Braybrooke, J.
Clarke, M.
Gray, R.
Holt, F.
Liu, Z.
Pan, H.
Peto, R.
Straiton, E.
Coles, C.
Duane, F.
Hennequin, C.
Jones, G.
Kühn, T.
Oliveros, S.
Overgaard, J.
Pritchard, K.I.
Suh, C.-.
Beake, G.
Boddington, C.
Davies, C.
Davies, L.
Evans, V.
Gay, J.
Gettins, L.
Godwin, J.
James, S.
Kerr, A.
Liu, H.
MacKinnon, E.
Mannu, G.
McHugh, T.
Morris, P.
Nakahara, M.
Read, S.
Taylor, H.
Ferguson, J.
Scheurlen, H.
Zurrida, S.
Galimberti, V.
Ingle, J.
Valagussa, P.
Veronesi, U.
Anderson, S.
Tang, G.
Fisher, B.
Fossa, S.
Valborg Reinertsen, K.
Host, H.
Muss, H.
Holli, K.
Albain, K.
Arriagada, R.
Bartlett, J.
Bergsten-Nordström, E.
Bliss, J.
Brain, E.
Carey, L.
Coleman, R.
Cuzick, J.
Davidson, N.
Del Mastro, L.
Di Leo, A.
Dignam, J.
Dowsett, M.
Ejlertsen, B.
Francis, P.
García-Sáenz, J.A.
Gelber, R.
Gnant, M.
Goetz, M.
Goodwin, P.
Halpin-Murphy, P.
Hayes, D.
Hill, C.
Jagsi, R.
Janni, W.
Loibl, S.
Mamounas, E.
Martín, M.
McIntosh, S.
Mukai, H.
Nekljudova, V.
Norton, L.
Ohashi, Y.
Piccart, M.
Pierce, L.
Raina, V.
Rea, D.
Regan, M.
Robertson, J.
Rutgers, E.
Salgado, R.
Slamon, D.
Spanic, T.
Sparano, J.
Steger, G.
Toi, M.
Tutt, A.
Viale, G.
Wang, X.
Wilcken, N.
Wolmark, N.
Yu, K.-.
Cameron, D.
Bergh, J.
Swain, S.
Whelan, T.
Poortmans, P.
(2023). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. The lancet,
Vol.402
(10416),
pp. 1991-2003.
Bliss, J.M.
Tovey, H.
Evans, A.
Holcombe, C.
Horgan, K.
Mallon, E.
Vidya, R.
Skene, A.
Dodson, A.
Hills, M.
Detre, S.
Zabaglo, L.
Banerji, J.
Kilburn, L.
Morden, J.P.
Robertson, J.F.
Smith, I.
Dowsett, M.
POETIC Trialists,
(2023). Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast cancer res,
Vol.25
(1),
p. 39.
show abstract
full text
PURPOSE: Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with clinical benefit from endocrine therapies and residual Ki67 (Ki672week) with recurrence-free survival. The aim was to define the association between Ki67baseline and after aromatase inhibitor (AI) exposure ∆Ki672week and Ki672week with key prognostic and biologic factors utilising data from the POETIC study. PATIENTS AND METHODS: In POETIC 4480 postmenopausal patients with primary ER and/or PgR + breast cancer were randomised 2:1 to 2 weeks' presurgical AI (anastrozole or letrozole) or no presurgical treatment (control). Ki67 was measured centrally in core-cut biopsies taken prior to AI and in core-cuts or the excision biopsy at surgery. Relationships between the Ki67 and biologic factors were explored using linear regression. RESULTS: Established associations of Ki67baseline with biologic factors including PgR status, tumour grade, tumour size, histological subtype, nodal status, and vascular invasion were confirmed in the HER2- subpopulation. In the HER2 + subpopulation only grade and tumour size were significantly associated with Ki67baseline. In control group Ki672week was 18% lower than Ki67baseline (p < 0.001) when Ki672week was measured in excision biopsies but not when measured in core-cuts. Median suppression by AIs (∆Ki672week) was 79.3% (IQR: -89.9 to -54.6) and 53.7% (IQR: -78.9 to -21.1) for HER2-negative and HER2-positive cases, respectively. Significantly less suppression occurred in PgR- vs PgR + and HER2 + vs HER2- tumours which remained apparent after adjustment for 2-week sample type. CONCLUSIONS: The magnitude of this study allowed characterisation of relationships between Ki67baseline, ∆Ki672week and Ki672week with high degrees of confidence providing a reference source for other studies. Lower values of Ki67 occur when measured on excision biopsies and could lead to apparent but artefactual decreases in Ki67: this should be considered when either ∆Ki672week or Ki672week is used in routine clinical practice to aid treatment decisions or in clinical trials assessing new drug therapies..
Velikova, G.
Morden, J.P.
Haviland, J.S.
Emery, C.
Barrett-Lee, P.
Earl, H.
Bloomfield, D.
Brunt, A.M.
Canney, P.
Coleman, R.
Verrill, M.
Wardley, A.
Bertelli, G.
Ellis, P.
Stein, R.
Bliss, J.M.
Cameron, D.
TACT2 Trial Management Group,
(2023). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet oncol,
Vol.24
(12),
pp. 1359-1374.
show abstract
full text
BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior. As part of the QOL substudy, we aimed to assess the effect of chemotherapies on psychological distress, physical symptoms, and functional domains. METHODS: TACT2 was a multicentre, phase 3, open-label, parallel-group, randomised, controlled trial done in 129 UK centres. Participants were aged 18 years or older with histologically confirmed node-positive or high-risk node-negative invasive primary breast cancer, who had undergone complete excision, and due to receive adjuvant chemotherapy. Patients were randomly assigned (1:1:1:1) to four cycles of 100 mg/m2 epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either CMF (600 mg/m2 cyclophosphamide intravenously on days 1 and 8 or 100 mg/m2 orally on days 1-14; 40 mg/m2 methotrexate intravenously on days 1 and 8; and 600 mg/m2 fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m2 capecitabine (1250 mg/m2 given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs 1-3 vs ≥4), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). QOL was one of the secondary outcomes and is reported here. All patients from a subset of 44 centres were invited to complete QOL questionnaires (Hospital Anxiety and Depression Scale [HADS] and European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire 30-item core module [QLQ-C30] and Quality of Life Questionnaire breast module [QLQ-BR23]) at baseline, end of standard or accelerated epirubicin, end of CMF or capecitabine, and at 12 and 24 months after randomisation. The QOL substudy prespecified two coprimary QOL outcomes assessed in the intention-to-treat population: overall QOL (reported elsewhere) and HADS total score. Prespecified secondary QOL outcomes were EORTC QLQ-C30 subscales of physical function, role function, and fatigue and EORTC QLQ-BR23 subscales of sexual function and systemic therapy side-effects. This trial is registered with ISRCTN, ISRCTN68068041, and ClinicalTrials.gov, NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (20 [0·5%] of whom were male) were enrolled in TACT2; 1281 (85·8%) of 1493 eligible patients were included in the QOL substudy. Eight (0·6%) participants in the QOL substudy were male and 1273 (99·4%) were female. Median follow-up was 85·6 months (IQR 80·6-95·9). Analysis was performed on the complete QOL dataset (as of Sept 15, 2011) when all participants had passed the 24-month timepoint. Prerandomisation questionnaires were completed by 1172 (91·5%) patients and 1179 (92·0%) completed at least one postrandomisation questionnaire. End-of-treatment HADS depression score (p=0·0048) and HADS total change score (p=0·0093) were worse for CMF versus capecitabine. Accelerated epirubicin led to worse physical function (p=0·0065), role function (p<0·0001), fatigue (p=0·0002), and systemic side-effects (p=0·0001), but not sexual function (p=0·36), compared with standard epirubicin during treatment, but the effect did not persist. Worse physical function (p=0·0048), sexual function (p=0·0053), fatigue (p<0·0001), and systemic side-effects (p<0·0001), but not role functioning (p=0·013), were seen for CMF versus capecitabine at end of treatment; these differences persisted at 12 months and 24 months. INTERPRETATION: Accelerated epirubicin was associated with worse QOL than was standard epirubicin but only during treatment. These findings will help patients and clinicians make an informed choice about accelerated chemotherapy. CMF had worse QOL effects than did capecitabine, which were persistent for 24 months. The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche..
Castelo-Branco, L.
Pellat, A.
Martins-Branco, D.
Valachis, A.
Derksen, J.W.
Suijkerbuijk, K.P.
Dafni, U.
Dellaporta, T.
Vogel, A.
Prelaj, A.
Groenwold, R.H.
Martins, H.
Stahel, R.
Bliss, J.
Kather, J.
Ribelles, N.
Perrone, F.
Hall, P.S.
Dienstmann, R.
Booth, C.M.
Pentheroudakis, G.
Delaloge, S.
Koopman, M.
(2023). ESMO Guidance for Reporting Oncology real-World evidence (GROW). Ann oncol,
Vol.34
(12),
pp. 1097-1112.
full text
Tovey, H.
Sipos, O.
Parker, J.S.
Hoadley, K.A.
Quist, J.
Kernaghan, S.
Kilburn, L.
Salgado, R.
Loi, S.
Kennedy, R.D.
Roxanis, I.
Gazinska, P.
Pinder, S.E.
Bliss, J.
Perou, C.M.
Haider, S.
Grigoriadis, A.
Tutt, A.
Cheang, M.C.
(2023). Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clin cancer res,
Vol.29
(18),
pp. 3691-3705.
show abstract
full text
PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation subgroup. Broader response-predictive biomarkers are needed. We explored the predictive ability of DNA damage response (DDR) and immune markers. EXPERIMENTAL DESIGN: Tumor-infiltrating lymphocytes were evaluated for 222 of 376 patients. Primary tumors (PT) from 186 TNT participants (13 matched recurrences) were profiled using total RNA sequencing. Four transcriptional DDR-related and 25 immune-related signatures were evaluated. We assessed their association with objective response rate (ORR) and progression-free survival (PFS). Conditional inference forest clustering was applied to integrate multimodal data. The biology of subgroups was characterized by 693 gene expression modules and other markers. RESULTS: Transcriptional DDR-related biomarkers were not predictive of ORR to either treatment overall. Changes from PT to recurrence were demonstrated; in chemotherapy-naïve patients, transcriptional DDR markers separated carboplatin responders from nonresponders (P values = 0.017; 0.046). High immune infiltration was associated with docetaxel ORR (interaction P values < 0.05). Six subgroups were identified; the immune-enriched cluster had preferential docetaxel response [62.5% (D) vs. 29.4% (C); P = 0.016]. The immune-depleted cluster had preferential carboplatin response [8.0% (D) vs. 40.0% (C); P = 0.011]. DDR-related subgroups were too small to assess ORR. CONCLUSIONS: High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity. Treatment options for patients with immune-low and DDR-proficient tumors remains an outstanding need. Caution is needed using PT-derived transcriptional signatures to direct treatment in mTNBC, particularly DDR-related markers following prior chemotherapy..
Pfeiler, G.
Hlauschek, D.
Mayer, E.L.
Deutschmann, C.
Kacerovsky-Strobl, S.
Martin, M.
Meisel, J.L.
Zdenkowski, N.
Loibl, S.
Balic, M.
Park, H.
Prat, A.
Isaacs, C.
Bajetta, E.
Balko, J.M.
Bellet-Ezquerra, M.
Bliss, J.
Burstein, H.
Cardoso, F.
Fohler, H.
Foukakis, T.
Gelmon, K.A.
Goetz, M.
Haddad, T.C.
Iwata, H.
Jassem, J.
Lee, S.-.
Linderholm, B.
Los, M.
Mamounas, E.P.
Miller, K.D.
Morris, P.G.
Munzone, E.
Gal-Yam, E.N.
Ring, A.
Shepherd, L.
Singer, C.
Thomssen, C.
Tseng, L.-.
Valagussa, P.
Winer, E.P.
Wolff, A.C.
Zoppoli, G.
Machacek-Link, J.
Schurmans, C.
Huang, X.
Gauthier, E.
Fesl, C.
Dueck, A.C.
DeMichele, A.
Gnant, M.
PALLAS Groups and Investigators,
(2023). Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. J clin oncol,
Vol.41
(33),
pp. 5118-5130.
show abstract
PURPOSE: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS: Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS: Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION: This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome..
Coles, C.E.
Haviland, J.S.
Kirby, A.M.
Griffin, C.L.
Sydenham, M.A.
Titley, J.C.
Bhattacharya, I.
Brunt, A.M.
Chan, H.Y.
Donovan, E.M.
Eaton, D.J.
Emson, M.
Hopwood, P.
Jefford, M.L.
Lightowlers, S.V.
Sawyer, E.J.
Syndikus, I.
Tsang, Y.M.
Twyman, N.I.
Yarnold, J.R.
Bliss, J.M.
IMPORT Trial Management Group,
(2023). Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet,
Vol.401
(10394),
pp. 2124-2137.
show abstract
full text
BACKGROUND: A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated boost against sequential boost with the aim of reducing treatment duration while maintaining excellent local control and similar or reduced toxicity. METHODS: IMPORT HIGH is a phase 3, non-inferiority, open-label, randomised controlled trial that recruited women after breast-conserving surgery for pT1-3pN0-3aM0 invasive carcinoma from radiotherapy and referral centres in the UK. Patients were randomly allocated to receive one of three treatments in a 1:1:1 ratio, with computer-generated random permuted blocks used to stratify patients by centre. The control group received 40 Gy in 15 fractions to the whole breast and 16 Gy in 8 fractions sequential photon tumour-bed boost. Test group 1 received 36 Gy in 15 fractions to the whole breast, 40 Gy in 15 fractions to the partial breast, and 48 Gy in 15 fractions concomitant photon boost to the tumour-bed volume. Test group 2 received 36 Gy in 15 fractions to the whole breast, 40 Gy in 15 fractions to the partial breast, and 53 Gy in 15 fractions concomitant photon boost to the tumour-bed volume. The boost clinical target volume was the clip-defined tumour bed. Patients and clinicians were not masked to treatment allocation. The primary endpoint was ipsilateral breast tumour relapse (IBTR) analysed by intention to treat; assuming 5% 5-year incidence with the control group, non-inferiority was predefined as 3% or less absolute excess in the test groups (upper limit of two-sided 95% CI). Adverse events were assessed by clinicians, patients, and photographs. This trial is registered with the ISRCTN registry, ISRCTN47437448, and is closed to new participants. FINDINGS: Between March 4, 2009, and Sept 16, 2015, 2617 patients were recruited. 871 individuals were assigned to the control group, 874 to test group 1, and 872 to test group 2. Median boost clinical target volume was 13 cm3 (IQR 7 to 22). At a median follow-up of 74 months there were 76 IBTR events (20 for the control group, 21 for test group 1, and 35 for test group 2). 5-year IBTR incidence was 1·9% (95% CI 1·2 to 3·1) for the control group, 2·0% (1·2 to 3·2) for test group 1, and 3·2% (2·2 to 4·7) for test group 2. The estimated absolute differences versus the control group were 0·1% (-0·8 to 1·7) for test group 1 and 1·4% (0·03 to 3·8) for test group 2. The upper confidence limit for test group 1 versus the control group indicated non-inferiority for 48 Gy. Cumulative 5-year incidence of clinician-reported moderate or marked breast induration was 11·5% for the control group, 10·6% for test group 1 (p=0·40 vs control group), and 15·5% for test group 2 (p=0·015 vs control group). INTERPRETATION: In all groups 5-year IBTR incidence was lower than the 5% originally expected regardless of boost sequencing. Dose-escalation is not advantageous. 5-year moderate or marked adverse event rates were low using small boost volumes. Simultaneous integrated boost in IMPORT HIGH was safe and reduced patient visits. FUNDING: Cancer Research UK..
Patel, D.
Kilburn, L.
Fox, L.
Hall, E.
Bliss, J.
Lewis, R.
(2023). Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting. Bmc med ethics,
Vol.24
(1),
p. 105.
show abstract
full text
BACKGROUND: Clinical trials should be as inclusive as possible to facilitate equitable access to research and better reflect the population towards which any intervention is aimed. Informed by the UK's National Institute for Health and Care Research (NIHR) Innovations in Clinical Trial Design and Delivery for the Under-served (INCLUDE) guidance, we audited oncology trials conducted by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London (ICR-CTSU) to identify whether essential documents were overtly excluding any groups and whether sufficient data were collected to assess diversity of trial participants from groups suggested by INCLUDE as under-served by research in the UK. METHODS: Thirty cancer clinical trials managed by ICR-CTSU and approved between 2011-2021 were audited. The first ethics approved version of each trial's protocol, patient information sheet, and patient completed questionnaire, together with the first case report forms (CRFs) version were reviewed. A range of items aligned with the INCLUDE under-served groups were assessed, including age, sex and gender, socio-economic and health factors. The scope did not cover trial processes in participating hospitals. RESULTS: Data relating to participants' age, ethnic group and health status were well collected and no upper age limit was specified in any trials' eligibility criteria. 23/30 (77%) information sheets used at least one gendered term to address patients. Most CRFs did not specify whether they were collecting sex or gender and only included male or female categories. The median reading age for information sheets was 15-16 years (IQR: 14-15 - 16-17). Socio-economic factors were not routinely collected and not commonly mentioned in trial protocols. CONCLUSIONS: No systemic issues were identified in protocols which would explicitly prevent any under-served group from participating. Areas for improvement include reducing use of gendered words and improving readability of patient information. The challenge of fully assessing adequate inclusion of under-served populations remains, as socio-economic factors are not routinely collected because they fall beyond the data generally required for protocol-specified trial endpoint assessments. This audit has highlighted the need to agree and standardise demographic data collection to permit adequate monitoring of the under-served groups identified by the NIHR..
Dowsett, M.
Kilburn, L.
Rimawi, M.F.
Osborne, C.K.
Pogue-Geile, K.
Liu, Y.
Jacobs, S.A.
Finnigan, M.
Puhalla, S.
Dodson, A.
Martins, V.
Cheang, M.
Perry, S.
Holcombe, C.
Turner, N.
Swift, C.
Bliss, J.M.
Johnston, S.
PALLET trialists,
(2022). Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer. Clin cancer res,
Vol.28
(1),
pp. 163-174.
show abstract
full text
PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; and (ii) the pharmacodynamic effect of the agents on the biomarkers. EXPERIMENTAL DESIGN: 307 postmenopausal women with ER+/HER2- primary breast cancer were randomly assigned to neoadjuvant treatment with letrozole for 14 weeks; letrozole for 2 weeks, then letrozole+palbociclib to 14 weeks; palbociclib for 2 weeks, then letrozole+palbociclib to 14 weeks; or letrozole+palbociclib for 14 weeks. Biopsies were taken at baseline, 2 and 14 weeks and surgery at varying times after stopping palbociclib. Immunohistochemical analyses were conducted for Ki67, c-PARP, ER, PgR, RB1, CCNE1, and CCND1. RESULTS: Higher baselines ER and PgR were significantly associated with a greater chance of complete cell-cycle arrest (CCCA: Ki67 <2.7%) at 14 weeks and higher baseline Ki67, c-PARP, and CCNE1 with a lower chance. The interaction with treatment was significant only for c-PARP. CCND1 levels were decreased c.20% by letrozole at 2 and 14 weeks but showed a tendency to increase with palbociclib. CCNE1 levels fell 82% (median) in tumors showing CCCA but were unchanged in those with no CCCA. Only 2/9 tumors showed CCCA 3-9 days after stopping palbociclib. ESR1 mutations were found in 2/4 tumors for which surgery took place ≥6 months after starting treatment. CONCLUSIONS: High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule..
Vanderbeek, A.M.
Bliss, J.M.
Yin, Z.
Yap, C.
(2022). Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemp clin trials,
Vol.112,
p. 106625.
show abstract
full text
MOTIVATION: Platform designs - master protocols that allow for new treatment arms to be added over time - have gained considerable attention in recent years. Between 2001 and 2019, 16 platform trials were initiated globally. The COVID-19 pandemic seems to have provided a new motivation for these designs. We conducted a rapid review to quantify and describe platform trials used in COVID-19. METHODS: We cross-referenced PubMed, ClinicalTrials.gov, and the Cytel COVID-19 Clinical Trials Tracker to identify platform trials, defined by their stated ability to add future arms. RESULTS: We identified 58 COVID-19 platform trials globally registered between January 2020 and May 2021. According to trial registries, 16 trials have added new therapies (median 3, IQR 4) and 11 have dropped arms (median 3, IQR 2.5). About 50% of trials publicly share their protocol, and 31 trials (53%) intend to share trial data. Forty-nine trials (84%) explicitly report adaptive features, and 21 trials (36%) state Bayesian methods. CONCLUSIONS: During the pandemic, there has been a surge in the number of platform trials compared to historical use. While transparency in statistical methods and clarity of data sharing policies needs improvement, platform trials appear particularly well-suited for rapid evidence generation. Trials secured funding quickly and many succeeded in adding new therapies in a short time period, thus demonstrating the potential for these trial designs to be implemented beyond the pandemic. The evidence gathered here may provide ample insight to further inform operational, statistical, and regulatory aspects of future platform trial conduct..
Bliss, J.
Porta, N.
Emson, M.
Miller, S.
Morden, J.
(2022). Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002. Clinical cancer research,
.
full text
Bundred, N.
Porta, N.
Brunt, A.M.
Cramer, A.
Hanby, A.
Shaaban, A.M.
Rakha, E.A.
Armstrong, A.
Cutress, R.I.
Dodwell, D.
Emson, M.A.
Evans, A.
Hartup, S.M.
Horgan, K.
Miller, S.E.
McIntosh, S.A.
Morden, J.P.
Naik, J.
Narayanan, S.
Ooi, J.
Skene, A.I.
Cameron, D.A.
Bliss, J.M.
(2022). Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin cancer res,
Vol.28
(7),
pp. 1323-1334.
show abstract
full text
PURPOSE: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. PATIENTS AND METHODS: This randomized phase II, two-part, multicenter trial included newly diagnosed women with HER2-positive invasive breast cancer due to undergo surgery. Patients were randomized to: part 1 (1:2:2), no treatment (control), trastuzumab or lapatinib; part 2 (1:1:2) control, trastuzumab, or lapatinib and trastuzumab combination. Treatment was given for 11 days presurgery. Coprimary endpoints were change in Ki67 and apoptosis between baseline and surgery tumor samples (biologic response: ≥30% change). Central pathology review scored residual cancer burden (RCB). Relapse-free survival (RFS) explored long-term effects. RESULTS: Between November 2010 and September 2015, 257 patients were randomized (part 1: control 22, trastuzumab 57, lapatinib 51; part 2: control 29, trastuzumab 32, combination 66). Ki67 response was evaluable for 223 patients: in part 1 Ki67 response occurred in 29/44 (66%) lapatinib versus 18/49 (37%) trastuzumab (P = 0.007) and 1/22 (5%) control (P < 0.0001); in part 2 in 36/49 (74%) combination versus 14/31 (45%) trastuzumab (P = 0.02) and 2/28 (7%) control (P < 0.0001). No significant increase in apoptosis after 11 days was seen in treatment groups. Six patients achieved complete pathologic response (pCR, RCB0) and 13 RCB1, all but two in the combination group. After 6 years median follow-up, 28 (11%) had recurrence and 19 (7%) died. No recurrences or deaths were observed among patients who achieved a pCR. Ki67% falls ≥50% associated with fewer recurrences (P = 0.002). CONCLUSIONS: Early response after short duration anti-HER2 dual therapy identifies cancers dependent on the HER2 pathway providing a strategy for exploring risk-adapted individualized treatment de-escalation..
Malorni, L.
Tyekucheva, S.
Hilbers, F.S.
Ignatiadis, M.
Neven, P.
Colleoni, M.
Henry, S.
Ballestrero, A.
Bonetti, A.
Jerusalem, G.
Papadimitriou, K.
Bernardo, A.
Seles, E.
Duhoux, F.P.
MacPherson, I.R.
Thomson, A.
Davies, D.M.
Bergqvist, M.
Migliaccio, I.
Gebhart, G.
Zoppoli, G.
Bliss, J.M.
Benelli, M.
McCartney, A.
Kammler, R.
De Swert, H.
Ruepp, B.
Fumagalli, D.
Maibach, R.
Cameron, D.
Loi, S.
Piccart, M.
Regan, M.M.
International Breast Cancer Study Group,
Breast International Group and PYTHIA Collaborators,
(2022). Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur j cancer,
Vol.164,
pp. 39-51.
show abstract
full text
BACKGROUND: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively investigated the prognostic role of serum thymidine kinase activity (sTKa), in patients treated with Palbociclib + fulvestrant. PATIENTS AND METHODS: PYTHIA was a phase II, single-arm, multicentre, trial that enrolled 124 post-menopausal women with endocrine-resistant hormone receptor-positive/HER2-negative metastatic breast cancer. Serum samples were collected pre-treatment (pre-trt; n = 122), at day 15 of cycle 1 (D15; n = 108), during the one week-off palbociclib before initiating cycle 2 (D28; n = 108) and at end of treatment (n = 76). sTKa was determined centrally using Divitum®, a refined ELISA-based assay with a limit of detection of 20 Divitum Units (Du)/L. The primary study endpoint was progression-free survival, assessed for its association with pre- and on-treatment sTKa. RESULTS: Data from 122 women were analysed. Pre-treatment sTKa was not associated with clinical characteristics and moderately correlated with tissue Ki-67. Palbociclib + fulvestrant markedly suppressed sTKa levels at D15, with 83% of patients recording levels below limit of detection. At D28, sTKa showed a rebound in 60% of patients. At each timepoint, higher sTKa was associated with shorter progression-free survival (each p < 0.001), with the strongest effect at D15. CONCLUSIONS: STKa is an independent prognostic biomarker in patients treated with palbociclib. High pre-treatment sTKa and its incomplete suppression during treatment may identify patients with poorer prognosis and primary resistance. This warrants validation in prospective comparative trials. CLINICALTRIALS. GOV IDENTIFIER: NCT02536742; EudraCT 2014-005387-15..
Andreyev, H.J.
Matthews, J.
Adams, C.
Gothard, L.
Lucy, C.
Tovey, H.
Boyle, S.
Anbalagan, S.
Musallam, A.
Yarnold, J.
Abraham, D.
Bliss, J.
Abdi, B.A.
Taylor, A.
Hauer-Jensen, M.
(2022). Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study. Radiother oncol,
Vol.168,
pp. 130-137.
show abstract
full text
BACKGROUND: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. AIM: To test whether gastrointestinal symptoms arising after radiotherapy, and persisting after maximal medical therapy, can be improved using Tocovid SupraBio 200 mg and pentoxifylline 400 mg orally twice daily for one year. Patients stratified by severity of symptoms, and randomised to active treatment or matched placebo were assessed after 12 months. The primary end point was improvement in gastrointestinal symptoms measured using the Inflammatory Bowel Disease Questionnaire, bowel subset score. Changes in bio-markers of fibrosis were assessed. RESULTS: 62 patients, median age 66, 34(55%) treated for prostate, 21(34%) gynaecological, 6(10%) anal and one(1%) rectal cancer were recruited; 40(65%) randomised to treatment, 22(35%) to placebo, 39 months (median) after radiotherapy completion. Gamma tocotrienol was not detected in serum in 41% of treated patients, despite good compliance with study medication. Treatment was completed in 28(70%) and 17(77%) patients in the treatment and placebo groups respectively. No improvement in symptom scores nor in quality of life was identified. Thirteen serious adverse events occurred. A transient ischaemic attack, was possibly related to pentoxifylline, others were assessed as unlikely to be related to treatment. Levels of EGF, PDGF and FGF were significantly reduced and consistent trends in reduced inflammation were seen during treatment but were not sustained once treatment ended. SUMMARY: This single centre study closed prematurely and therefore data interpretation is of necessity limited. No clinical benefit was demonstrated. However, biochemical data suggest that this intervention does have anti-inflammatory and anti-fibrotic effects..
Love, S.B.
Cafferty, F.
Snowdon, C.
Carty, K.
Savage, J.
Pallmann, P.
McParland, L.
Brown, L.
Masters, L.
Schiavone, F.
Hague, D.
Townsend, S.
Amos, C.
South, A.
Sturgeon, K.
Langley, R.
Maughan, T.
James, N.
Hall, E.
Kernaghan, S.
Bliss, J.
Turner, N.
Tutt, A.
Yap, C.
Firth, C.
Kong, A.
Mehanna, H.
Watts, C.
Hills, R.
Thomas, I.
Copland, M.
Bell, S.
Sebag-Montefiore, D.
Jones, R.
Parmar, M.K.
Sydes, M.R.
(2022). Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials,
Vol.23
(1),
p. 757.
show abstract
full text
BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. METHODS: Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. RESULTS: We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. DISCUSSION: Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently..
Snowdon, C.
Kernaghan, S.
Moretti, L.
Turner, N.C.
Ring, A.
Wilkinson, K.
Martin, S.
Foster, S.
Kilburn, L.S.
Bliss, J.M.
(2022). Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials,
Vol.23
(1),
p. 372.
show abstract
full text
BACKGROUND: Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these trial designs can be challenging to operationalise. The use of platform trials in oncology clinical research has increased considerably in recent years as advances in molecular biology enable molecularly defined stratification of patient populations and targeted therapy evaluation. Whereas multiple separate trials may be deemed infeasible, platform designs allow efficient, parallel evaluation of multiple targeted therapies in relatively small biologically defined patient sub-populations with the promise of increased molecular screening efficiency and reduced time for drug evaluation. Whilst the theoretical efficiencies are widely reported, the operational challenges associated with these designs (complexity, cost, regulatory, resource) are not always well understood. MAIN: In this commentary, we describe our practical experience of the implementation and delivery of the UK plasmaMATCH trial, a platform trial in advanced breast cancer, comprising an integrated screening component and multiple parallel downstream mutation-directed therapeutic cohorts. plasmaMATCH reported its primary results within 3 years of opening to recruitment. We reflect on the operational challenges encountered and share lessons learnt to inform the successful conduct of future trials. Key to the success of the plasmaMATCH trial was well co-ordinated stakeholder engagement by an experienced clinical trials unit with expert methodology and trial management expertise, a federated model of clinical leadership, a well-written protocol integrating screening and treatment components and including justification for the chosen structure and intentions for future adaptions, and an integrated funding model with streamlined contractual arrangements across multiple partners. Findings based on our practical experience include the importance of early engagement with the regulators and consideration of a flexible resource infrastructure to allow adequate resource allocation to support concurrent trial activities as adaptions are implemented in parallel to the continued management of patient safety and data quality of the ongoing trial cohorts. CONCLUSION: Platform trial designs allow the efficient reporting of multiple treatment cohorts. Operational challenges can be overcome through multidisciplinary engagement, streamlined contracting processes, rationalised protocol and database design and appropriate resourcing..
Bergamino, M.A.
López-Knowles, E.
Morani, G.
Tovey, H.
Kilburn, L.
Schuster, E.F.
Alataki, A.
Hills, M.
Xiao, H.
Holcombe, C.
Skene, A.
Robertson, J.F.
Smith, I.E.
Bliss, J.M.
Dowsett, M.
Cheang, M.C.
POETIC investigators,
(2022). HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. Ebiomedicine,
Vol.83,
p. 104205.
show abstract
full text
BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+ tumours are poorly characterised. Our aim was to identify biomarkers of response to 2 weeks' presurgical AI treatment in ER+/HER2+ BCs. METHODS: All available ER+/HER2+ BC baseline tumours (n=342) in the POETIC trial were gene expression profiled using BC360™ (NanoString) covering intrinsic subtypes and 46 key biological signatures. Early response to AI was assessed by changes in Ki67 expression and residual Ki67 at 2 weeks (Ki672wk). Time-To-Recurrence (TTR) was estimated using Kaplan-Meier methods and Cox models adjusted for standard clinicopathological variables. New molecular subgroups (MS) were identified using consensus clustering. FINDINGS: HER2-enriched (HER2-E) subtype BCs (44.7% of the total) showed poorer Ki67 response and higher Ki672wk (p<0.0001) than non-HER2-E BCs. High expression of ERBB2 expression, homologous recombination deficiency (HRD) and TP53 mutational score were associated with poor response and immune-related signatures with High Ki672wk. Five new MS that were associated with differential response to AI were identified. HER2-E had significantly poorer TTR compared to Luminal BCs (HR 2.55, 95% CI 1.14-5.69; p=0.0222). The new MS were independent predictors of TTR, adding significant value beyond intrinsic subtypes. INTERPRETATION: Our results show HER2-E as a standardised biomarker associated with poor response to AI and worse outcome in ER+/HER2+. HRD, TP53 mutational score and immune-tumour tolerance are predictive biomarkers for poor response to AI. Lastly, novel MS identify additional non-HER2-E tumours not responding to AI with an increased risk of relapse. FUNDING: Cancer Research UK (CRUK/07/015)..
Bachelot, T.
Cottu, P.
Chabaud, S.
Dalenc, F.
Allouache, D.
Delaloge, S.
Jacquin, J.-.
Grenier, J.
Venat Bouvet, L.
Jegannathen, A.
Campone, M.
Del Piano, F.
Debled, M.
Hardy-Bessard, A.-.
Giacchetti, S.
Mouret-Reynier, M.-.
Barthelemy, P.
Kaluzinski, L.
Mailliez, A.
Legouffe, E.
Sephton, M.
Bliss, J.
Canon, J.-.
Penault-Llorca, F.
Lemonnier, J.
Cameron, D.
Andre, F.
(2022). Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. J clin oncol,
Vol.40
(32),
pp. 3699-3708.
show abstract
full text
PURPOSE: Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor-resistant metastatic breast cancer. However, the benefit of adding everolimus to ET in the adjuvant setting in early breast cancer is unknown. PATIENTS AND METHODS: In this randomized double-blind phase III study, women with high-risk, hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer were randomly assigned to everolimus or placebo for 2 years combined with standard ET. Stratification factors included ET agent, receipt of neoadjuvant versus adjuvant chemotherapy, progesterone receptor status, duration of ET before random assignment, and lymph node involvement. The primary end point was disease-free survival (DFS). The trial is registered with ClinicalTrials.gov (identifier: NCT01805271). RESULTS: Between June 2013 and March 2020, 1,278 patients were randomly allocated to receive everolimus or placebo. At the first interim analysis, the trial was stopped for futility and a full analysis undertaken once data snapshot complete. One hundred forty-seven patients have had a DFS event reported and at 3 years, DFS did not differ between patients who received ET plus everolimus (88% [95% CI, 85 to 91]) or ET plus placebo (89% [95% CI, 86 to 91; hazard ratio, 0.95; 95% CI, 0.69 to 1.32; P = .77]). Grade ≥ 3 adverse events were reported in 22.9% of patients (29.9% with everolimus v 15.9% with placebo, P < .001). 53.4% everolimus-treated patients permanently discontinued experimental treatment early compared with placebo-treated 22.3%. CONCLUSION: Among high-risk patients, everolimus added to adjuvant ET did not improve DFS. Tolerability was a concern, with more than half of patients stopping everolimus before study completion. Everolimus cannot be recommended in the adjuvant setting..
Lopez-Knowles, E.
Detre, S.
Hills, M.
Schuster, E.F.
Cheang, M.C.
Tovey, H.
Kilburn, L.S.
Bliss, J.M.
Robertson, J.
Mallon, E.
Skene, A.
Evans, A.
Smith, I.
Dowsett, M.
(2022). Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study. Breast cancer res,
Vol.24
(1),
p. 61.
show abstract
full text
BACKGROUND: In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of < 1% (negative) and 1-10% (low) cells positive. There is uncertainty whether patients with ER low tumours benefit from endocrine therapy. We aimed to assess IHC and mRNA cut-points for ER versus biological response of primary breast cancer to 2 weeks' aromatase inhibitor treatment as measured by change in Ki67. METHODS: Cases were selected from the aromatase inhibitor treatment group of POETIC. We selected the 15% with the poorest Ki67 response (PR, < 40% Ki67 suppression, n = 230) and a random 30% of the remainder categorised as intermediate (IR, 40-79% Ki67 suppression, n = 150) and good-responders (GR, ≥ 80% Ki67 suppression, n = 230) from HER2 - group. All HER2 + cases available were selected irrespective of their response category (n = 317). ER expression was measured by IHC and qPCR. RESULTS: ER IHC was available from 515 HER2 - and 186 HER2 + tumours and ER qPCR from 367 HER2 - and 171 HER2 + tumours. Ninety-one percentage of patients with ER IHC < 10% were PRs with similar rates in HER2 - and HER2 + cases. At or above ER IHC 10% substantial numbers of patients showed IR or GR. Similar proportions of patients were defined by cut-points of ER IHC < 10% and ER mRNA < 5 units. In addition, loss of PgR expression altered ER anti-proliferation response with 92% of PgR - cases with ER IHC < 40% being PRs. CONCLUSIONS: There was little responsiveness at IHC < 10% and no distinction between < 1% and 1-10% cells positive. Similar separation of PRs from IR/GRs was achieved by IHC and mRNA..
Geyer, C.E.
Garber, J.E.
Gelber, R.D.
Yothers, G.
Taboada, M.
Ross, L.
Rastogi, P.
Cui, K.
Arahmani, A.
Aktan, G.
Armstrong, A.C.
Arnedos, M.
Balmaña, J.
Bergh, J.
Bliss, J.
Delaloge, S.
Domchek, S.M.
Eisen, A.
Elsafy, F.
Fein, L.E.
Fielding, A.
Ford, J.M.
Friedman, S.
Gelmon, K.A.
Gianni, L.
Gnant, M.
Hollingsworth, S.J.
Im, S.-.
Jager, A.
Jóhannsson, Ó.Þ.
Lakhani, S.R.
Janni, W.
Linderholm, B.
Liu, T.-.
Loman, N.
Korde, L.
Loibl, S.
Lucas, P.C.
Marmé, F.
Martinez de Dueñas, E.
McConnell, R.
Phillips, K.-.
Piccart, M.
Rossi, G.
Schmutzler, R.
Senkus, E.
Shao, Z.
Sharma, P.
Singer, C.F.
Španić, T.
Stickeler, E.
Toi, M.
Traina, T.A.
Viale, G.
Zoppoli, G.
Park, Y.H.
Yerushalmi, R.
Yang, H.
Pang, D.
Jung, K.H.
Mailliez, A.
Fan, Z.
Tennevet, I.
Zhang, J.
Nagy, T.
Sonke, G.S.
Sun, Q.
Parton, M.
Colleoni, M.A.
Schmidt, M.
Brufsky, A.M.
Razaq, W.
Kaufman, B.
Cameron, D.
Campbell, C.
Tutt, A.N.
OlympiA Clinical Trial Steering Committee and Investigators,
(2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann oncol,
Vol.33
(12),
pp. 1250-1268.
show abstract
full text
BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS: One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS: With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION: With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals..
Bergamino, M.A.
Morani, G.
Parker, J.
Schuster, E.F.
Leal, M.F.
López-Knowles, E.
Tovey, H.
Bliss, J.M.
Robertson, J.F.
Smith, I.E.
Dowsett, M.
Cheang, M.C.
(2022). Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers. Clin cancer res,
Vol.28
(6),
pp. 1217-1228.
show abstract
full text
PURPOSE: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still unknown. We evaluated and compared changes of gene expression profiles under short-term (2-week) versus longer-term neoadjuvant AIs. EXPERIMENTAL DESIGN: Global gene expression profiles from the PeriOperative Endocrine Therapy for Individualised Care (POETIC) trial (137 received 2 weeks of AIs and 47 received no treatment) and targeted gene expression from 80 patients with breast cancer treated with NET for more than 1 month (NeoAI) were assessed. Intrinsic subtyping, module scores covering different cancer pathways and immune-related genes were calculated for pretreated and posttreated tumors. RESULTS: The differences in intrinsic subtypes after NET were comparable between the two cohorts, with most Luminal B (90.0% in the POETIC trial and 76.3% in NeoAI) and 50.0% of HER2 enriched at baseline reclassified as Luminal A or normal-like after NET. Downregulation of proliferative-related pathways was observed after 2 weeks of AIs. However, more changes in genes from cancer-signaling pathways such as MAPK and PI3K/AKT/mTOR and immune response/immune-checkpoint components that were associated with AI-resistant tumors and differential outcome were observed in the NeoAI study. CONCLUSIONS: Tumor transcriptional profiles undergo bigger changes in response to longer NET. Changes in HER2-enriched and Luminal B subtypes are similar between the two cohorts, thus AI-sensitive intrinsic subtype tumors associated with good survival might be identified after 2 weeks of AI. The changes of immune-checkpoint component expression in early AI resistance and its impact on survival outcome warrants careful investigation in clinical trials..
Agostinetto, E.
Ameye, L.
Martel, S.
Aftimos, P.
Pondé, N.
Maurer, C.
El-Abed, S.
Wang, Y.
Vicente, M.
Chumsri, S.
Bliss, J.
Kroep, J.
Colleoni, M.
Petrelli, F.
Del Mastro, L.
Moreno-Aspitia, A.
Piccart, M.
Paesmans, M.
de Azambuja, E.
Lambertini, M.
(2022). PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. Npj breast cancer,
Vol.8
(1),
p. 87.
show abstract
full text
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic performance using data extracted from ALTTO, a phase III trial evaluating adjuvant lapatinib ± trastuzumab vs. trastuzumab alone in patients with HER2-positive EBC. Our analysis included 2794 patients. After a median follow-up of 6.0 years (IQR, 5.8-6.7), 182 deaths were observed. Overall, PREDICT underestimated 5-year OS by 6.7% (95% CI, 5.8-7.6): observed 5-year OS was 94.7% vs. predicted 88.0%. The underestimation was consistent across all subgroups, including those according to the type of anti HER2-therapy. The highest absolute differences were observed for patients with hormone receptor negative-disease, nodal involvement, and large tumor size (13.0%, 15.8%, and 15.3%, respectively). AUC under the ROC curve was 73.7% (95% CI 69.7-77.8) in the overall population, ranging between 61.7% and 77.7% across the analyzed subgroups. In conclusion, our analysis showed that PREDICT highly underestimated OS in HER2-positive EBC. Hence, it should be used with caution to give prognostic estimation to HER2-positive EBC patients treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies..
Gnant, M.
Dueck, A.C.
Frantal, S.
Martin, M.
Burstein, H.J.
Greil, R.
Fox, P.
Wolff, A.C.
Chan, A.
Winer, E.P.
Pfeiler, G.
Miller, K.D.
Colleoni, M.
Suga, J.M.
Rubovsky, G.
Bliss, J.M.
Mayer, I.A.
Singer, C.F.
Nowecki, Z.
Hahn, O.
Thomson, J.
Wolmark, N.
Amillano, K.
Rugo, H.S.
Steger, G.G.
Hernando Fernández de Aránguiz, B.
Haddad, T.C.
Perelló, A.
Bellet, M.
Fohler, H.
Metzger Filho, O.
Jallitsch-Halper, A.
Solomon, K.
Schurmans, C.
Theall, K.P.
Lu, D.R.
Tenner, K.
Fesl, C.
DeMichele, A.
Mayer, E.L.
PALLAS groups and investigators,
(2022). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J clin oncol,
Vol.40
(3),
pp. 282-293.
show abstract
full text
PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer-free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer..
Goodwin, P.J.
Chen, B.E.
Gelmon, K.A.
Whelan, T.J.
Ennis, M.
Lemieux, J.
Ligibel, J.A.
Hershman, D.L.
Mayer, I.A.
Hobday, T.J.
Bliss, J.M.
Rastogi, P.
Rabaglio-Poretti, M.
Mukherjee, S.D.
Mackey, J.R.
Abramson, V.G.
Oja, C.
Wesolowski, R.
Thompson, A.M.
Rea, D.W.
Stos, P.M.
Shepherd, L.E.
Stambolic, V.
Parulekar, W.R.
(2022). Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA 32 Randomized Clinical Trial. Jama,
Vol.327
(20),
pp. 1963-1973.
show abstract
full text
IMPORTANCE: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. OBJECTIVE: To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes. DESIGN, SETTING, AND PARTICIPANTS: MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020. INTERVENTIONS: Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2, formerly HER2 or HER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years. MAIN OUTCOMES AND MEASURES: The primary outcome was invasive disease-free survival in hormone receptor-positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse-free survival, and breast cancer-free interval were analyzed. RESULTS: Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR-, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease-free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease-free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21; P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41; P = .47). Among patients who were ER/PgR-, followed up for a median of 94.1 months, incidence of invasive disease-free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30; P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively, P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%). CONCLUSIONS AND RELEVANCE: Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01101438..
Sipos, O.
Tovey, H.
Quist, J.
Haider, S.
Nowinski, S.
Gazinska, P.
Kernaghan, S.
Toms, C.
Maguire, S.
Orr, N.
Linn, S.C.
Owen, J.
Gillett, C.
Pinder, S.E.
Bliss, J.M.
Tutt, A.
Cheang, M.C.
Grigoriadis, A.
(2021). Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. Ann oncol,
Vol.32
(1),
pp. 58-65.
show abstract
full text
BACKGROUND: In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider patient subgroup within TNT with preferential benefit from carboplatin over docetaxel. PATIENTS AND METHODS: Copy number aberrations (CNAs) were established from 135 formalin-fixed paraffin-embedded primary carcinomas using Illumina OmniExpress SNP-arrays. Seven published [allelic imbalanced CNA (AiCNA); allelic balanced CNA (AbCNA); copy number neutral loss of heterozygosity (CnLOH); number of telomeric allelic imbalances (NtAI); BRCA1-like status; percentage of genome altered (PGA); homologous recombination deficiency (HRD) scores] and two novel [Shannon diversity index (SI); high-level amplifications (HLAMP)] CIN-measurements were derived. HLAMP was defined based on the presence of at least one of the top 5% amplified cytobands located on 1q, 8q and 10p. Continuous CIN-measurements were divided into tertiles. All nine CIN-measurements were used to analyse objective response rate (ORR) and progression-free survival (PFS). RESULTS: Patients with tumours without HLAMP had a numerically higher ORR and significantly longer PFS in the carboplatin (C) than in the docetaxel (D) arm [56% (C) versus 29% (D), PHLAMP,quiet = 0.085; PFS 6.1 months (C) versus 4.1 months (D), Pinteraction/HLAMP = 0.047]. In the carboplatin arm, patients with tumours showing intermediate telomeric NtAI and AiCNA had higher ORR [54% (C) versus 20% (D), PNtAI,intermediate = 0.03; 62% (C) versus 33% (D), PAiCNA,intermediate = 0.076]. Patients with high AiCNA and PGA had shorter PFS in the carboplatin arm [3.4 months (high) versus 5.7 months (low/intermediate); and 3.8 months (high) versus 5.6 months (low/intermediate), respectively; Pinteraction/AiCNA = 0.027, Padj.interaction/AiCNA = 0.125 and Pinteraction/PGA = 0.053, Padj.interaction/PGA = 0.176], whilst no difference was observed in the docetaxel arm. CONCLUSIONS: Patients with tumours lacking HLAMP and demonstrating intermediate CIN-measurements formed a subgroup benefitting from carboplatin relative to docetaxel treatment within the TNT trial. This suggests a complex and paradoxical relationship between the extent of genomic instability in primary tumours and treatment response in the metastatic setting..
Coombes, R.C.
Tovey, H.
Kilburn, L.
Mansi, J.
Palmieri, C.
Bartlett, J.
Hicks, J.
Makris, A.
Evans, A.
Loibl, S.
Denkert, C.
Murray, E.
Grieve, R.
Coleman, R.
Borley, A.
Schmidt, M.
Rautenberg, B.
Kunze, C.A.
Rhein, U.
Mehta, K.
Mousa, K.
Dibble, T.
Lu, X.L.
von Minckwitz, G.
Bliss, J.M.
Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators,
(2021). Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. Jama oncol,
Vol.7
(9),
pp. 1291-1301.
show abstract
full text
IMPORTANCE: Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. OBJECTIVE: To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The Randomized European Celecoxib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing 2 years of adjuvant celecoxib vs placebo among 2639 patients recruited between January 19, 2007, and November 1, 2012, with follow-up 10 years after treatment completion. Eligible patients had completely resected breast cancer with local and systemic therapy according to local practice. Patients with ERBB2-positive or node-negative and T1, grade 1 tumors were not eligible. Randomization was in a 2:1 ratio between celecoxib or placebo. Statistical analysis was performed from May 5, 2019, to March 5, 2020. INTERVENTIONS: Patients received celecoxib, 400 mg, or placebo once daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population using Cox proportional hazards regression and log-rank analysis. Follow-up is complete. RESULTS: A total of 2639 patients (median age, 55.2 years [range, 26.8-86.0 years]) were recruited; 1763 received celecoxib, and 876 received placebo. Most patients' tumors (1930 [73%]) were estrogen receptor positive or progesterone receptor positive and ERBB2 negative. A total of 1265 patients (48%) had node-positive disease, and 1111 (42%) had grade 3 tumors. At a median follow-up of 74.3 months (interquartile range, 61.4-93.6 years), DFS events had been reported for 487 patients (19%): 18% for those who received celecoxib (n = 323; 5-year DFS rate = 84%) vs 19% for those who received placebo (n = 164; 5-year DFS rate = 83%); the unadjusted hazard ratio was 0.97 (95% CI, 0.80-1.17; log-rank P = .75). Rates of toxic effects were low across both treatment groups, with no evidence of a difference. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, patients showed no evidence of a DFS benefit for 2 years' treatment with celecoxib compared with placebo as adjuvant treatment of ERBB2-negative breast cancer. Longer-term treatment or use of a higher dose of celecoxib may lead to a DFS benefit, but further studies would be required to test this possibility. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02429427 and isrctn.org Identifier: ISRCTN48254013..
Obeng-Gyasi, S.
Coles, C.E.
Jones, J.
Sacks, R.
Lightowlers, S.
Bliss, J.M.
Brunt, A.M.
Haviland, J.S.
Kirby, A.M.
Kalinsky, K.
(2021). When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. Am soc clin oncol educ book,
Vol.41,
pp. 1-11.
show abstract
In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant therapy, such as monitoring for response, as well as an increased rate of breast conservation and reduction of potential morbidity associated with breast surgery, including axillary management. Among patients with highly proliferative tumors, such as HER2-positive or triple-negative breast cancer, those with residual disease are at higher risk of recurrence, which informs the recommended systemic therapy in the adjuvant setting. For instance, in patients with residual disease after neoadjuvant chemotherapy and HER2-targeted therapy, there is a role for adjuvant trastuzumab emtansine for those with residual disease at the time of surgery. The same holds true regarding the role of adjuvant capecitabine in patients with residual disease after neoadjuvant chemotherapy. With the added complexities of treating patients in the era of the COVID-19 outbreak, additional considerations are critical, including initiation of surgery within an appropriate time from completion of neoadjuvant therapy. National consensus guidelines on time to surgery must be developed to improve measurement and comparison across systems. In addition, there is emerging radiation treatment management research addressing a number of factors, including hypofractionation, role of proton beam therapy, safe omission of radiotherapy, and preoperative radiotherapy with or without drug combination. In this article, the multidisciplinary approach of treating patients with operable breast cancer is highlighted, with updates and future considerations described..
Brunt, A.M.
Haviland, J.S.
Kirby, A.M.
Somaiah, N.
Wheatley, D.A.
Bliss, J.M.
Yarnold, J.R.
(2021). Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clin oncol (r coll radiol),
Vol.33
(7),
pp. 430-439.
show abstract
full text
INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule. IPSILATERAL BREAST TUMOUR RELAPSE (IBTR): Published estimated 5-year IBTR with 95% CI after 40 Gy in 15 fractions was 2.1% (95% CI 1.4-3.1), 1.7% (1.2-1.6) after 27 Gy and 1.4% (0.2-2.2) after 26 Gy, emphatically showing non-inferiority of the 5-fraction regimens. Subgroup analyses comparing IBTR in 26 Gy versus 40 Gy show no evidence of differential effect regarding age, grade, pathological tumour size, nodal status, tumour bed boost, adjuvant chemotherapy, HER2 status and triple negative status. The number of events in these analyses is small and results should be interpreted with caution. There was only 1 IBTR event post-mastectomy. NORMAL TISSUE EFFECTS: The 26 Gy schedule, on the basis of similar NTE to 40 Gy in 15 fractions, is the recommended regimen for clinical implementation. There is a low absolute rate of moderate/marked NTE, these are predominantly moderate not severe change. Subgroup analyses comparing clinician-assessed moderate or marked adverse effect for 26 Gy versus 40 Gy show no evidence of differential effects according to age, breast size, surgical deficit, tumour bed boost, or adjuvant chemotherapy. RADIOBIOLOGICAL CONSIDERATIONS: The design of the FAST-Forward trial does not control for time-related effects, and the ability to interpret clinical outcomes in terms of underlying biology is limited. There could conceivably be a time-effect for tumour control. A slight reduction in α/β estimate for the late normal tissue effects of test regimens might be a chance effect, but if real could reflect fewer consequential late effects due to lower rates of moist desquamation. CONCLUSION: The 26 Gy 5-fraction daily regimen for breast radiotherapy can be implemented now..
Early Breast Cancer Trialists’ Collaborative group (EBCTCG),
(2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet oncol,
Vol.22
(8),
pp. 1139-1150.
show abstract
full text
BACKGROUND: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. METHODS: We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs). FINDINGS: Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between February, 2000, and December, 2005. Mean scheduled treatment duration was 14·4 months and median follow-up was 10·7 years (IQR 9·5 to 11·9). The risks of breast cancer recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001) and death from breast cancer (0·67, 0·61 to 0·73; p<0·0001) were lower with trastuzumab plus chemotherapy than with chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9·0% (95% CI 7·4 to 10·7; p<0·0001) and 10-year breast cancer mortality was reduced by 6·4% (4·9 to 7·8; p<0·0001), with a 6·5% reduction (5·0 to 8·0; p<0·0001) in all-cause mortality, and no increase in death without recurrence (0·4%, -0·3 to 1·1; p=0·35). The proportional reduction in recurrence was largest in years 0-1 after randomisation (0·53, 99% CI 0·46 to 0·61), with benefits persisting through years 2-4 (0·73, 0·62 to 0·85) and 5-9 (0·80, 0·64 to 1·01), and little follow-up beyond year 10. Proportional recurrence reductions were similar irrespective of recorded patient and tumour characteristics, including ER status. The more high risk the tumour, the larger the absolute reductions in 5-year recurrence (eg, 5·7% [95% CI 3·1 to 8·3], 6·8% [4·7 to 9·0], and 10·7% [7·7 to 13·6] in N0, N1-3, and N4+ disease). INTERPRETATION: Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded patient and tumour characteristics. FUNDING: Cancer Research UK, UK Medical Research Council..
Aftimos, P.
Oliveira, M.
Irrthum, A.
Fumagalli, D.
Sotiriou, C.
Gal-Yam, E.N.
Robson, M.E.
Ndozeng, J.
Di Leo, A.
Ciruelos, E.M.
de Azambuja, E.
Viale, G.
Scheepers, E.D.
Curigliano, G.
Bliss, J.M.
Reis-Filho, J.S.
Colleoni, M.
Balic, M.
Cardoso, F.
Albanell, J.
Duhem, C.
Marreaud, S.
Romagnoli, D.
Rojas, B.
Gombos, A.
Wildiers, H.
Guerrero-Zotano, A.
Hall, P.
Bonetti, A.
Larsson, K.F.
Degiorgis, M.
Khodaverdi, S.
Greil, R.
Sverrisdóttir, Á.
Paoli, M.
Seyll, E.
Loibl, S.
Linderholm, B.
Zoppoli, G.
Davidson, N.E.
Johannsson, O.T.
Bedard, P.L.
Loi, S.
Knox, S.
Cameron, D.A.
Harbeck, N.
Montoya, M.L.
Brandão, M.
Vingiani, A.
Caballero, C.
Hilbers, F.S.
Yates, L.R.
Benelli, M.
Venet, D.
Piccart, M.J.
(2021). Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer discov,
Vol.11
(11),
pp. 2796-2811.
show abstract
full text
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA, and RB1 mutations; MDM4 and MYC amplifications; and ARID1A deletions. An increase in clonality was observed in driver genes such as ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune-permissive cells. High tumor mutational burden correlated to shorter time to relapse in HR+/HER2- cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could affect treatment strategies in MBC. SIGNIFICANCE: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic samples from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients.This article is highlighted in the In This Issue feature, p. 2659..
Banerjee, S.
Stewart, J.
Porta, N.
Toms, C.
Leary, A.
Lheureux, S.
Khalique, S.
Tai, J.
Attygalle, A.
Vroobel, K.
Lord, C.J.
Natrajan, R.
Bliss, J.
(2021). ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int j gynecol cancer,
Vol.31
(11),
pp. 1471-1475.
show abstract
full text
BACKGROUND: ARID1A (AT-rich interactive domain containing protein 1A) loss-of-function mutations have been reported in gynecological cancers, including rarer subtypes such as clear cell carcinoma. Preclinical studies indicate that ARID1A mutant cancers display sensitivity to ATR inhibition while tumors without ARID1A mutations may be sensitive to Ataxia telangiectasia and Rad3 related (ATR) inhibitors in combination with poly-ADP ribose polymerase (PARP) inhibitors. PRIMARY OBJECTIVE: To determine whether the ATR inhibitor, ceralasertib, has clinical activity as a single agent and in combination with the PARP inhibitor, olaparib, in patients with ARID1A 'loss' and 'no loss' clear cell carcinomas and other relapsed gynecological cancers. STUDY HYPOTHESIS: ARID1A deficient clear cell carcinoma of the ovary or endometrium is sensitive to ATR inhibition, while the combination of ATR and PARP inhibition has activity in other gynecological tumors, irrespective of ARID1A status. TRIAL DESIGN: ATARI (ENGOT/GYN1/NCRI) is a multicenter, international, proof-of-concept, phase II, parallel cohort trial assessing ceralasertib activity as a single agent and in combination with olaparib in ARID1A stratified gynecological cancers. Patients with relapsed ovarian/endometrial clear cell carcinoma with ARID1A loss will receive ceralasertib monotherapy (cohort 1A). Relapsed ovarian/endometrial clear cell carcinoma patients with no ARID1A loss (cohort 2) or patients with other histological subtypes (endometrioid, carcinosarcoma, cervical) (cohort 3) will receive combination therapy (olaparib/ceralasertib). Treatment will continue until disease progression. MAJOR INCLUSION/EXCLUSION CRITERIA: Patients with histologically confirmed recurrent clear cell (ovarian, endometrial, or endometriosis related), endometrioid (ovarian, endometrial, or endometriosis related), cervical (adenocarcinomas or squamous), or carcinosarcomas (ovarian or endometrial) are eligible. Patients progressing after ≥1 prior platinum with evidence of measurable (RECIST v1.1) radiological disease progression since last systemic anticancer therapy and prior to trial entry are eligible. Previous ATR or PARP inhibitor treatment is not permissible. PRIMARY ENDPOINT: Best overall objective response rate (RECIST v1.1). SAMPLE SIZE: A minimum of 40 and a maximum of 116. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Accrual is anticipated to be complete by the second quarter of 2022, with reporting of results by the fourth quarter of 2022. Overall accrual targets and reporting timelines are dependent on individual cohort progression to stage 2. TRIAL REGISTRATION NUMBER: NCT0405269..
Robertson, J.F.
Di Leo, A.
Johnston, S.
Chia, S.
Bliss, J.M.
Paridaens, R.J.
Lichfield, J.
Bradbury, I.
Campbell, C.
(2021). Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. Npj breast cancer,
Vol.7
(1),
p. 11.
show abstract
full text
Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of ET in patients with visceral metastases (VM) versus patients whose disease is limited to non-visceral metastases (non-VM) is debated. Meta-analyses including available data from randomised controlled trials of first- and second-line endocrine monotherapies for patients with HR+ ABC were performed to address this question. In one and two-stage meta-analyses, progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and duration of clinical benefit (DoCB) outcomes were analysed. In the first-line meta-analysis (seven trials; n = 1988) tamoxifen and fulvestrant significantly improved PFS, OS and CBR for patients with non-VM versus those whose disease included VM. The most substantial hazard ratios were observed for fulvestrant 500 mg; 0.56 (95% confidence interval [CI] 0.45-0.70) and 0.55 (95% CI 0.42-0.72) for PFS and OS, respectively. In the second-line meta-analysis (seven trials; n = 2324), all ET combined was more effective (in terms of PFS, OS and DoCB) for non-VM versus VM. In both meta-analyses, patients with non-liver VM had better clinical outcomes than patients with liver VM for all types of ET. Patients whose disease included non-VM sites had better clinical outcomes with endocrine monotherapy compared with patients whose disease included VM. These findings may facilitate better informed treatment decision-making..
Bhattacharya, I.S.
Haviland, J.S.
Turner, L.
Stobart, H.
Balasopoulou, A.
Stones, L.
Kirby, A.M.
Kirwan, C.C.
Coles, C.E.
Bliss, J.M.
PRIMETIME Trialists,
(2021). Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design. Trials,
Vol.22
(1),
p. 397.
show abstract
full text
BACKGROUND: For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional conflict), which may be lessened with patient decision aids (PDA). PRIMETIME (ISRCTN 41579286) is a UK-led biomarker-directed study evaluating omission of adjuvant radiotherapy in breast cancer; an embedded Study Within A Trial (SWAT) investigated whether PDA reduces decisional conflict using a cluster stepped-wedge trial design. METHODS: PDA diagrams and a video explaining risks and benefits of radiotherapy were developed in close collaboration between patient advocates and PRIMETIME trialists. The SWAT used a cluster stepped-wedge trial design, where each cluster represented the radiotherapy centre and referring peripheral centres. All clusters began in the standard information group (patient information and diagrams) and were randomised to cross-over to the enhanced information group (standard information plus video) at 2, 4 or 6 months. Primary endpoint was the decisional conflict scale (0-100, higher scores indicating greater conflict) which was assessed on an individual participant level. Multilevel mixed effects models used a random effect for cluster and a fixed effect for each step to adjust for calendar time and clustering. Robust standard errors were also adjusted for the clustering effect. RESULTS: Five hundred twenty-one evaluable questionnaires were returned from 809 eligible patients (64%) in 24 clusters between April 2018 and October 2019. Mean decisional conflict scores in the standard group (N = 184) were 10.88 (SD 11.82) and 8.99 (SD 11.82) in the enhanced group (N = 337), with no statistically significant difference [mean difference - 1.78, 95%CI - 3.82-0.25, p = 0.09]. Compliance with patient information and diagrams was high in both groups although in the enhanced group only 121/337 (36%) reported watching the video. CONCLUSION: The low levels of decisional conflict in PRIMETIME are reassuring and may reflect the high-quality information provision, such that not everyone required the video. This reinforces the importance of working with patients as partners in clinical trials especially in the development of patient-centred information and decision aids..
Tolaney, S.M.
Garrett-Mayer, E.
White, J.
Blinder, V.S.
Foster, J.C.
Amiri-Kordestani, L.
Hwang, E.S.
Bliss, J.M.
Rakovitch, E.
Perlmutter, J.
Spears, P.A.
Frank, E.
Tung, N.M.
Elias, A.D.
Cameron, D.
Denduluri, N.
Best, A.F.
DiLeo, A.
Baizer, L.
Butler, L.P.
Schwartz, E.
Winer, E.P.
Korde, L.A.
(2021). Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2 0. J clin oncol,
Vol.39
(24),
pp. 2720-2731.
show abstract
full text
PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvements in outcomes, a panel of experts reviewed the STEEP criteria to determine whether modifications are needed. METHODS: We conducted systematic searches of ClinicalTrials.gov for adjuvant systemic and local-regional therapy trials for breast cancer to investigate if the primary end points reported met STEEP criteria. On the basis of common STEEP deviations, we performed a series of simulations to evaluate the effect of excluding non-breast cancer deaths and new nonbreast primary cancers from the invasive disease-free survival end point. RESULTS: Among 11 phase III breast cancer trials with primary efficacy end points, three had primary end points that followed STEEP criteria, four used STEEP definitions but not the corresponding end point names, and four used end points that were not included in the original STEEP manuscript. Simulation modeling demonstrated that inclusion of second nonbreast primary cancer can increase the probability of incorrect inferences, can decrease power to detect clinically relevant efficacy effects, and may mask differences in recurrence rates, especially when recurrence rates are low. CONCLUSION: We recommend an additional end point, invasive breast cancer-free survival, which includes all invasive disease-free survival events except second nonbreast primary cancers. This end point should be considered for trials in which the toxicities of agents are well-known and where the risk of second primary cancer is small. Additionally, we provide end point recommendations for local therapy trials, low-risk populations, noninferiority trials, and trials incorporating patient-reported outcomes..
Kingston, B.
Cutts, R.J.
Bye, H.
Beaney, M.
Walsh-Crestani, G.
Hrebien, S.
Swift, C.
Kilburn, L.S.
Kernaghan, S.
Moretti, L.
Wilkinson, K.
Wardley, A.M.
Macpherson, I.R.
Baird, R.D.
Roylance, R.
Reis-Filho, J.S.
Hubank, M.
Faull, I.
Banks, K.C.
Lanman, R.B.
Garcia-Murillas, I.
Bliss, J.M.
Ring, A.
Turner, N.C.
(2021). Genomic profile of advanced breast cancer in circulating tumour DNA. Nat commun,
Vol.12
(1),
p. 2423.
show abstract
full text
The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating tumour DNA sequencing to interrogate the genomic profile of ABC in 800 patients in the plasmaMATCH trial. We demonstrate diverse subclonal resistance mutations, including enrichment of HER2 mutations in HER2 positive disease, co-occurring ESR1 and MAP kinase pathway mutations in HR + HER2- disease that associate with poor overall survival (p = 0.0092), and multiple PIK3CA mutations in HR + disease that associate with short progression free survival on fulvestrant (p = 0.0036). The fraction of cancer with a mutation, the clonal dominance of a mutation, varied between genes, and within hotspot mutations of ESR1 and PIK3CA. In ER-positive breast cancer subclonal mutations were enriched in an APOBEC mutational signature, with second hit PIK3CA mutations acquired subclonally and at sites characteristic of APOBEC mutagenesis. This study utilises circulating tumour DNA analysis in a large clinical trial to demonstrate the subclonal diversification of pre-treated advanced breast cancer, identifying distinct mutational processes in advanced ER-positive breast cancer, and novel therapeutic opportunities..
Turner, N.C.
Swift, C.
Kilburn, L.
Fribbens, C.
Beaney, M.
Garcia-Murillas, I.
Budzar, A.U.
Robertson, J.F.
Gradishar, W.
Piccart, M.
Schiavon, G.
Bliss, J.M.
Dowsett, M.
Johnston, S.R.
Chia, S.K.
(2020). ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clin cancer res,
Vol.26
(19),
pp. 5172-5177.
show abstract
full text
PURPOSE: ESR1 mutations are acquired frequently in hormone receptor-positive metastatic breast cancer after prior aromatase inhibitors. We assessed the clinical utility of baseline ESR1 circulating tumor DNA (ctDNA) analysis in the two phase III randomized trials of fulvestrant versus exemestane. EXPERIMENTAL DESIGN: The phase III EFECT and SoFEA trials randomized patients with hormone receptor-positive metastatic breast cancer who had progressed on prior nonsteroidal aromatase inhibitor therapy, between fulvestrant 250 mg and exemestane. Baseline serum samples from 227 patients in EFECT, and baseline plasma from 161 patients in SoFEA, were analyzed for ESR1 mutations by digital PCR. The primary objectives were to assess the impact of ESR1 mutation status on progression-free (PFS) and overall survival (OS) in a combined analysis of both studies. RESULTS: ESR1 mutations were detected in 30% (151/383) baseline samples. In patients with ESR1 mutation detected, PFS was 2.4 months [95% confidence interval (CI), 2.0-2.6] on exemestane and 3.9 months (95% CI, 3.0-6.0) on fulvestrant [hazard ratio (HR), 0.59; 95% CI, 0.39-0.89; P = 0.01). In patients without ESR1 mutations detected, PFS was 4.8 months (95% CI, 3.7-6.2) on exemestane and 4.1 months (95% CI, 3.6-5.5) on fulvestrant (HR, 1.05; 95% CI, 0.81-1.37; P = 0.69). There was an interaction between ESR1 mutation and treatment (P = 0.02). Patients with ESR1 mutation detected had 1-year OS of 62% (95% CI, 45%-75%) on exemestane and 80% (95% CI, 68%-87%) on fulvestrant (P = 0.04; restricted mean survival analysis). Patients without ESR1 mutations detected had 1-year OS of 79% (95% CI, 71%-85%) on exemestane and 81% (95% CI, 74%-87%) on fulvestrant (P = 0.69). CONCLUSIONS: Detection of ESR1 mutations in baseline ctDNA is associated with inferior PFS and OS in patients treated with exemestane versus fulvestrant..
Piccart, M.J.
Hilbers, F.S.
Bliss, J.M.
Caballero, C.
Frank, E.S.
Renault, P.
Naït Kaoudjt, R.
Schumacher, E.
Spears, P.A.
Regan, M.M.
Gelber, R.D.
Davidson, N.E.
Norton, L.
Winer, E.P.
BIG-NABCG Collaboration,
(2020). Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. J clin oncol,
Vol.38
(34),
pp. 4120-4129.
show abstract
full text
An important challenge in the field of cancer is finding the balance between delivering effective treatments and avoiding adverse effects and financial toxicity caused by innovative, yet expensive, drugs. To address this, several treatment de-escalation trials have been conducted, but only a few of these have provided clear answers. A few trials had poor accrual or had design flaws that led to conflicting results. Members of the Breast International Group (BIG) and North American Breast Cancer Group (NABCG) believe the way forward is to understand the lessons from these trials and listen more carefully to what truly matters to our patients. We reviewed several adjuvant trials of different cancer types and developed a road map for improving the design and implementation of future de-escalation trials. The road map incorporates patients' insights obtained through focused group discussions across the BIG-NABCG networks. Considerations for the development of de-escalation trials for systemic adjuvant treatment, including noninferiority trial design, choice of end points, and prioritization of a patient's perspectives, are presented in this consensus article..
Brunt, A.M.
Haviland, J.S.
Sydenham, M.
Agrawal, R.K.
Algurafi, H.
Alhasso, A.
Barrett-Lee, P.
Bliss, P.
Bloomfield, D.
Bowen, J.
Donovan, E.
Goodman, A.
Harnett, A.
Hogg, M.
Kumar, S.
Passant, H.
Quigley, M.
Sherwin, L.
Stewart, A.
Syndikus, I.
Tremlett, J.
Tsang, Y.
Venables, K.
Wheatley, D.
Bliss, J.M.
Yarnold, J.R.
(2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J clin oncol,
Vol.38
(28),
pp. 3261-3272.
show abstract
full text
PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented. METHODS: Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy. The primary end point was change in photographic breast appearance at 2 and 5 years; secondary end points were physician assessments of NTE and local tumor control. Odds ratios (ORs) from longitudinal analyses compared regimens. RESULTS: A total of 915 women were recruited from 18 UK centers (2004-2007). Five-year photographs were available for 615/862 (71%) eligible patients. ORs for change in photographic breast appearance were 1.64 (95% CI, 1.08 to 2.49; P = .019) for 30 Gy and 1.10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy. α/β estimate for photographic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr. ORs for any moderate/marked physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95% CI, 1.55 to 2.89; P < .001) for 30 Gy and 1.22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy. With 9.9 years median follow-up, 11 ipsilateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred. CONCLUSION: At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr. Results confirm the published 3-year findings that a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiobiologically comparable for NTE to a conventionally fractionated regimen..
Dowsett, M.
Ellis, M.J.
Dixon, J.M.
Gluz, O.
Robertson, J.
Kates, R.
Suman, V.J.
Turnbull, A.K.
Nitz, U.
Christgen, M.
Kreipe, H.
Kuemmel, S.
Bliss, J.M.
Barry, P.
Johnston, S.R.
Jacobs, S.A.
Ma, C.X.
Smith, I.E.
Harbeck, N.
(2020). Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. Npj breast cancer,
Vol.6
(1),
p. 21.
show abstract
full text
Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of patients who may have insufficiently endocrine-sensitive tumors and should be prioritised for early surgery or neoadjuvant chemotherapy rather than NeoET during or in the aftermath of the COVID-19 pandemic for safety or when surgical activity needs to be prioritized. For postmenopausal patients, our data provide strong support for the use of ER and PgR status at diagnosis for triaging of patients into three groups in which (taking into account clinical factors): (i) NeoET is likely to be inappropriate (Allred ER <6 or ER 6 and PgR <6) (ii) a biopsy for Ki67 analysis (on-treatment Ki67) could be considered after 2-4 weeks of NeoET (a: ER 7 or 8 and PgR <6 or b: ER 6 or 7 and PgR ≥6) or (iii) NeoET is an acceptable course of action (ER 8 and PgR ≥6). Cut-offs for percentage of cells positive are also given. For group (ii), a high early on-treatment level of Ki67 (>10%) indicates a higher priority for early surgery. Too few data were available for premenopausal patients to provide a similar treatment algorithm. These guidelines should be helpful for managing patients with early ER+ HER2- breast cancer during and in the aftermath of the COVID-19 crisis..
Turner, N.C.
Kingston, B.
Kilburn, L.S.
Kernaghan, S.
Wardley, A.M.
Macpherson, I.R.
Baird, R.D.
Roylance, R.
Stephens, P.
Oikonomidou, O.
Braybrooke, J.P.
Tuthill, M.
Abraham, J.
Winter, M.C.
Bye, H.
Hubank, M.
Gevensleben, H.
Cutts, R.
Snowdon, C.
Rea, D.
Cameron, D.
Shaaban, A.
Randle, K.
Martin, S.
Wilkinson, K.
Moretti, L.
Bliss, J.M.
Ring, A.
(2020). Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet oncol,
Vol.21
(10),
pp. 1296-1308.
show abstract
full text
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy. METHODS: We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncology Group performance status 0-2. Patients had completed at least one previous line of treatment for advanced breast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA: cohort A comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B comprised patients with HER2 mutations (treated with oral neratinib 240 mg, and if oestrogen receptor-positive with intramuscular standard-dose fulvestrant); cohort C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant); and cohort D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation (treated with oral capivasertib 480 mg). Each cohort had a primary endpoint of confirmed objective response rate. For cohort A, 13 or more responses among 78 evaluable patients were required to infer activity and three or more among 16 were required for cohorts B, C, and D. Recruitment to all cohorts is complete and long-term follow-up is ongoing. This trial is registered with ClinicalTrials.gov, NCT03182634; the European Clinical Trials database, EudraCT2015-003735-36; and the ISRCTN registry, ISRCTN16945804. FINDINGS: Between Dec 21, 2016, and April 26, 2019, 1051 patients registered for the study, with ctDNA results available for 1034 patients. Agreement between ctDNA digital PCR and targeted sequencing was 96-99% (n=800, kappa 0·89-0·93). Sensitivity of digital PCR ctDNA testing for mutations identified in tissue sequencing was 93% (95% CI 83-98) overall and 98% (87-100) with contemporaneous biopsies. In all cohorts, combined median follow-up was 14·4 months (IQR 7·0-23·7). Cohorts B and C met or exceeded the target number of responses, with five (25% [95% CI 9-49]) of 20 patients in cohort B and four (22% [6-48]) of 18 patients in cohort C having a response. Cohorts A and D did not reach the target number of responses, with six (8% [95% CI 3-17]) of 74 in cohort A and two (11% [1-33]) of 19 patients in cohort D having a response. The most common grade 3-4 adverse events were raised gamma-glutamyltransferase (13 [16%] of 80 patients; cohort A); diarrhoea (four [25%] of 20; cohort B); fatigue (four [22%] of 18; cohort C); and rash (five [26%] of 19; cohort D). 17 serious adverse reactions occurred in 11 patients, and there was one treatment-related death caused by grade 4 dyspnoea (in cohort C). INTERPRETATION: ctDNA testing offers accurate, rapid genotyping that enables the selection of mutation-directed therapies for patients with breast cancer, with sufficient clinical validity for adoption into routine clinical practice. Our results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, confirming these mutations could be targetable for breast cancer treatment. FUNDING: Cancer Research UK, AstraZeneca, and Puma Biotechnology..
Smith, I.
Robertson, J.
Kilburn, L.
Wilcox, M.
Evans, A.
Holcombe, C.
Horgan, K.
Kirwan, C.
Mallon, E.
Sibbering, M.
Skene, A.
Vidya, R.
Cheang, M.
Banerji, J.
Morden, J.
Sidhu, K.
Dodson, A.
Bliss, J.M.
Dowsett, M.
(2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet oncol,
Vol.21
(11),
pp. 1443-1454.
show abstract
full text
BACKGROUND: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki672W) of POAI predicts individual patient outcome better than baseline Ki67 (Ki67B). The POETIC trial aimed to test these two hypotheses. METHODS: POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control). Adjuvant treatment was given as per UK standard local practice. Randomisation was done centrally by computer-generated permuted block method (variable block size of six or nine) and was stratified by hospital. Treatment allocation was not masked. The primary endpoint was time to recurrence. A key second objective explored association between Ki67 (dichotomised at 10%) and disease outcomes. The primary analysis for clinical endpoints was by modified intention to treat (excluding patients who withdrew consent). For Ki67 biomarker association and endpoint analysis, the evaluable population included all randomly assigned patients who had paired Ki67 values available. This study is registered with ClinicalTrials.gov, NCT02338310; the European Clinical Trials database, EudraCT2007-003877-21; and the ISRCTN registry, ISRCTN63882543. Recruitment is complete and long-term follow-up is ongoing. FINDINGS: Between Oct 13, 2008, and April 16, 2014, 4480 women were recruited and randomly assigned to POAI (n=2976) or control (n=1504). On Feb 6, 2018, median follow-up was 62·9 months (IQR 58·1-74·1). 434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ratio 0·92 (95% CI 0·75-1·12); p=0·40 with the proportion free from breast cancer recurrence at 5 years of 91·0% (95% CI 89·9-92·0) for patients in the POAI group and 90·4% (88·7-91·9) in the control group. Within the POAI-treated HER2-negative subpopulation, 5-year recurrence risk in women with low Ki67B and Ki672W (low-low) was 4·3% (95% CI 2·9-6·3), 8·4% (6·8-10·5) with high Ki67B and low Ki672W (high-low) and 21·5% (17·1-27·0) with high Ki67B and Ki672W (high-high). Within the POAI-treated HER2-positive subpopulation, 5-year recurrence risk in the low-low group was 10·1% (95% CI 3·2-31·3), 7·7% (3·4-17·5) in the high-low group, and 15·7% (10·1-24·4) in the high-high group. The most commonly reported grade 3 adverse events were hot flushes (20 [1%] of 2801 patients in the POAI group vs six [<1%] of 1400 in the control group) and musculoskeletal pain (29 [1%] vs 13 [1%]). No treatment-related deaths were reported. INTERPRETATION: POAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67B or low POAI-induced Ki672W do well with adjuvant standard endocrine therapy (giving consideration to clinical-pathological factors), whereas those whose POAI-induced Ki672W remains high might benefit from further adjuvant treatment or trials of new therapies. FUNDING: Cancer Research UK..
Murray Brunt, A.
Haviland, J.S.
Wheatley, D.A.
Sydenham, M.A.
Alhasso, A.
Bloomfield, D.J.
Chan, C.
Churn, M.
Cleator, S.
Coles, C.E.
Goodman, A.
Harnett, A.
Hopwood, P.
Kirby, A.M.
Kirwan, C.C.
Morris, C.
Nabi, Z.
Sawyer, E.
Somaiah, N.
Stones, L.
Syndikus, I.
Bliss, J.M.
Yarnold, J.R.
FAST-Forward Trial Management Group,
(2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet,
Vol.395
(10237),
pp. 1613-1626.
show abstract
full text
BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial. METHODS: FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring hospitals) in the UK. Patients aged at least 18 years with invasive carcinoma of the breast (pT1-3, pN0-1, M0) after breast conservation surgery or mastectomy were eligible. We randomly allocated patients to either 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractions (over 1 week), or 26 Gy in five fractions (over 1 week) to the whole breast or chest wall. Allocation was not masked because of the nature of the intervention. The primary endpoint was ipsilateral breast tumour relapse; assuming a 2% 5-year incidence for 40 Gy, non-inferiority was predefined as ≤1·6% excess for five-fraction schedules (critical hazard ratio [HR] of 1·81). Normal tissue effects were assessed by clinicians, patients, and from photographs. This trial is registered at isrctn.com, ISRCTN19906132. FINDINGS: Between Nov 24, 2011, and June 19, 2014, we recruited and obtained consent from 4096 patients from 97 UK centres, of whom 1361 were assigned to the 40 Gy schedule, 1367 to the 27 Gy schedule, and 1368 to the 26 Gy schedule. At a median follow-up of 71·5 months (IQR 71·3 to 71·7), the primary endpoint event occurred in 79 patients (31 in the 40 Gy group, 27 in the 27 Gy group, and 21 in the 26 Gy group); HRs versus 40 Gy in 15 fractions were 0·86 (95% CI 0·51 to 1·44) for 27 Gy in five fractions and 0·67 (0·38 to 1·16) for 26 Gy in five fractions. 5-year incidence of ipsilateral breast tumour relapse after 40 Gy was 2·1% (1·4 to 3·1); estimated absolute differences versus 40 Gy in 15 fractions were -0·3% (-1·0 to 0·9) for 27 Gy in five fractions (probability of incorrectly accepting an inferior five-fraction schedule: p=0·0022 vs 40 Gy in 15 fractions) and -0·7% (-1·3 to 0·3) for 26 Gy in five fractions (p=0·00019 vs 40 Gy in 15 fractions). At 5 years, any moderate or marked clinician-assessed normal tissue effects in the breast or chest wall was reported for 98 of 986 (9·9%) 40 Gy patients, 155 (15·4%) of 1005 27 Gy patients, and 121 of 1020 (11·9%) 26 Gy patients. Across all clinician assessments from 1-5 years, odds ratios versus 40 Gy in 15 fractions were 1·55 (95% CI 1·32 to 1·83, p<0·0001) for 27 Gy in five fractions and 1·12 (0·94 to 1·34, p=0·20) for 26 Gy in five fractions. Patient and photographic assessments showed higher normal tissue effect risk for 27 Gy versus 40 Gy but not for 26 Gy versus 40 Gy. INTERPRETATION: 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer. FUNDING: National Institute for Health Research Health Technology Assessment Programme..
Chopra, N.
Tovey, H.
Pearson, A.
Cutts, R.
Toms, C.
Proszek, P.
Hubank, M.
Dowsett, M.
Dodson, A.
Daley, F.
Kriplani, D.
Gevensleben, H.
Davies, H.R.
Degasperi, A.
Roylance, R.
Chan, S.
Tutt, A.
Skene, A.
Evans, A.
Bliss, J.M.
Nik-Zainal, S.
Turner, N.C.
(2020). Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat commun,
Vol.11
(1),
p. 2662.
show abstract
full text
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43 patients with untreated TNBC. The primary end point, decreased Ki67, occured in 12% of TNBC. In secondary end point analyses, HR deficiency was identified in 69% of TNBC with the mutational-signature-based HRDetect assay. Cancers with HRDetect mutational signatures of HR deficiency had a functional defect in HR, assessed by impaired RAD51 foci formation on end of treatment biopsy. Following rucaparib treatment there was no association of Ki67 change with HR deficiency. In contrast, early circulating tumor DNA dynamics identified activity of rucaparib, with end of treatment ctDNA levels suppressed by rucaparib in mutation-signature HR-deficient cancers. In ad hoc analysis, rucaparib induced expression of interferon response genes in HR-deficient cancers. The majority of TNBCs have a defect in DNA repair, identifiable by mutational signature analysis, that may be targetable with PARP inhibitors..
Banerjee, S.
Tovey, H.
Bowen, R.
Folkerd, E.
Kilburn, L.
McLachlan, J.
Hall, M.
Tunariu, N.
Attygalle, A.
Lima, J.P.
Perry, S.
Chatfield, P.
Hills, M.
Kaye, S.
Attard, G.
Dowsett, M.
Bliss, J.M.
(2020). Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037). Ther adv med oncol,
Vol.12,
p. 1758835920975352.
show abstract
full text
BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Abiraterone (CORAL) trial was designed to evaluate the clinical activity of abiraterone in EOC. PATIENTS & METHODS: CORAL was a multi-centre, open-label, non-randomised, 2-stage phase II clinical trial. Eligible patients had progression within 12 months of last systemic therapy and no prior hormonal anti-cancer agents. Patients received abiraterone 1000 mg daily plus 5 mg prednisone until progression. The primary endpoint was objective response rate (ORR) according to combined Response Evaluation Criteria in Solid Tumours/Gynaecological Cancer Intergroup (RECIST/GCIG) criteria at 12 weeks. Secondary endpoints included clinical benefit rate (CBR) at 12 weeks. RESULTS: A total of 42 patients were recruited; median age 65 (range 34-85) years; 37 (88.1%) had high-grade serous tumours; 20 (48%) had at least three prior lines of therapy; 29/40 (72.5%) were AR+. In stage 1, 1/26 response was observed (in an AR+, low-grade serous EOC); response lasted 47 weeks. Overall, 12 week ORR was 1/42 (2%), CBR was 11/42 (26%) (8/29 (28%) in AR+ patients). Disease control was ⩾6 months for 4/29 (14%). One patient (AR+, low-grade serous) had a RECIST response at 82 weeks. Four (10%) had grade ⩾3 hypokalaemia; 11 (26%) had dose delays. CONCLUSIONS: CORAL represents the first trial of an AR targeted agent in ovarian cancer. While responses were rare, a subset of patients achieved sustained clinical benefit. Targeting AR in EOC including low-grade serous cancer warrants further investigation. TRIAL REGISTRATION: CORAL is registered on the ISRCTN registry: ISRCTN63407050; http://www.isrctn.com/ISRCTN63407050..
Bhattacharya, I.S.
Haviland, J.S.
Kirby, A.M.
Kirwan, C.C.
Hopwood, P.
Yarnold, J.R.
Bliss, J.M.
Coles, C.E.
IMPORT Trialists,
(2019). Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. J clin oncol,
Vol.37
(4),
pp. 305-317.
show abstract
full text
PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported outcome measures collected at serial time points are now reported. PATIENTS AND METHODS: IMPORT LOW recruited women with low-risk breast cancer after breast-conserving surgery. Patients were randomly assigned to 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and Breast Cancer-Specific Module, Body Image Scale, protocol-specific items, and the Hospital Anxiety and Depression Scale were administered at baseline, 6 months, and 1, 2, and 5 years. Patterns of moderate/marked adverse effects (AEs) were assessed using longitudinal regression models, and baseline predictors were investigated. RESULTS: A total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years. Breast appearance change was most prevalent and persisted over time (approximately 20% at each time point). Prevalence of breast hardness, pain, oversensitivity, edema, and skin changes reduced over time ( P < .001 for each), whereas breast shrinkage increased ( P < .001). Analysis by treatment group showed average number of AEs per person was lower in partial-breast (incidence rate ratio, 0.77; 95% CI, 0.71 to 0.84; P < .001) and reduced-dose (incidence rate ratio, 0.83; 95% CI, 0.76 to 0.90; P < .001) versus whole-breast group and decreased over time in all groups. Younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression were baseline predictors of subsequent AE reporting. CONCLUSION: Most AEs reduced over time, with fewer AEs in the partial-breast and reduced-dose groups. Baseline predictors for AE reporting were identified. These findings will facilitate informed discussion and shared decision making for future patients receiving moderately hypofractionated breast radiotherapy..
Szijgyarto, Z.
Flach, K.D.
Opdam, M.
Palmieri, C.
Linn, S.C.
Wesseling, J.
Ali, S.
Bliss, J.M.
Cheang, M.C.
Zwart, W.
Coombes, R.C.
(2019). Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. Breast cancer res treat,
Vol.175
(1),
pp. 149-163.
show abstract
full text
PURPOSE: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can differentiate between patient responses for switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane and continued tamoxifen monotherapy in the Intergroup Exemestane Study (IES). METHODS: Of the 4724 patients in IES, 1506 were managed in a subset of centres (N = 89) participating in PathIES. These centres recruited 1282 (85%, 1282/1506) women into PathIES of whom 1036 had phospho-marker data. All phospho-markers were analysed by immunohistochemistry staining. Multivariable Cox proportional hazards models of the phospho-markers for disease-free survival (DFS) and overall survival (OS) were adjusted for clinicopathological factors. Treatment effects on the biomarker expression were determined by interaction tests. Benjamini-Hochberg adjustment for multiple testing with a false discovery rate of 10% was applied (pBH). RESULTS: Phospho-T202/T204MAPK, pS118ERα and pS167ERα were all found to be correlated (pBH = 0.0002). These markers were not associated with either DFS or OS when controlling for the established clinicopathological factors. Interaction terms between the phospho-markers and treatment strategies for either DFS or OS were not statistically significant (pBH > 0.05 for all). CONCLUSIONS: This PathIES study confirmed previously described associations between the phosphorylation site markers of AKT, MAPK and ERα activity in postmenopausal breast cancer patients. No prognostic correlations between the phosphorylation markers and clinical outcome were found, nor were they predictive for clinical outcomes among patients who switched therapy over those treated with tamoxifen alone..
Bhattacharya, I.S.
Haviland, J.S.
Hopwood, P.
Coles, C.E.
Yarnold, J.R.
Bliss, J.M.
Kirby, A.M.
IMPORT Trialists,
(2019). Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiother oncol,
Vol.134,
pp. 220-230.
show abstract
full text
BACKGROUND: In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome measures (PROMs), clinician-reported outcomes (CRO) and photographs. This analysis investigates whether PROMs can be used as primary NTE endpoints in breast radiotherapy trials. METHODS: Analyses were conducted within IMPORT LOW (ISRCTN12852634) at 2 and 5 years. NTE were recorded by CRO, photographs and PROMs. Measures of agreement tested concordance, risk ratios for radiotherapy groups were compared, and influence of baseline characteristics on concordance investigated. RESULTS: In 1095 patients who consented to PROMS and photographs, PROMs were available at 2 and/or 5 years for 976 patients, of whom 909 had CRO and 844 had photographs. Few patients had moderate/marked NTE, irrespective of method used (eg. 19% patients and 9% clinicians reported breast shrinkage at year-5). Patients reported more NTE than assessed from CRO or photographs (p < 0.001 for most NTE). Concordance between assessments was poor on an individual patient level; eg. for year-5 breast shrinkage, % agreement = 48% and weighted kappa = 0.17. Risk ratios comparing radiotherapy schedules were consistent between PROMs and CRO or photographs. CONCLUSIONS: Few patients had moderate/marked NTE irrespective of method used. Patients reported more NTE than CRO and photographs, therefore NTE may be underestimated if PROMs are not used. Despite poor concordance between methods, effect sizes from PROMs were consistent with CRO and photographs, suggesting PROMs can be used as primary NTE endpoints in breast radiotherapy trials..
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
(2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet,
Vol.393
(10179),
pp. 1440-1452.
show abstract
full text
BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. METHODS: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios (RRs). FINDINGS: Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more dose-intense arm. Combining data from all 26 trials, fewer breast cancer recurrences were seen with dose-intense than with standard-schedule chemotherapy (10-year recurrence risk 28·0% vs 31·4%; RR 0·86, 95% CI 0·82-0·89; p<0·0001). 10-year breast cancer mortality was similarly reduced (18·9% vs 21·3%; RR 0·87, 95% CI 0·83-0·92; p<0·0001), as was all-cause mortality (22·1% vs 24·8%; RR 0·87, 95% CI 0·83-0·91; p<0·0001). Death without recurrence was, if anything, lower with dose-intense than with standard-schedule chemotherapy (10-year risk 4·1% vs 4·6%; RR 0·88, 95% CI 0·78-0·99; p=0·034). Recurrence reductions were similar in the seven trials (n=10 004) that compared 2-weekly chemotherapy with the same chemotherapy given 3-weekly (10-year risk 24·0% vs 28·3%; RR 0·83, 95% CI 0·76-0·91; p<0·0001), in the six trials (n=11 028) of sequential versus concurrent anthracycline plus taxane chemotherapy (28·1% vs 31·3%; RR 0·87, 95% CI 0·80-0·94; p=0·0006), and in the six trials (n=6532) testing both shorter intervals and sequential administration (30·4% vs 35·0%; RR 0·82, 95% CI 0·74-0·90; p<0·0001). The proportional reductions in recurrence with dose-intense chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor (ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics. INTERPRETATION: Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes. FUNDING: Cancer Research UK, Medical Research Council..
Bhattacharya, I.S.
Haviland, J.S.
Perotti, C.
Eaton, D.
Gulliford, S.
Harris, E.
Coles, C.E.
Kirwan, C.C.
Bliss, J.M.
Kirby, A.M.
IMPORT Trialists,
(2019). Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial. Radiother oncol,
Vol.136,
pp. 190-196.
show abstract
full text
BACKGROUND: Seroma describes a collection of serous fluid within a cavity, occurring following surgery. Seroma is associated with normal tissue effects (NTE) following breast radiotherapy, as reported by clinicians and on photographs. This study investigates the association between seroma and the NTE breast appearance change collected using patient-reported outcome measures (PROMs) in IMPORT HIGH, as well as investigating the association between breast appearance change and patient/tumour/treatment factors. METHODS: Case-control methodology was used for seroma analysis within IMPORT HIGH. Cases were patients reporting moderate/marked breast appearance change and controls reported none/mild changes at year-3. One control was selected at random for each case. Seromas were graded as not visible/subtle or visible/highly visible on CT radiotherapy planning scans. Logistic regression tested associations, adjusting for patient/tumour/treatment factors. RESULTS: 1078/1149 patients consented to PROMs, of whom 836 (78%) reported whether they had 3-year breast appearance change; 231 cases and 231 controls were identified. 304/462 (66%) patients received chemotherapy. Seroma prevalence was 20% (41/202) in cases and 16% (32/205) in controls, and less frequent in patients receiving adjuvant chemotherapy [10% (24/246) compared with 29% (40/138) without]. Visible seroma was not significantly associated with breast appearance change [OR 1.38 (95%CI 0.83-2.29), p = 0.219]. Larger tumour size, haematoma, current smoking and body image concerns at baseline were independent risk factors. CONCLUSIONS: Seroma was not associated with patient-reported breast appearance change, but haematoma and smoking were significant risk factors. Lack of association may be related to lower prevalence of seroma compared with previous reports, perhaps reflecting patients receiving adjuvant chemotherapy in whom seroma resolves prior to radiotherapy..
Bhattacharya, I.S.
Bliss, J.M.
(2019). Clinical Trials From the Other Side: Lessons Learned by a Clinician Venturing Into a Clinical Trials Unit. Clin oncol (r coll radiol),
Vol.31
(7),
pp. 420-423.
full text
Judson, I.
Morden, J.P.
Kilburn, L.
Leahy, M.
Benson, C.
Bhadri, V.
Campbell-Hewson, Q.
Cubedo, R.
Dangoor, A.
Fox, L.
Hennig, I.
Jarman, K.
Joubert, W.
Kernaghan, S.
López Pousa, A.
McNeil, C.
Seddon, B.
Snowdon, C.
Tattersall, M.
Toms, C.
Martinez Trufero, J.
Bliss, J.M.
(2019). Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet oncol,
Vol.20
(7),
pp. 1023-1034.
show abstract
full text
BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from the intrinsically indolent nature of ASPS. METHODS: In this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants from 12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2). Patients were eligible if they were aged 16 years or older; metastatic ASPS that had progressed in the previous 6 months; had an ECOG performance status of 0-1; life expectancy of more than 12 weeks; and adequate bone marrow, hepatic, and renal function. Participants had to have no anti-cancer treatment within 4 weeks before trial entry, with exception of palliative radiotherapy. Participants were randomly assigned (2:1), with allocation by use of computer-generated random permuted blocks of six, to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Treatment was supplied in number-coded bottles, masking participants and clinicians to assignment. Participants were unblinded at week 24 or sooner if they had progression defined by Response Evaluation Criteria in Solid Tumors (version 1.1); those on placebo crossed over to cediranib and all participants continued on treatment until progression or death. The primary endpoint was percentage change in sum of target marker lesion diameters between baseline and week 24 or progression if sooner, assessed in the evaluable population (all randomly assigned participants who had a scan at week 24 [or sooner if they progressed] with target marker lesions measured). Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01337401; the European Clinical Trials database, number EudraCT2010-021163-33; and the ISRCTN registry, number ISRCTN63733470 recruitment is complete and follow-up is ongoing. FINDINGS: Between July 15, 2011, and July 29, 2016, of 48 participants recruited, all were randomly assigned to cediranib (n=32) or placebo (n=16). 23 (48%) were female and the median age was 31 years (IQR 27-45). Median follow-up was 34·3 months (IQR 23·7-55·6) at the time of data cutoff for these analyses (April 11, 2018). Four participants in the cediranib group were not evaluable for the primary endpoint (one did not start treatment, and three did not have their scan at 24 weeks). Median percentage change in sum of target marker lesion diameters for the evaluable population was -8·3% (IQR -26·5 to 5·9) with cediranib versus 13·4% (IQR 1·1 to 21·3) with placebo (one-sided p=0·0010). The most common grade 3 adverse events on (blinded) cediranib were hypertension (six [19%] of 31) and diarrhoea (two [6%]). 15 serious adverse reactions in 12 patients were reported; 12 of these reactions occurred on open-label cediranib, and the most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2). One probable treatment-related death (intracranial haemorrhage) occurred 41 days after starting open-label cediranib in a patient who was assigned to placebo in the masked phase. INTERPRETATION: Given the high incidence of metastatic disease and poor long-term prognosis of ASPS, together with the lack of efficacy of conventional chemotherapy, our finding of significant clinical activity with cediranib in this disease is an important step towards the goal of long-term disease control for these young patients. Future clinical trials in ASPS are also likely to involve immune checkpoint inhibitors. FUNDING: Cancer Research UK and AstraZeneca..
Antoniou, M.
Kolamunnage-Dona, R.
Wason, J.
Bathia, R.
Billingham, C.
Bliss, J.M.
Brown, L.C.
Gillman, A.
Paul, J.
Jorgensen, A.L.
(2019). Biomarker-guided trials: Challenges in practice. Contemp clin trials commun,
Vol.16,
p. 100493.
show abstract
full text
Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been proposed in the literature, many of which have been adopted in practice. Implementing such trial designs in practice can be challenging, and identifying those challenges was the main objective of a workshop organised by the MRC Hubs for Trials Methodology Research Network's Stratified Medicine Working Group in March 2017. Participants reflected on completed and ongoing biomarker-guided trials to identify the practical challenges encountered. Here, the key challenges identified during the workshop including those related to funding, ethical and regulatory issues, recruitment, monitoring of samples and laboratories, biomarker assessment, and data sharing and resources, are discussed. Despite the complexities often associated with biomarker-guided trials, the workshop concluded that they can play an important role in advancing the field of personalised medicine. Therefore, it is important that the practical challenges surrounding their implementation are acknowledged and addressed..
Gao, Q.
López-Knowles, E.
Cheang, M.C.
Morden, J.
Ribas, R.
Sidhu, K.
Evans, D.
Martins, V.
Dodson, A.
Skene, A.
Holcombe, C.
Mallon, E.
Evans, A.
Bliss, J.M.
Robertson, J.
Smith, I.
Martin, L.-.
Dowsett, M.
POETIC Trial Management Group and Trialists,
(2019). Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. Breast cancer res,
Vol.22
(1),
p. 2.
show abstract
full text
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify gene modules representing key biological pathways that relate to early AI therapy resistance. METHODS: Global gene expression was measured on pairs of core-cut biopsies taken at baseline and at surgery from 254 patients with ER-positive primary breast cancer randomised to receive 2-week presurgical AI (n = 198) or no presurgical treatment (control n = 56) from the POETIC trial. Data from the AI group was adjusted to eliminate artefactual process-related changes identified in the control group. The response was assessed by changes in the proliferation marker, Ki67. RESULTS: High baseline ESR1 expression associated with better AI response in HER2+ tumours but not HER2- tumours. In HER2- tumours, baseline expression of 48 genes associated with poor antiproliferative response (p < 0.005) including PERP and YWHAQ, the two most significant, and the transcription co-regulators (SAP130, HDAC4, and NCOA7) which were among the top 16 most significant. Baseline gene signature scores measuring cell proliferation, growth factor signalling (ERBB2-GS, RET/GDNF-GS, and IGF-1-GS), and immune activity (STAT1-GS) were significantly higher in poor AI responders. Two weeks of AI caused downregulation of genes involved in cell proliferation and ER signalling, as expected. Signature scores of E2F activation and TP53 dysfunction after 2-week AI were associated with poor AI response in both HER2- and HER2+ patients. CONCLUSIONS: There is a high degree of heterogeneity in adaptive mechanisms after as little as 2-week AI therapy; however, all appear to converge on cell cycle regulation. Our data support the evaluation of whether an E2F signatures after short-term exposure to AI may identify those patients most likely to benefit from the early addition of CDK4/6 inhibitors. TRIAL REGISTRATION: ISRCTN, ISRCTN63882543, registered on 18 December 2007..
Schuster, E.F.
Gellert, P.
Segal, C.V.
López-Knowles, E.
Buus, R.
Cheang, M.C.
Morden, J.
Robertson, J.
Bliss, J.M.
Smith, I.
Dowsett, M.
POETIC Trial Management Group and Trialists,
(2019). Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment. Jco precis oncol,
Vol.3.
show abstract
full text
PURPOSE: Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy number alterations (SCNAs), is important in breast cancer development and prognosis. SCNAs to specific genes may drive intrinsic resistance, or high genomic instability may drive tumor heterogeneity, which allows differential response across tumors and surviving cells to evolve resistance to treatment rapidly. We therefore evaluated the relationship between SCNAs and intrinsic resistance to treatment as measured by a poor antiproliferative response. PATIENTS AND METHODS: SCNAs were determined by single nucleotide polymorphism array in baseline and surgery core-cuts from 73 postmenopausal patients randomly assigned to receive 2 weeks of preoperative AI or no AI in the Perioperative Endocrine Therapy-Individualizing Care (POETIC) trial. Fifty-six samples from the AI group included 28 poor responders (PrRs, less than 60% reduction in protein encoded by the MKI67 gene [Ki-67]) and 28 good responders (GdRs, greater than 75% reduction in Ki-67). Exome sequencing was available for 72 pairs of samples. RESULTS: Genomic instability correlated with Ki-67 expression at both baseline (P < .001) and surgery (P < .001) and was higher in PrRs (P = .048). The SCNA with the largest difference between GdRs and PrRs was loss of heterozygosity observed at 17p (false discovery rate, 0.08), which includes TP53. Nine of 28 PrRs had loss of wild-type TP53 as a result of mutations and loss of heterozygosity compared with three of 28 GdRs. In PrRs, somatic alterations of TP53 were associated with higher genomic instability, higher baseline Ki-67, and greater resistance to AI treatment compared with wild-type TP53. CONCLUSION: We observed that primary tumors with high genomic instability have an intrinsic resistance to AI treatment and do not require additional evolution to develop resistance to estrogen deprivation therapy..
Haviland, J.S.
Mannino, M.
Griffin, C.
Porta, N.
Sydenham, M.
Bliss, J.M.
Yarnold, J.R.
START Trialists' Group,
(2018). Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother oncol,
Vol.126
(1),
pp. 155-162.
show abstract
full text
BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with similarly-hypofractionated breast/chest wall radiotherapy (RT). MATERIAL AND METHODS: The Standardisation of Breast Radiotherapy (START) pilot, A and B trials randomised women with early breast cancer to schedules of 2.67-3.3 Gy versus 2.0 Gy fractions (control). RT adverse effects were assessed by patients using the EORTC QLQ-BR23 and protocol-specific questions, and by physicians. Rates of arm/shoulder effects were compared between schedules for patients given LNRT. RESULTS: 864/5861 (14.7%) patients received LNRT (385 START-pilot, 318 START-A, 161 START-B). Prevalences of moderate/marked arm/shoulder effects were low up to 10 years. There were no significant differences between the hypofractionated and control groups for patient- and physician-assessed symptoms in START-A or START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 Gy, consistent with effects reported in the breast/chest wall (significant for shoulder stiffness, HR 3.07, 95%CI 1.62-5.83, p = 0.001). CONCLUSIONS: The START trial results suggest that appropriately-dosed hypofractionated LNRT is safe in the long-term, according to patient and physician-assessed arm and shoulder symptoms. These findings are consistent with those reported after the same schedules delivered to the breast/chest wall..
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
(2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet oncol,
Vol.19
(1),
pp. 27-39.
show abstract
full text
BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. METHODS: We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively. Primary outcomes were tumour response, extent of local therapy, local and distant recurrence, breast cancer death, and overall mortality. Analyses by intention-to-treat used standard regression (for response and frequency of breast-conserving therapy) and log-rank methods (for recurrence and mortality). FINDINGS: Patients entered the trials from 1983 to 2002 and median follow-up was 9 years (IQR 5-14), with the last follow-up in 2013. Most chemotherapy was anthracycline based (3838 [81%] of 4756 women). More than two thirds (1349 [69%] of 1947) of women allocated NACT had a complete or partial clinical response. Patients allocated NACT had an increased frequency of breast-conserving therapy (1504 [65%] of 2320 treated with NACT vs 1135 [49%] of 2318 treated with adjuvant chemotherapy). NACT was associated with more frequent local recurrence than was adjuvant chemotherapy: the 15 year local recurrence was 21·4% for NACT versus 15·9% for adjuvant chemotherapy (5·5% increase [95% CI 2·4-8·6]; rate ratio 1·37 [95% CI 1·17-1·61]; p=0·0001). No significant difference between NACT and adjuvant chemotherapy was noted for distant recurrence (15 year risk 38·2% for NACT vs 38·0% for adjuvant chemotherapy; rate ratio 1·02 [95% CI 0·92-1·14]; p=0·66), breast cancer mortality (34·4% vs 33·7%; 1·06 [0·95-1·18]; p=0·31), or death from any cause (40·9% vs 41·2%; 1·04 [0·94-1·15]; p=0·45). INTERPRETATION: Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered-eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. FUNDING: Cancer Research UK, British Heart Foundation, UK Medical Research Council, and UK Department of Health..
O'Leary, B.
Hrebien, S.
Morden, J.P.
Beaney, M.
Fribbens, C.
Huang, X.
Liu, Y.
Bartlett, C.H.
Koehler, M.
Cristofanilli, M.
Garcia-Murillas, I.
Bliss, J.M.
Turner, N.C.
(2018). Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat commun,
Vol.9
(1),
p. 896.
show abstract
full text
CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA (ctDNA) level may provide early response prediction, but the impact of tumor heterogeneity is unknown. Here we use plasma samples from patients in the randomized phase III PALOMA-3 study of CDK4/6 inhibitor palbociclib and fulvestrant for women with advanced breast cancer and show that relative change in PIK3CA ctDNA level after 15 days treatment strongly predicts PFS on palbociclib and fulvestrant (hazard ratio 3.94, log-rank p = 0.0013). ESR1 mutations selected by prior hormone therapy are shown to be frequently sub clonal, with ESR1 ctDNA dynamics offering limited prediction of clinical outcome. These results suggest that early ctDNA dynamics may provide a robust biomarker for CDK4/6 inhibitors, with early ctDNA dynamics demonstrating divergent response of tumor sub clones to treatment..
Cheang, M.C.
Bliss, J.M.
Viale, G.
Speirs, V.
Palmieri, C.
Shaaban, A.
Lønning, P.E.
Morden, J.
Porta, N.
Jassem, J.
van De Velde, C.J.
Rasmussen, B.B.
Verhoeven, D.
Bartlett, J.M.
Coombes, R.C.
PathIES Sub-Committee,
(2018). Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast cancer res treat,
Vol.168
(1),
pp. 169-178.
show abstract
full text
BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane. PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27% of IES population). Only patients for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score (PathIEscore) (N = 350) was also estimated. RESULTS: Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95% CI 1.29-23.70) for a change from 1st quartile (Q1) to Q1-Q3 and HR of 15.54 (95% CI 3.70-65.24) for a change from Q1 to Q4. CONCLUSION: In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years..
Bhattacharya, I.S.
Kirby, A.M.
Bliss, J.M.
Coles, C.E.
(2018). Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?. Clin oncol (r coll radiol),
Vol.30
(3),
pp. 158-165.
show abstract
full text
Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local relapse rates over recent decades. Although the proportional benefits of adjuvant radiotherapy are similar for different prognostic risk groups of patients, the absolute benefits depend on the risk of relapse and therefore vary considerably between prognostic groups. Radiotherapy is not without risk and for some patients at very low risk of relapse the risks of radiotherapy may outweigh the benefit, leading to potential overtreatment. Randomised controlled trial (RCT) evidence shows that omission of radiotherapy in low risk early breast cancer does not reduce overall survival or increase breast cancer mortality and local recurrences are salvageable. Despite this there has not been a change in practice regarding omission of radiotherapy. The reasons for this may include challenges in patient selection. Recent advances in immunohistochemistry and genomic profiling may improve risk stratification and the development of biomarkers to directed therapies. Several RCTs have quantified the benefit of radiotherapy in reducing local relapse. Where a treatment benefit is known but is considered to be so small not to be clinically relevant then alternatives to RCTs may be considered to answer the question of need. This is because we can assess risk against a fixed 'absolute' boundary rather than needing a randomised comparator. The prospective cohort study is an alternative to the RCT design to answer the question of need for radiotherapy. The feasibility of recruitment into biomarker-directed de-escalation studies will become apparent as more studies open. The challenge is to determine if we are able to accurately risk stratify patients and avoid unnecessary toxicity, thereby tailoring the need for adjuvant breast radiotherapy on an individual patient basis..
Gao, Q.
López-Knowles, E.
U Cheang, M.C.
Morden, J.
Ribas, R.
Sidhu, K.
Evans, D.
Martins, V.
Dodson, A.
Skene, A.
Holcombe, C.
Mallon, E.
Evans, A.
Bliss, J.M.
Robertson, J.
Smith, I.
Martin, L.-.
Dowsett, M.
POETIC Trial Management Group and Trialists,
(2018). Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. Jnci cancer spectr,
Vol.2
(2),
p. pky005.
show abstract
full text
To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n = 157) or no presurgical treatment (n = 56). Those genes most markedly altered in the AI group (eg, FOS, DUSP1, RGS1, FOSB) were similarly altered in the no treatment group; some widely investigated genes that were apparently unaffected in the AI group (eg, MYC) were counter-altered in the control group, masking actual AI-dependent changes. In the absence of a control group, these artefactual changes would likely lead to the most affected genes being the erroneous focus of research. The findings are likely relevant to all archival collections of ER+ breast cancer..
Tutt, A.
Tovey, H.
Cheang, M.C.
Kernaghan, S.
Kilburn, L.
Gazinska, P.
Owen, J.
Abraham, J.
Barrett, S.
Barrett-Lee, P.
Brown, R.
Chan, S.
Dowsett, M.
Flanagan, J.M.
Fox, L.
Grigoriadis, A.
Gutin, A.
Harper-Wynne, C.
Hatton, M.Q.
Hoadley, K.A.
Parikh, J.
Parker, P.
Perou, C.M.
Roylance, R.
Shah, V.
Shaw, A.
Smith, I.E.
Timms, K.M.
Wardley, A.M.
Wilson, G.
Gillett, C.
Lanchbury, J.S.
Ashworth, A.
Rahman, N.
Harries, M.
Ellis, P.
Pinder, S.E.
Bliss, J.M.
(2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat med,
Vol.24
(5),
pp. 628-637.
show abstract
full text
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive. Cancers in putative 'BRCAness' subgroups-tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes-may also be sensitive to platinum. We assessed the efficacy of carboplatin and another mechanistically distinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC. A prespecified protocol enabled biomarker-treatment interaction analyses in gBRCA-BC and BRCAness subgroups. The primary endpoint was objective response rate (ORR). In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than docetaxel (ORR, 31.4% versus 34.0%, respectively; P = 0.66). In contrast, in subjects with gBRCA-BC, carboplatin had double the ORR of docetaxel (68% versus 33%, respectively; biomarker, treatment interaction P = 0.01). Such benefit was not observed for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay. Significant interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup. We conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy. Additionally, gene expression analysis of basal-like cancers may also influence treatment selection..
Mills, J.
Haviland, J.S.
Moynihan, C.
Bliss, J.M.
Hopwood, P.
START Trial Management Group,
(2018). Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer. Clin oncol (r coll radiol),
Vol.30
(7),
pp. 433-441.
show abstract
full text
AIMS: Exploratory analysis of patients' unsolicited written comments in the first 2 years of the Standardisation of Breast Radiotherapy (START) trial quality of life study highlighted a potential effect of non-treatment-related problems on the ratings and interpretation of patient self-reported questionnaires. At 5 years of follow-up all eligible subjects were invited to write comments to further explore these findings. MATERIALS AND METHODS: Using inductive qualitative methods informed by the exploratory analysis, comments were allocated to relevant themes. Key patient-reported outcome measures (PROMs), clinical and demographic factors were collated for patients who did and did not comment at 5 years and comparisons between the groups explored. RESULTS: Of 2208 women completing baseline PROMs, 482 proffered comments from 0 to 24 months, forming nine distinct themes, including chronic conditions, life events and psychosocial concerns. At 5 years, 1041/1727 (60.3%) women contributed comments, of whom 500 randomly selected participants formed the sample for analysis. Findings revealed comorbidity, impaired physical functioning and psychosocial problems as key themes, with prevalent adverse effects from local and systemic treatments. Eight new themes emerged at 5 years, including ageing, concerns about future cancer and positive aspects of care. Women commenting were better educated, slightly older and more likely to have had chemotherapy compared with non-commenters. They had significantly worse PROM scores for global health and key quality of life domains relevant to the difficulties they revealed. CONCLUSIONS: Difficult personal circumstances and other health concerns affected many women's PROM ratings at 5 years of follow-up, in addition to ongoing cancer treatment effects. Greater attention to multiple sources of distress and adversity could facilitate personalised care and aid interpretation of PROMs..
Wilkins, A.
Chauhan, R.
Rust, A.
Pearson, A.
Daley, F.
Manodoro, F.
Fenwick, K.
Bliss, J.
Yarnold, J.
Somaiah, N.
(2018). FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. Breast cancer res treat,
Vol.170
(3),
pp. 573-581.
show abstract
full text
BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. METHODS: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively. RESULTS: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson's correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94. CONCLUSIONS: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material..
Blok, E.J.
Engels, C.C.
Dekker-Ensink, G.
Meershoek-Klein Kranenbarg, E.
Putter, H.
Smit, V.T.
Liefers, G.-.
Morden, J.P.
Bliss, J.M.
Coombes, R.C.
Bartlett, J.M.
Kroep, J.R.
van de Velde, C.J.
Kuppen, P.J.
(2018). Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. Breast cancer res treat,
Vol.171
(1),
pp. 65-74.
show abstract
full text
PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. EXPERIMENTAL DESIGN: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane. The numbers of CD8-positive TILs were analysed for correlations with disease-free survival (DFS) and overall survival (OS). A similar analysis was performed on 2596 patients in the TEAM trial who were randomized between the sequential scheme and the exemestane monotherapy. RESULTS: In the first cohort, patients with low (below median) numbers of CD8-positive TILs had a univariate hazard ratio (HR) for DFS of 0.27 (95% CI 0.13-0.55) in favour of treatment with exemestane, whereas this benefit was not observed in patients with high numbers of CD8-positive TILs (HR 1.34, 95% CI 0.71-2.50, HR for interaction 5.02, p = 0.001). In the second cohort, patients with low numbers of CD8-positive TILs showed a benefit of exemestane treatment on recurrence-free survival (RFS HR 0.67, 95% CI 0.45-0.99), and not with above-median numbers of CD8-positive TILs (HR 0.86, 95% CI 0.59-1.26, HR for interaction 1.29, p = 0.36). CONCLUSIONS: This study is the first to propose the number of CD8-positive TILs as potential predictive markers for endocrine therapy, with the low presence of CD8-positive TILs associated to benefit for exemestane-inclusive therapy. However, treatment-by-marker interactions were only significant in one cohort, indicating the need for further validation..
Haviland, J.
Moynihan, C.
Hopwood, P.
Bliss, J.
(2018). An exploratory analysis of women’s free-text comments on their Quality of Life in the UK Standardisation of Breast Radiotherapy (START) Trials for early breast cancer. Clinical oncology,
.
full text
Francis, P.A.
Pagani, O.
Fleming, G.F.
Walley, B.A.
Colleoni, M.
Láng, I.
Gómez, H.L.
Tondini, C.
Ciruelos, E.
Burstein, H.J.
Bonnefoi, H.R.
Bellet, M.
Martino, S.
Geyer, C.E.
Goetz, M.P.
Stearns, V.
Pinotti, G.
Puglisi, F.
Spazzapan, S.
Climent, M.A.
Pavesi, L.
Ruhstaller, T.
Davidson, N.E.
Coleman, R.
Debled, M.
Buchholz, S.
Ingle, J.N.
Winer, E.P.
Maibach, R.
Rabaglio-Poretti, M.
Ruepp, B.
Di Leo, A.
Coates, A.S.
Gelber, R.D.
Goldhirsch, A.
Regan, M.M.
SOFT and TEXT Investigators and the International Breast Cancer Study Group,
(2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N engl j med,
Vol.379
(2),
pp. 122-137.
show abstract
full text
BACKGROUND: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials. METHODS: Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy. RESULTS: In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression, and 85.9% with exemestane plus ovarian suppression (P=0.009 for tamoxifen alone vs. tamoxifen plus ovarian suppression). The 8-year rate of overall survival was 91.5% with tamoxifen alone, 93.3% with tamoxifen plus ovarian suppression, and 92.1% with exemestane plus ovarian suppression (P=0.01 for tamoxifen alone vs. tamoxifen plus ovarian suppression); among the women who remained premenopausal after chemotherapy, the rates were 85.1%, 89.4%, and 87.2%, respectively. Among the women with cancers that were negative for HER2 who received chemotherapy, the 8-year rate of distant recurrence with exemestane plus ovarian suppression was lower than the rate with tamoxifen plus ovarian suppression (by 7.0 percentage points in SOFT and by 5.0 percentage points in TEXT). Grade 3 or higher adverse events were reported in 24.6% of the tamoxifen-alone group, 31.0% of the tamoxifen-ovarian suppression group, and 32.3% of the exemestane-ovarian suppression group. CONCLUSIONS: Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. The frequency of adverse events was higher in the two groups that received ovarian suppression than in the tamoxifen-alone group. (Funded by Pfizer and others; SOFT and TEXT ClinicalTrials.gov numbers, NCT00066690 and NCT00066703 , respectively.)..
Batten, L.M.
Bhattacharya, I.S.
Moretti, L.
Haviland, J.S.
Emson, M.A.
Miller, S.E.
Jefford, M.
MacKenzie, M.
Wilcox, M.
Hyslop, M.
Todd, R.
Snowdon, C.F.
Bliss, J.M.
(2018). Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies. Res involv engagem,
Vol.4,
p. 22.
show abstract
full text
PLAIN ENGLISH SUMMARY: Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast cancer clinical trials where multiple biopsies are required. ICR-CTSU recognises that patient advocates (patients who have previously had, or cared for someone with, cancer) are key members of the trial design group and should be involved in the clinical trial throughout its lifespan. Patient advocates can provide reassurance regarding the acceptability of trial designs involving multiple biopsies from a patient perspective. This paper summarises patient advocate involvement in ICR-CTSU breast cancer trials activity and how this has benefited our research. ABSTRACT: The importance of collecting tissue samples in breast cancer has become increasingly recognised, as the diversity of the disease has become better known. It has been documented in recent research that tumours may change in response to treatment prior to surgery (the neoadjuvant treatment setting). The collection of sequential biopsies over time can identify changes within tumours and potentially predict how the tumour may respond to certain treatments. However, the acceptability of multiple biopsies amongst patients, clinicians and other research staff in hospitals is variable and recruitment into clinical trials requiring multiple biopsies may be challenging.The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) is responsible for a portfolio of breast cancer trials where multiple biopsies are key to the trial design. Patient advocate involvement has been essential in helping us to design and deliver complex and innovative cancer trials which require multiple invasive tissue biopsies, often without any direct benefit to the trial participants. The views expressed by patient advocates involved in ICR-CTSU trials supports the published evidence that patients are willing to donate additional tissue for research and that clinicians' concerns about approaching patients for trials involving multiple biopsies are often unfounded.Patient advocate involvement in ICR-CTSU trials activity takes various forms, from membership on protocol development groups and trial management groups, attendance at focus groups and forums, and presentations at trial development and launch meetings. This involvement has provided reassurance to research teams within the NHS and research ethics committees of the importance and acceptability of our trials from a patient perspective. Patient advocate involvement throughout the lifetime of our trials ensures that the patient remains central to our research considerations..
Morden, J.P.
Alvarez, I.
Bertelli, G.
Coates, A.S.
Coleman, R.
Fallowfield, L.
Jassem, J.
Jones, S.
Kilburn, L.
Lønning, P.E.
Ortmann, O.
Snowdon, C.
van de Velde, C.
Andersen, J.
Del Mastro, L.
Dodwell, D.
Holmberg, S.
Nicholas, H.
Paridaens, R.
Bliss, J.M.
Coombes, R.C.
(2017). Long-Term Follow-Up of the Intergroup Exemestane Study. J clin oncol,
Vol.35
(22),
pp. 2507-2514.
show abstract
full text
Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane was associated with clinically relevant improvements in efficacy. Here, we report the final efficacy analyses of this cohort. Patients and Methods Patients who remained disease free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete a total of 5 years of adjuvant endocrine therapy. Given the large number of non-breast cancer-related deaths now reported, breast cancer-free survival (BCFS), with censorship of intercurrent deaths, was the primary survival end point of interest. Analyses focus on patients with estrogen receptor-positive or unknown tumors (n = 4,599). Results At the time of the data snapshot, median follow-up was 120 months. In the population that was estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were observed with 508 (22.1%) of 2,294 patients in the exemestane group and 603 (26.2%) of 2,305 patients in the tamoxifen group. The data corresponded to an absolute difference (between exemestane and tamoxifen) at 10 years of 4.0% (95% CI, 1.2% to 6.7%), and the hazard ratio (HR) of 0.81 (95% CI, 0.72 to 0.92) favored exemestane. This difference remained in multivariable analysis that was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR, 0.80; 95% CI, 0.71 to 0.90; P < .001). A modest improvement in overall survival was seen with exemestane; the absolute difference (between exemestane and tamoxifen) at 10 years in the population that was estrogen receptor positive or had unknown estrogen receptor status was 2.1% (95% CI, -0.5% to 4.6%), and the HR was 0.89 (95% CI, 0.78 to 1.01; P = .08). For the intention-to-treat population, the absolute difference was 1.6% (95% CI, -0.9% to 4.1%); the HR was 0.91 (95% CI, 0.80 to 1.03, P = .15). No statistically significant difference was observed in the proportion of patients who reported a fracture event in the post-treatment period. Conclusion The Intergroup Exemestane Study and contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2 to 3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality..
Muller, I.
Kilburn, L.S.
Taylor, P.N.
Barrett-Lee, P.J.
Bliss, J.M.
Ellis, P.
Ludgate, M.E.
Dayan, C.M.
(2017). TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). Eur thyroid j,
Vol.6
(4),
pp. 197-207.
show abstract
full text
BACKGROUND: Small-scale studies correlated the presence of thyroid autoimmunity with both improved or worsened breast cancer outcome. OBJECTIVES: We aimed to clarify this association in a large cohort using the phase III, randomized, controlled Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). METHODS: TACT women >18 years old with node-positive or high-risk node-negative early breast cancer (pT1-3a, pN0-1, M0), with stored plasma (n = 1,974), taken 15.5 (median; IQR 7.0-24.0) months after breast surgery were studied. Patients had also received chemotherapy (100%), radiotherapy (1,745/1,974; 88.4%), hormonal therapy (1,378/ 1,974; 69.8%), or trastuzumab (48/1,974; 2.4%). History of thyroid diseases and/or related treatments was not available. The prognostic significance of autoantibodies to thyroid peroxidase (TPOAb; positive ≥6 kIU/L), free-thyroxine and thyrotropin (combined: euthyroid, hypothyroid, hyperthyroid) was evaluated for disease-free survival (DFS), overall-survival (OS), and time-to-recurrence (TTR), with Cox regression models in univariate and multivariable analyses. The extended median follow-up was 97.5 months. RESULTS: No difference in DFS was found by TPOAb status (unadjusted hazard ratio [HR]: 0.97, 95%CI: 0.78-1.19; p = 0.75) and/or thyroid function (unadjusted HR [hypothyroid vs. euthyroid]: 1.15, 95% CI: 0.79-1.68; p = 0.46; unadjusted HR [hyperthyroid vs. euthyroid]: 1.14, 95% CI: 0.82-1.61; p = 0.44). Similar results were obtained for OS, TTR, multivariable analyses, when TPOAb titre by tertiles was considered, and in a subgroup of 123 patients with plasma collected before adjuvant treatments. CONCLUSIONS: No evidence for a prognostic role of TPOAb and/or thyroid function in moderate-to-high-risk early breast cancer was found in the largest and longest observational study to date..
Cameron, D.
Morden, J.P.
Canney, P.
Velikova, G.
Coleman, R.
Bartlett, J.
Agrawal, R.
Banerji, J.
Bertelli, G.
Bloomfield, D.
Brunt, A.M.
Earl, H.
Ellis, P.
Gaunt, C.
Gillman, A.
Hearfield, N.
Laing, R.
Murray, N.
Couper, N.
Stein, R.C.
Verrill, M.
Wardley, A.
Barrett-Lee, P.
Bliss, J.M.
TACT2 Investigators,
(2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet oncol,
Vol.18
(7),
pp. 929-945.
show abstract
full text
BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both. METHODS: In this multicentre, phase 3, randomised, controlled trial, we enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy. Patients were randomly assigned to receive four cycles of 100 mg/m2 epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m2 cyclophosphamide intravenously on days 1 and 8 or 100 mg/m2 orally on days 1-14; 40 mg/m2 methotrexate intravenously on days 1 and 8; and 600 mg/m2 fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m2 capecitabine (1250 mg/m2 given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs one to three vs four or more), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). The primary endpoint was TTR, defined as time from randomisation to first invasive relapse or breast cancer death, with intention-to-treat analysis of standard versus accelerated epirubicin and per-protocol analysis of CMF versus capecitabine. This trial is registered with ISRCTN, number 68068041, and with ClinicalTrials.gov, number NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (4371 women and 20 men) were recruited. At a median follow-up of 85·6 months (IQR 80·6-95·9) no significant difference was seen in the proportions of patients free from TTR events between the accelerated and standard epirubicin groups (overall hazard ratio [HR] 0·94, 95% CI 0·81-1·09; stratified p=0·42). At 5 years, 85·9% (95% CI 84·3-87·3) of patients receiving standard epirubicin and 87·1% (85·6-88·4) of those receiving accelerated epirubicin were free from TTR events. 4358 patients were included in the per-protocol analysis, and no difference was seen in the proportions of patients free from TTR events between the CMF and capecitabine groups (HR 0·98, 95% CI 0·85-1.14; stratified p=0·00092 for non-inferiority). Compared with baseline, significantly more patients taking CMF than those taking capecitabine had clinically relevant worsening of quality of life at end of treatment (255 [58%] of 441 vs 235 [50%] of 475; p=0·011) and at 12 months (114 [34%] of 334 vs 89 [22%] of 401; p<0·001 at 12 months) and had worse quality of life over time (p<0·0001). Detailed toxicity and quality-of-life data were collected from 2115 (48%) of treated patients. The most common grade 3 or higher adverse events in cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 1070 patients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]) of the 1045 patients treated with accelerated epirubicin. In cycles 5-8, the most common grade 3 or higher adverse events were neutropenia (321 [31%]) and fatigue (109 [11%]) in the patients treated with CMF, and hand-foot syndrome (129 [12%]) and diarrhoea (67 [6%]) in the 1044 patients treated with capcitabine. INTERPRETATION: We found no benefit from increasing the dose density of the anthracycline component of chemotherapy. However, capecitabine could be used in place of CMF without significant loss of efficacy and with improved quality of life. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche..
Pan, H.
Gray, R.
Braybrooke, J.
Davies, C.
Taylor, C.
McGale, P.
Peto, R.
Pritchard, K.I.
Bergh, J.
Dowsett, M.
Hayes, D.F.
EBCTCG,
(2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N engl j med,
Vol.377
(19),
pp. 1836-1846.
show abstract
full text
BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment. METHODS: In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (TN), tumor grade, and other factors with patients' outcomes during the period from 5 to 20 years. RESULTS: Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status. Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1-3), and 34% with four to nine nodes involved (T1N4-9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1-3, and 41% with T2N4-9. The risk of death from breast cancer was similarly dependent on TN status, but the risk of contralateral breast cancer was not. Given the TN status, the factors of tumor grade (available in 43,590 patients) and Ki-67 status (available in 7692 patients), which are strongly correlated with each other, were of only moderate independent predictive value for distant recurrence, but the status regarding the progesterone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) was not predictive. During the study period from 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively. CONCLUSIONS: After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.)..
Coles, C.E.
Griffin, C.L.
Kirby, A.M.
Titley, J.
Agrawal, R.K.
Alhasso, A.
Bhattacharya, I.S.
Brunt, A.M.
Ciurlionis, L.
Chan, C.
Donovan, E.M.
Emson, M.A.
Harnett, A.N.
Haviland, J.S.
Hopwood, P.
Jefford, M.L.
Kaggwa, R.
Sawyer, E.J.
Syndikus, I.
Tsang, Y.M.
Wheatley, D.A.
Wilcox, M.
Yarnold, J.R.
Bliss, J.M.
IMPORT Trialists,
(2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet,
Vol.390
(10099),
pp. 1048-1060.
show abstract
full text
BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy. METHODS: IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634. FINDINGS: Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7-83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5-2·3) of patients in the control group, 0·2% (0·02-1·2) in the reduced-dose group, and 0·5% (0·2-1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were -0·73% (-0·99 to 0·22) for the reduced-dose and -0·38% (-0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy. INTERPRETATION: We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide. FUNDING: Cancer Research UK..
von Minckwitz, G.
Procter, M.
de Azambuja, E.
Zardavas, D.
Benyunes, M.
Viale, G.
Suter, T.
Arahmani, A.
Rouchet, N.
Clark, E.
Knott, A.
Lang, I.
Levy, C.
Yardley, D.A.
Bines, J.
Gelber, R.D.
Piccart, M.
Baselga, J.
APHINITY Steering Committee and Investigators,
(2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N engl j med,
Vol.377
(2),
pp. 122-131.
show abstract
full text
BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer. METHODS: We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab. We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with placebo. RESULTS: In the trial population, 63% of the patients who were randomly assigned to receive pertuzumab (2400 patients) or placebo (2405 patients) had node-positive disease and 36% had hormone-receptor-negative disease. Disease recurrence occurred in 171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P=0.045). The estimates of the 3-year rates of invasive-disease-free survival were 94.1% in the pertuzumab group and 93.2% in the placebo group. In the cohort of patients with node-positive disease, the 3-year rate of invasive-disease-free survival was 92.0% in the pertuzumab group, as compared with 90.2% in the placebo group (hazard ratio for an invasive-disease event, 0.77; 95% CI, 0.62 to 0.96; P=0.02). In the cohort of patients with node-negative disease, the 3-year rate of invasive-disease-free survival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard ratio for an invasive-disease event, 1.13; 95% CI, 0.68 to 1.86; P=0.64). Heart failure, cardiac death, and cardiac dysfunction were infrequent in both treatment groups. Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%). CONCLUSIONS: Pertuzumab significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. (Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877 .)..
Kilburn, L.S.
Aresu, M.
Banerji, J.
Barrett-Lee, P.
Ellis, P.
Bliss, J.M.
(2017). Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. Trials,
Vol.18
(1),
p. 561.
show abstract
full text
BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine datasets could provide a cost-effective alternative for ascertaining follow-up information required to evaluate disease outcomes. This project explores the potential for routine data to inform cancer trials, using, the historical National Cancer Data Repository (NCDR) for English NHS sites and, for validation, mature data available from the TACT trial. METHODS: Datasets were matched using patients' NHS number, date of birth (dob) and name/initials. Demographics, clinical characteristics and outcomes were assessed for agreement and completeness. Overall survival was compared between NCDR and TACT. RESULTS: A total of 3151 patients underwent linkage; 3047 (96.7%) of which had matched records. Extensive cleaning was required for some registry data fields, e.g. cause of death, whilst others had large amounts of missing data, e.g. tumour size (22.1%). Other data had high levels of matching such as dob (99.6%) and date of death (89.6%). There was no evidence of differential survival rates (8-year survival: TACT = 75% (95% CI 73, 76); NCDR = 76% (95% CI 74, 77)). CONCLUSIONS: Data quality and completeness requires improvement before routine data could be used for RCTs. Introduction of new routine datasets, including COSD, is welcomed although reporting of disease-recurrence events remains a concern. Prospective validation of such datasets is required before RCTs can confidently switch patient follow-up to utilise routinely collected NHS-based data. TACT TRIAL REGISTRATION: Clinicaltrials.gov NCT00033683 , registered on 9 April 2002; ISRCTN79718493 , registered on 1 July 2001..
Fox, L.
Toms, C.
Kernaghan, S.
Snowdon, C.
Bliss, J.M.
(2017). Conducting non-commercial international clinical trials: the ICR-CTSU experience. Trials,
Vol.18
(1),
p. 440.
show abstract
full text
BACKGROUND: Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly targeted at molecular subtypes, and with priority placed on developing new treatments for rare tumour types, the need for international trial participation to access sufficient patient numbers for successful trial conduct is growing. However, lack of harmonisation of international legal, ethical and financial systems can make this challenging and the cost and effort of conducting trials internationally can be considered prohibitive, particularly where the sample size is comparatively small. METHODS: The Institute of Cancer Research - Clinical Trials and Statistics Unit (ICR-CTSU) is a UK-based academic clinical trials unit that specialises in the design, conduct and analysis of clinical trials of cancer treatments with an expanding portfolio of trials in molecular subtypes of breast and urological cancers and in other rare cancer types. Implementing appropriate mechanisms to enable international participation has therefore been imperative. In this article, we explain how we have approached the challenges involved and describe examples of successful international trial conduct, achieved through robust collaborations with academic and industry partners. CONCLUSION: Conducting academic trials internationally is challenging but can and should be achieved through appropriate governance mechanisms and strong collaborations..
López-Knowles, E.
Gao, Q.
Cheang, M.C.
Morden, J.
Parker, J.
Martin, L.-.
Pinhel, I.
McNeill, F.
Hills, M.
Detre, S.
Afentakis, M.
Zabaglo, L.
Dodson, A.
Skene, A.
Holcombe, C.
Robertson, J.
Smith, I.
Bliss, J.M.
Dowsett, M.
POETIC trialists,
(2016). Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. Breast cancer res,
Vol.18
(1),
p. 39.
show abstract
full text
BACKGROUND: Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements but is poorly documented. We studied the variability of global gene expression between core-cuts of primary ER+ breast cancers and the impact of delays to tissue stabilisation due to sample X-ray and of diagnostic core cutting. METHODS: Twenty-six paired core-cuts were taken immediately after tumour excision and up to 90 minutes delay due to sample X-ray; 57 paired core-cuts were taken at diagnosis and 2 weeks later at surgical excision. Whole genome expression analysis was conducted on extracted RNA. Correlations and differences were assessed between the expression of individual genes, gene sets/signatures and intrinsic subtypes. RESULTS: Twenty-three and 56 sample pairs, respectively, were suitable for analysis. The range of correlations for both sample sets were similar with the majority being >0.97 in both. Correlations between pairs for 18 commonly studied genes were also similar between the studies and mainly with Pearson correlation coefficients >0.6 except for a small number of genes, which had a narrow-dynamic range (e.g. MKI67, SNAI2). There was no systematic difference in intrinsic subtyping between the first and second sample of either set but there was c.15 % discordance between the subtype assignments between the pairs, mainly where the subtyping of individual samples was less certain. Increases in the expression of several stress/early-response genes (e.g. FOS, FOSB, JUN) were found in both studies and confirmed findings in earlier smaller studies. Increased expression of IL6, IGFBP2 and MYC (by 17 %, 14 % and 44 %, respectively) occurred between the samples taken 2 weeks apart and again confirmed findings from an earlier study. CONCLUSIONS: There is generally good correlation in gene expression between pairs of core-cuts except where genes have a narrow dynamic range. Similar correlation coefficients to the average gene expression profiles of intrinsic subtype, particularly LumA and LumB, can lead to discordances between assigned subtypes. Substantial changes in expression of early-response genes occur within an hour after surgery and in IL6, IGFB2 and MYC as a result of diagnostic core-cut biopsy. TRIAL REGISTRATION: Trial number CRUK/07/015 . Study start date September 2008..
Mansi, J.
Morden, J.
Bliss, J.M.
Neville, M.
Coombes, R.C.
(2016). Bone marrow micrometastases in early breast cancer-30-year outcome. Br j cancer,
Vol.114
(3),
pp. 243-247.
show abstract
BACKGROUND: Micrometastases in bone marrow of women with early breast cancer were first identified immunocytochemically in the 1980s. We report on the original cohort of women with a median follow-up of 30 years. PATIENTS AND METHODS: In total, 350 women with primary breast cancer had eight bone marrow aspirates examined with antibody to epithelial membrane antigen. Data on long-term mortality were obtained via record linkage to death certification. RESULTS: At a 30-year median follow-up, 79 out of 89 (89%) patients with micrometastases have died compared with 202 out of 261 (77%) without (hazard ratio=1.46 (95% CI 1.12-1.90), P=0.0043). Most marked effect of micrometastases on overall survival (OS) was seen in patients aged ⩽ 50 at surgery (N=97, P=0.012), and on all patients within 10 years of diagnosis. In multivariable analyses, the presence of micrometastases was no longer a statistically significant prognostic factor. CONCLUSIONS: Bone marrow micrometastases are predictive for OS, particularly in the first decade and in younger patients..
Bidad, N.
MacDonald, L.
Winters, Z.E.
Edwards, S.J.
Emson, M.
Griffin, C.L.
Bliss, J.
Horne, R.
(2016). How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction). Trials,
Vol.17
(1),
p. 431.
show abstract
full text
BACKGROUND: Randomised controlled trials (RCTs) often fail to recruit sufficient participants, despite altruism being cited as their motivation. Previous investigations of factors influencing participation decisions have been methodologically limited. This study evaluated how women weigh up different motivations after initially expressing altruism, and explored their understanding of a trial and its alternatives. The trial was the 'Quality of Life after Mastectomy and Breast Reconstruction' (QUEST) trial. METHODS: Thirty-nine women participated in qualitative interviews 1 month post-surgery. Twenty-seven women (10 trial decliners and 17 acceptors) who spontaneously mentioned 'altruism' were selected for thematic analysis. Verbatim transcripts were coded independently by two researchers. Participants' motivations to accept or decline randomisation were cross-referenced with their understanding of the QUEST trials and the process of randomisation. RESULTS: The seven emerging themes were: (1) altruism expressed by acceptors and decliners; (2) overriding personal needs in decliners; (3) pure altruism in acceptors; (4) 'hypothetical altruism' amongst acceptors; (5) weak altruism amongst acceptors; (6) conditional altruism amongst acceptors; and (7) sense of duty to participate. Poor understanding of the trial rationale and its implications was also evident. CONCLUSIONS: Altruism was a motivating factor for participation in the QUEST randomised controlled trials where the main outcomes comprised quality of life and allocated treatments comprised established surgical procedures. Women's decisions were influenced by their understanding of the trial. Both acceptors and decliners of the trial expressed 'altruism', but most acceptors lacked an obvious treatment preference, hoped for personal benefits regarding a treatment allocation, or did not articulate complete understanding of the trial. TRIAL REGISTRATION: QUEST A, ISRCTN38846532 ; Date assigned 6 January 2010. QUEST B, ISRCTN92581226 ; Date assigned 6 January 2010..
Hayes, A.J.
Maynard, L.
Coombes, G.
Newton-Bishop, J.
Timmons, M.
Cook, M.
Theaker, J.
Bliss, J.M.
Thomas, J.M.
UK Melanoma Study Group,
British Association of Plastic,
Reconstructive and Aesthetic Surgeons, and the Scottish Cancer Therapy Network,
(2016). Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet oncol,
Vol.17
(2),
pp. 184-192.
show abstract
full text
BACKGROUND: The necessary margin of excision for cutaneous melanomas greater than 2 mm in thickness is controversial. At a median follow-up of 5 years, findings from our previously published randomised trial of narrow (1 cm) versus wide (3 cm) excision margins in patients with thick cutaneous melanomas showed that narrow margins were associated with an increased frequency of locoregional relapse, but no significant difference in overall survival was apparent. We now report a long-term survival analysis of that trial. METHODS: We did a randomised, open-label multicentre trial in 59 hospitals--57 in the UK, one in Poland, and one in South Africa. Patients with one primary localised cutaneous melanoma greater than 2 mm in Breslow thickness on the trunk or limbs (excluding palms or soles) were randomly assigned (1:1) centrally to receive surgery with either a 1 cm or 3 cm excision margin following an initial surgery. The randomisation lists were generated with random permuted blocks and stratified by centre and extent of initial surgery. The endpoints of this analysis were overall survival and melanoma-specific survival. Analyses were done in the intention-to-treat population. This trial was not registered because it predated mandatory trial registration. FINDINGS: Between Dec 16, 1992, and May 22, 2001, we randomly assigned 900 patients to surgery with either a 1 cm excision margin (n=453) or a 3 cm excision margin (n=447). At a median follow-up of 8·8 years (106 months [IQR 76-135], 494 patients had died, with 359 of these deaths attributed to melanoma. 194 deaths were attributed to melanoma in the 1 cm group compared with 165 in the 3 cm group (unadjusted hazard ratio [HR] 1·24 [95% CI 1·01-1·53]; p=0·041). Although a higher number of deaths overall occurred in the 1 cm group compared with the 3 cm group (253 vs 241), the difference was not significant (unadjusted HR 1·14 [95% CI 0·96-1·36]; p=0·14). Surgical complications were reported in 35 (8%) patients in the 1 cm excision margin group and 65 (15%) patients in the 3 cm group. INTERPRETATION: Our findings suggest that a 1 cm excision margin is inadequate for cutaneous melanoma with Breslow thickness greater than 2 mm on the trunk and limbs. Current guidelines advise a 2 cm margin for melanomas greater than 2 mm in thickness but only a 1 cm margin for thinner melanomas. The adequacy of a 1 cm margin for thinner melanomas with poor prognostic features should be addressed in future randomised studies. FUNDING: Cancer Research UK, North Thames National Health Service Executive, Northern and Yorkshire National Health Service Executive, British United Provident Association Foundation, British Association of Plastic Surgeons, the Meirion Thomas Cancer Research Fund, and the National Institute for Health and Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust..
Haviland, J.S.
Hopwood, P.
Mills, J.
Sydenham, M.
Bliss, J.M.
Yarnold, J.R.
START Trialists' Group,
(2016). Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer. Clin oncol (r coll radiol),
Vol.28
(6),
pp. 345-353.
show abstract
full text
AIMS: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data from the Standardisation of Breast Radiotherapy (START) trials are examined. MATERIALS AND METHODS: NTEs in the treated breast were recorded by (i) annual clinical assessments, (ii) photographs at 2 and 5 years, (iii) PROMs at 6 months, 1, 2 and 5 years after radiotherapy. Hazard ratios for the radiotherapy schedules were compared. Measures of agreement of assessments at 2 and 5 years tested concordance. RESULTS: PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had clinical and 1444 had photographic assessments. All methods were sensitive to the dose difference between schedules. Patients reported a higher prevalence for all NTE end points than clinicians or photographs (P < 0.001 for most NTEs). Concordance was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 0.21 (shrinkage and oedema). The percentage agreement was lowest between PROMs and photographic assessments of change in breast appearance (38%). CONCLUSIONS: All three methods produced similar conclusions for the comparison of trial schedules, despite low concordance between the methods on an individual patient basis. Careful consideration should be given to the different contributions of the measures of NTE in future radiotherapy trials..
Coombes, R.C.
Kilburn, L.S.
Tubiana-Mathieu, N.
Olmos, T.
Van Bochove, A.
Perez-Lopez, F.R.
Palmieri, C.
Stebbing, J.
Bliss, J.M.
(2016). Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. Eur j cancer,
Vol.60,
pp. 146-153.
show abstract
full text
BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node positive breast cancer and to the benefits of tailored endocrine therapy in such patients. PATIENTS AND METHODS: HMFEC was a multi-centre, phase III, open label, randomised controlled trial with a 2 × 2 factorial design. Eligible patients were premenopausal with node positive early breast cancer; significant cardiac disease or uncontrolled hypertension was exclusion criterion. Patients were allocated to receive either eight cycles of FE50C or FE75C (given 3 weekly) with or without hormone manipulation (HM; tamoxifen or luteinising hormone releasing hormone (LHRH) agonists according to residual hormone levels at the end of chemotherapy) irrespective of ER status. The primary end-point was disease free survival (DFS). Principal analyses were by intention to treat (ITT); however, to reflect contemporary practice, subgroup analyses according to ER status were also conducted. The mature follow-up now available from this modest sized trial enables presentation of definitive results. RESULTS: Between 1992 and 2000 a total of 785 patients were randomised into the HMFEC trial (203 FE50C-HM, 191 FE50C+HM, 198 FE75C-HM, 193 FE75C+HM). At a median follow-up of 7.4 years, 245 DFS events have been reported (92 ER-, 153 ER+/unknown). The effects on DFS were not statistically significantly different according to epirubicin dose (hazard ratio [HR] = 0.82, 95% confidence interval [CI] 0.63-1.06; p = 0.13 FE75C versus FE50C); however, FE75C appeared to induce more alopecia and neutropenia. No statistically significant evidence was observed to support an improvement in DFS in patients allocated HM either overall (HR = 0.88, 95% CI 0.68-1.13; p = 0.32) or in patients with ER+/unknown disease (HR = 0.85, 95% CI 0.62-1.17; p = 0.32) although effect sizes are consistent with worthwhile clinical effects. Overall, there was no evidence of a difference in survival between any of the four treatment groups of the trial. CONCLUSION: Higher doses of epirubicin cause more adverse events in the absence of clear improvement in overall survival. Endocrine therapy with either tamoxifen or goserelin provided no significant added benefit to cytotoxic chemotherapy in this group of patients. TRIAL REGISTRATION NUMBER: ISRCTN98335268..
Brunt, A.M.
Wheatley, D.
Yarnold, J.
Somaiah, N.
Kelly, S.
Harnett, A.
Coles, C.
Goodman, A.
Bahl, A.
Churn, M.
Zotova, R.
Sydenham, M.
Griffin, C.L.
Morden, J.P.
Bliss, J.M.
FAST-Forward Trial Management Group,
(2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother oncol,
Vol.120
(1),
pp. 114-118.
show abstract
full text
BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions. MATERIAL AND METHODS: Patients were randomly allocated to 40Gy/15 fractions (F)/3-weeks, 27Gy/5F/1-week or 26Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4weeks after completion. RESULTS: 190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40Gy/15F 6/44 (13.6%); 27Gy/5F 5/51 (9.8%); 26Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40Gy/15F 0/43; 27Gy/5F 1/41 (2.4%); 26Gy/5F 0/53. CONCLUSIONS: Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild..
Gellert, P.
Segal, C.V.
Gao, Q.
López-Knowles, E.
Martin, L.-.
Dodson, A.
Li, T.
Miller, C.A.
Lu, C.
Mardis, E.R.
Gillman, A.
Morden, J.
Graf, M.
Sidhu, K.
Evans, A.
Shere, M.
Holcombe, C.
McIntosh, S.A.
Bundred, N.
Skene, A.
Maxwell, W.
Robertson, J.
Bliss, J.M.
Smith, I.
Dowsett, M.
POETIC Trial Management Group and Trialists,
(2016). Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nat commun,
Vol.7,
p. 13294.
show abstract
full text
Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I of this study, we perform exome sequencing on baseline, surgical core-cuts and blood from 60 patients (40 AI treated, 20 controls). In poor responders (based on Ki67 change), we find significantly more somatic mutations than good responders. Subclones exclusive to baseline or surgical cores occur in ∼30% of tumours. In phase II, we combine targeted sequencing on another 28 treated patients with phase I. We find six genes frequently mutated: PIK3CA, TP53, CDH1, MLL3, ABCA13 and FLG with 71% concordance between paired cores. TP53 mutations are associated with poor response. We conclude that multiple biopsies are essential for confident mutational profiling of ER+ breast cancer and TP53 mutations are associated with resistance to oestrogen deprivation therapy..
Haviland, J.S.
Bentzen, S.M.
Bliss, J.M.
Yarnold, J.R.
START Trial Management Group,
(2016). Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiother oncol,
Vol.121
(3),
pp. 420-423.
show abstract
full text
BACKGROUND: Tests of tumour treatment time effect in patients prescribed post-operative radiotherapy for early breast cancer have focussed on time to start of radiotherapy rather than overall treatment time. The START randomised trials of radiotherapy fractionation provide an opportunity to directly estimate the effect of treatment acceleration. METHODS: Between 1986 and 2002, a total of 5861 women with early breast cancer were recruited into the UK START pilot (START-P), START-A and START-B randomised trials. START-P and START-A tested 13 fractions of 3.0-3.3Gy against 25 fractions of 2.0Gy with a fixed treatment duration of 5weeks for all schedules; START-B tested 15 fractions of 2.67Gy in 3weeks against 25 fractions of 2.0Gy over 5weeks. Estimates of the effect of length of treatment for local-regional relapse and for a measure of late normal tissue effects (change in photographic breast appearance, for patients following breast conserving surgery) were obtained from Cox proportional hazards regression analyses stratified according to trial. RESULTS: At a median follow-up of 10years, 444/5831 (7.6%) patients with data available had a local-regional relapse, and 1135/3185 (35.6%) had mild or marked change in photographic breast appearance by 5years. Adjusting for prognostic factors, the estimate of the overall treatment time effect for local-regional relapse was 0.60Gy/day (95%CI 0.10 to 1.18Gy/day, p=0.02), and 0.14Gy/day (95%CI -0.09 to 0.34Gy/day, p=0.29) for change in photographic breast appearance. CONCLUSIONS: Combined analysis of the START trials generates the hypothesis that overall treatment time is a significant determinant of local cancer control after adjuvant whole breast radiotherapy, with approximately 0.6Gy per day 'wasted' in compensating for tumour cell proliferation..
Seibold, P.
Behrens, S.
Schmezer, P.
Helmbold, I.
Barnett, G.
Coles, C.
Yarnold, J.
Talbot, C.J.
Imai, T.
Azria, D.
Koch, C.A.
Dunning, A.M.
Burnet, N.
Bliss, J.M.
Symonds, R.P.
Rattay, T.
Suga, T.
Kerns, S.L.
Bourgier, C.
Vallis, K.A.
Sautter-Bihl, M.-.
Claßen, J.
Debus, J.
Schnabel, T.
Rosenstein, B.S.
Wenz, F.
West, C.M.
Popanda, O.
Chang-Claude, J.
(2015). XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. Int j radiat oncol biol phys,
Vol.92
(5),
pp. 1084-1092.
show abstract
PURPOSE: To identify single-nucleotide polymorphisms (SNPs) in oxidative stress-related genes associated with risk of late toxicities in breast cancer patients receiving radiation therapy. METHODS AND MATERIALS: Using a 2-stage design, 305 SNPs in 59 candidate genes were investigated in the discovery phase in 753 breast cancer patients from 2 prospective cohorts from Germany. The 10 most promising SNPs in 4 genes were evaluated in the replication phase in up to 1883 breast cancer patients from 6 cohorts identified through the Radiogenomics Consortium. Outcomes of interest were late skin toxicity and fibrosis of the breast, as well as an overall toxicity score (Standardized Total Average Toxicity). Multivariable logistic and linear regression models were used to assess associations between SNPs and late toxicity. A meta-analysis approach was used to summarize evidence. RESULTS: The association of a genetic variant in the base excision repair gene XRCC1, rs2682585, with normal tissue late radiation toxicity was replicated in all tested studies. In the combined analysis of discovery and replication cohorts, carrying the rare allele was associated with a significantly lower risk of skin toxicities (multivariate odds ratio 0.77, 95% confidence interval 0.61-0.96, P=.02) and a decrease in Standardized Total Average Toxicity scores (-0.08, 95% confidence interval -0.15 to -0.02, P=.016). CONCLUSIONS: Using a stage design with replication, we identified a variant allele in the base excision repair gene XRCC1 that could be used in combination with additional variants for developing a test to predict late toxicities after radiation therapy in breast cancer patients..
Winters, Z.E.
Emson, M.
Griffin, C.
Mills, J.
Hopwood, P.
Bidad, N.
MacDonald, L.
Turton, E.P.
Horne, R.
Bliss, J.M.
QUEST Trial Management Group,
QUEST Trial Management Group,
(2015). Learning from the QUEST multicentre feasibility randomization trials in breast reconstruction after mastectomy. Br j surg,
Vol.102
(1),
pp. 45-56.
show abstract
BACKGROUND: Breast reconstruction aims to improve health-related quality of life after mastectomy. However, evidence guiding patients and surgeons in shared decision-making concerning the optimal type or timing of surgery is lacking. METHODS: QUEST comprised two parallel feasibility phase III randomized multicentre trials to assess the impact of the type and timing of latissimus dorsi breast reconstruction on health-related quality of life when postmastectomy radiotherapy is unlikely (QUEST A) or highly probable (QUEST B). The primary endpoint for the feasibility phase was the proportion of women who accepted randomization, and it would be considered feasible if patient acceptability rates exceeded 25 per cent of women approached. A companion QUEST Perspectives Study (QPS) of patients (both accepting and declining trial participation) and healthcare professionals assessed trial acceptability. RESULTS: The QUEST trials opened in 15 UK centres. After 18 months of recruitment, 17 patients were randomized to QUEST A and eight to QUEST B, with overall acceptance rates of 19 per cent (17 of 88) and 22 per cent (8 of 36) respectively. The QPS recruited 56 patients and 51 healthcare professionals. Patient preference was the predominant reason for declining trial entry, given by 47 (53 per cent) of the 88 patients approached for QUEST A and 22 (61 per cent) of the 36 approached for QUEST B. Both trials closed to recruitment in December 2012, acknowledging the challenges of achieving satisfactory patient accrual. CONCLUSION: Despite extensive efforts to overcome recruitment barriers, it was not feasible to reach timely recruitment targets within a feasibility study. Patient preferences for breast reconstruction types and timings were common, rendering patients unwilling to enter the trial..
Leary, A.
Evans, A.
Johnston, S.R.
A'Hern, R.
Bliss, J.M.
Sahoo, R.
Detre, S.
Haynes, B.P.
Hills, M.
Harper-Wynne, C.
Bundred, N.
Coombes, G.
Smith, I.
Dowsett, M.
(2015). Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). Clin cancer res,
Vol.21
(13),
pp. 2932-2940.
show abstract
PURPOSE: Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors. EXPERIMENTAL DESIGN: Women with primary breast cancer were randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial (ISRCTN68509377). Biopsies pre-/posttreatment were analyzed for Ki67, apoptosis, HER2, EGFR, ER, PgR, pAKT, pERK, and stathmin by IHC. Further markers were measured by RT-PCR. Primary endpoint was change in Ki67. HER2(+) was defined as 2+/3+ by IHC and FISH(+). RESULTS: One hundred twenty-one patients (lapatinib, 94; placebo, 27) were randomized; of these, 21% were HER2(+), 78% were HER2(-) nonamplified, 26% were EGFR(+). Paired samples containing tumor were obtained for 98% (118 of 121). Ki67 fell significantly with lapatinib (-31%; P < 0.001), but not with placebo (-3%). Whereas Ki67 reduction with lapatinib was greatest in HER2(+) breast cancer (-46%; P = 0.003), there was a significant Ki67 decrease in HER2(-) breast cancer (-27%; P = 0.017) with 14% of HER2(-) breast cancer demonstrating ≥50% Ki67 reduction with lapatinib. Among HER2(+) patients, the only biomarker predictive of Ki67 response was the EGFR/HER4 ligand epiregulin (EREG) (rho = -0.7; P = 0.002). Among HER2(-) tumors, only HER3 mRNA levels were significantly associated with Ki67 response on multivariate analysis (P = 0.01). In HER2(-) breast cancer, HER2 and HER3 mRNA levels were highly correlated (rho = 0.67, P < 0.001), with all Ki67 responders having elevated HER3 and HER2 expression. CONCLUSIONS: Lapatinib has antiproliferative effects in a subgroup of HER2(-) nonamplified tumors characterized by high HER3 expression. The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2(-) tumors..
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
(2015). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet,
Vol.386
(10001),
pp. 1353-1361.
show abstract
BACKGROUND: Bisphosphonates have profound effects on bone physiology, and could modify the process of metastasis. We undertook collaborative meta-analyses to clarify the risks and benefits of adjuvant bisphosphonate treatment in breast cancer. METHODS: We sought individual patient data from all unconfounded trials in early breast cancer that randomised between bisphosphonate and control. Primary outcomes were recurrence, distant recurrence, and breast cancer mortality. Primary subgroup investigations were site of first distant recurrence (bone or other), menopausal status (postmenopausal [combining natural and artificial] or not), and bisphosphonate class (aminobisphosphonate [eg, zoledronic acid, ibandronate, pamidronate] or other [ie, clodronate]). Intention-to-treat log-rank methods yielded bisphosphonate versus control first-event rate ratios (RRs). FINDINGS: We received data on 18,766 women (18,206 [97%] in trials of 2-5 years of bisphosphonate) with median follow-up 5·6 woman-years, 3453 first recurrences, and 2106 subsequent deaths. Overall, the reductions in recurrence (RR 0·94, 95% CI 0·87-1·01; 2p=0·08), distant recurrence (0·92, 0·85-0·99; 2p=0·03), and breast cancer mortality (0·91, 0·83-0·99; 2p=0·04) were of only borderline significance, but the reduction in bone recurrence was more definite (0·83, 0·73-0·94; 2p=0·004). Among premenopausal women, treatment had no apparent effect on any outcome, but among 11 767 postmenopausal women it produced highly significant reductions in recurrence (RR 0·86, 95% CI 0·78-0·94; 2p=0·002), distant recurrence (0·82, 0·74-0·92; 2p=0·0003), bone recurrence (0·72, 0·60-0·86; 2p=0·0002), and breast cancer mortality (0·82, 0·73-0·93; 2p=0·002). Even for bone recurrence, however, the heterogeneity of benefit was barely significant by menopausal status (2p=0·06 for trend with menopausal status) or age (2p=0·03), and it was non-significant by bisphosphonate class, treatment schedule, oestrogen receptor status, nodes, tumour grade, or concomitant chemotherapy. No differences were seen in non-breast cancer mortality. Bone fractures were reduced (RR 0·85, 95% CI 0·75-0·97; 2p=0·02). INTERPRETATION: Adjuvant bisphosphonates reduce the rate of breast cancer recurrence in the bone and improve breast cancer survival, but there is definite benefit only in women who were postmenopausal when treatment began. FUNDING: Cancer Research UK, Medical Research Council..
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
(2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet,
Vol.386
(10001),
pp. 1341-1352.
show abstract
BACKGROUND: The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain. METHODS: We undertook meta-analyses of individual data on 31,920 postmenopausal women with oestrogen-receptor-positive early breast cancer in the randomised trials of 5 years of aromatase inhibitor versus 5 years of tamoxifen; of 5 years of aromatase inhibitor versus 2-3 years of tamoxifen then aromatase inhibitor to year 5; and of 2-3 years of tamoxifen then aromatase inhibitor to year 5 versus 5 years of tamoxifen. Primary outcomes were any recurrence of breast cancer, breast cancer mortality, death without recurrence, and all-cause mortality. Intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded aromatase inhibitor versus tamoxifen first-event rate ratios (RRs). FINDINGS: In the comparison of 5 years of aromatase inhibitor versus 5 years of tamoxifen, recurrence RRs favoured aromatase inhibitors significantly during years 0-1 (RR 0·64, 95% CI 0·52-0·78) and 2-4 (RR 0·80, 0·68-0·93), and non-significantly thereafter. 10-year breast cancer mortality was lower with aromatase inhibitors than tamoxifen (12·1% vs 14·2%; RR 0·85, 0·75-0·96; 2p=0·009). In the comparison of 5 years of aromatase inhibitor versus 2-3 years of tamoxifen then aromatase inhibitor to year 5, recurrence RRs favoured aromatase inhibitors significantly during years 0-1 (RR 0·74, 0·62-0·89) but not while both groups received aromatase inhibitors during years 2-4, or thereafter; overall in these trials, there were fewer recurrences with 5 years of aromatase inhibitors than with tamoxifen then aromatase inhibitors (RR 0·90, 0·81-0·99; 2p=0·045), though the breast cancer mortality reduction was not significant (RR 0·89, 0·78-1·03; 2p=0·11). In the comparison of 2-3 years of tamoxifen then aromatase inhibitor to year 5 versus 5 years of tamoxifen, recurrence RRs favoured aromatase inhibitors significantly during years 2-4 (RR 0·56, 0·46-0·67) but not subsequently, and 10-year breast cancer mortality was lower with switching to aromatase inhibitors than with remaining on tamoxifen (8·7% vs 10·1%; 2p=0·015). Aggregating all three types of comparison, recurrence RRs favoured aromatase inhibitors during periods when treatments differed (RR 0·70, 0·64-0·77), but not significantly thereafter (RR 0·93, 0·86-1·01; 2p=0·08). Breast cancer mortality was reduced both while treatments differed (RR 0·79, 0·67-0·92), and subsequently (RR 0·89, 0·81-0·99), and for all periods combined (RR 0·86, 0·80-0·94; 2p=0·0005). All-cause mortality was also reduced (RR 0·88, 0·82-0·94; 2p=0·0003). RRs differed little by age, body-mass index, stage, grade, progesterone receptor status, or HER2 status. There were fewer endometrial cancers with aromatase inhibitors than tamoxifen (10-year incidence 0·4% vs 1·2%; RR 0·33, 0·21-0·51) but more bone fractures (5-year risk 8·2% vs 5·5%; RR 1·42, 1·28-1·57); non-breast-cancer mortality was similar. INTERPRETATION: Aromatase inhibitors reduce recurrence rates by about 30% (proportionately) compared with tamoxifen while treatments differ, but not thereafter. 5 years of an aromatase inhibitor reduces 10-year breast cancer mortality rates by about 15% compared with 5 years of tamoxifen, hence by about 40% (proportionately) compared with no endocrine treatment. FUNDING: Cancer Research UK, Medical Research Council..
Gourgou-Bourgade, S.
Cameron, D.
Poortmans, P.
Asselain, B.
Azria, D.
Cardoso, F.
A'Hern, R.
Bliss, J.
Bogaerts, J.
Bonnefoi, H.
Brain, E.
Cardoso, M.J.
Chibaudel, B.
Coleman, R.
Cufer, T.
Dal Lago, L.
Dalenc, F.
De Azambuja, E.
Debled, M.
Delaloge, S.
Filleron, T.
Gligorov, J.
Gutowski, M.
Jacot, W.
Kirkove, C.
MacGrogan, G.
Michiels, S.
Negreiros, I.
Offersen, B.V.
Penault Llorca, F.
Pruneri, G.
Roche, H.
Russell, N.S.
Schmitt, F.
Servent, V.
Thürlimann, B.
Untch, M.
van der Hage, J.A.
van Tienhoven, G.
Wildiers, H.
Yarnold, J.
Bonnetain, F.
Mathoulin-Pélissier, S.
Bellera, C.
Dabakuyo-Yonli, T.S.
(2015). Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann oncol,
Vol.26
(5),
pp. 873-879.
show abstract
BACKGROUND: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer clinical trials (RCTs) in breast cancer. PATIENTS AND METHODS: A literature review was carried out to identify TTE end points (primary or secondary) reported in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points based on a validated consensus method that formalize the degree of agreement among experts. RESULTS: Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings. CONCLUSION: The use of standardized definitions should facilitate comparisons of trial results and improve the quality of trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting, reporting, or assessment of RCT..
Jamal-Hanjani, M.
A'Hern, R.
Birkbak, N.J.
Gorman, P.
Grönroos, E.
Ngang, S.
Nicola, P.
Rahman, L.
Thanopoulou, E.
Kelly, G.
Ellis, P.
Barrett-Lee, P.
Johnston, S.R.
Bliss, J.
Roylance, R.
Swanton, C.
(2015). Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Ann oncol,
Vol.26
(7),
pp. 1340-1346.
show abstract
BACKGROUND: Chromosomal instability (CIN) has been shown to be associated with drug resistance and poor clinical outcome in several cancer types. However, in oestrogen receptor (ER)-negative breast cancer we have previously demonstrated that extreme CIN is associated with improved clinical outcome, consistent with a negative impact of CIN on tumour fitness and growth. The aim of this current study was to validate this finding using previously defined CIN thresholds in a much larger prospective cohort from a randomised, controlled, clinical trial. PATIENTS AND METHODS: As a surrogate measurement of CIN, dual centromeric fluorescence in situ hybridisation was performed for both chromosomes 2 and 15 on 1173 tumours from the breast cancer TACT trial (CRUK01/001). Each tumour was scored manually and the mean percentage of cells deviating from the modal centromere number was used to define four CIN groups (MCD1-4), where tumours in the MCD4 group were defined as having extreme CIN. RESULTS: In a multivariate analysis of disease-free survival, with a median follow-up of 91 months, increasing CIN was associated with improved outcome in patients with ER-negative cancer (P trend = 0.03). A similar pattern was seen in ER-negative/HER2-negative cancers (Ptrend = 0.007). CONCLUSIONS: This prospective validation cohort study further substantiated the association between extreme CIN and improved outcome in ER-negative breast cancers. Identifying such patients with extreme CIN may help distinguish good from poor prognostic groups, and therefore support treatment and risk stratification in this aggressive breast cancer subtype..
Speirs, V.
Viale, G.
Mousa, K.
Palmieri, C.
Reed, S.N.
Nicholas, H.
Cheang, M.
Jassem, J.
Lønning, P.E.
Kalaitzaki, E.
van de Velde, C.J.
Rasmussen, B.B.
Verhoeven, D.M.
Shaaban, A.M.
Bartlett, J.M.
Bliss, J.M.
Coombes, R.C.
PathIES Sub-Committee,
(2015). Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†. Ann oncol,
Vol.26
(9),
pp. 1890-1897.
show abstract
BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. PathIES aimed to assess the potential prognostic and predictive value of ERβ1 and ERβ2 expression in primary tumours in order to determine benefit in the two treatment arms. PATIENTS AND METHODS: Primary tumour samples were available for 1256 patients (27% IES population). ERβ1 and ERβ2 expression was dichotomised at the median IHC score (high if ERβ1 ≥ 191, ERβ2 ≥ 164). Hazard ratios (HRs) were estimated by multivariable Cox proportional hazards models adjusting for clinicopathological factors. Treatment effects with biomarker expressions were determined by interaction tests. Analysis explored effects of markers both as a continuous variable and with dichotomised cut-offs. RESULTS: Neither ERβ1 nor ERβ2 were associated with disease-free survival (DFS) or overall survival (OS) in the whole cohort. In patients treated with continued tamoxifen, high ERβ1 expression compared with low was associated with better DFS [HR = 0.38:95% confidence interval (CI) 0.21-0.68, P = 0.001]. DFS benefit of exemestane over tamoxifen (HR = 0.40:95% CI 0.22-0.70) was found in the low ERβ1 subgroup (interaction P = 0.01). No significant difference with treatment was observed for ERβ2 expression in either DFS or OS. CONCLUSION: In the PathIES population, exemestane appeared to be superior to tamoxifen among patients with low ERβ1 expression but not in those with high ERβ1 expression. This is the first trial of its kind to report a parameter potentially predicting benefit of an aromatase inhibitor when compared with tamoxifen and an independent validation is warranted..
Eeles, R.A.
Morden, J.P.
Gore, M.
Mansi, J.
Glees, J.
Wenczl, M.
Williams, C.
Kitchener, H.
Osborne, R.
Guthrie, D.
Harper, P.
Bliss, J.M.
(2015). Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. J clin oncol,
Vol.33
(35),
pp. 4138-4144.
show abstract
PURPOSE: To assess the effects of adjuvant hormone therapy (AHT) on survival and disease outcome in women with epithelial ovarian cancer. PATIENTS AND METHODS: Participants were premenopausal and postmenopausal women who had been diagnosed with epithelial ovarian cancer (any International Federation of Gynecology and Obstetrics stage) 9 or fewer months previously. Ineligible patients included those with deliberately preserved ovarian function, with a history of a hormone-dependent malignancy, or with any contraindications to hormone-replacement therapy. Patients were centrally randomly assigned in a 1:1 ratio to either AHT for 5 years after random assignment or no AHT (control). Main outcome measures were overall survival (OS), defined as time from random assignment to death (any cause), and relapse-free survival, defined as time from random assignment to relapse or death (any cause). Patients who continued, alive and relapse free, were censored at their last known follow-up. RESULTS: A total of 150 patients (n = 75, AHT; n = 75, control) were randomly assigned from 1990 to 1995 from 19 centers in the United Kingdom, Spain, and Hungary; all patients were included in intention-to-treat analyses. The median follow-up in alive patients is currently 19.1 years. Of the 75 patients with AHT, 53 (71%) have died compared with 68 (91%) of 75 patients in the control group. OS was significantly improved in patients who were receiving AHT (hazard ratio, 0.63; 95% CI, 0.44 to 0.90; P = .011). A similar effect was seen for relapse-free survival (hazard ratio, 0.67; 95% CI, 0.47 to 0.97; P = .032). Effects remained after adjustment for known prognostic factors. CONCLUSION: These results show that women who have severe menopausal symptoms after ovarian cancer treatment can safely take hormone-replacement therapy, and this may, in fact, infer benefits in terms of OS in addition to known advantages in terms of quality of life..
Yarnold, J.
Somaiah, N.
Bliss, J.M.
(2015). Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues. Breast,
Vol.24 Suppl 2,
pp. S108-S113.
Francis, P.A.
Regan, M.M.
Fleming, G.F.
Láng, I.
Ciruelos, E.
Bellet, M.
Bonnefoi, H.R.
Climent, M.A.
Da Prada, G.A.
Burstein, H.J.
Martino, S.
Davidson, N.E.
Geyer, C.E.
Walley, B.A.
Coleman, R.
Kerbrat, P.
Buchholz, S.
Ingle, J.N.
Winer, E.P.
Rabaglio-Poretti, M.
Maibach, R.
Ruepp, B.
Giobbie-Hurder, A.
Price, K.N.
Colleoni, M.
Viale, G.
Coates, A.S.
Goldhirsch, A.
Gelber, R.D.
SOFT Investigators,
International Breast Cancer Study Group,
(2015). Adjuvant ovarian suppression in premenopausal breast cancer. N engl j med,
Vol.372
(5),
pp. 436-446.
show abstract
BACKGROUND: Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain. METHODS: We randomly assigned 3066 premenopausal women, stratified according to prior receipt or nonreceipt of chemotherapy, to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression. The primary analysis tested the hypothesis that tamoxifen plus ovarian suppression would improve disease-free survival, as compared with tamoxifen alone. In the primary analysis, 46.7% of the patients had not received chemotherapy previously, and 53.3% had received chemotherapy and remained premenopausal. RESULTS: After a median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the tamoxifen-ovarian suppression group and 84.7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.83; 95% confidence interval [CI], 0.66 to 1.04; P=0.10). Multivariable allowance for prognostic factors suggested a greater treatment effect with tamoxifen plus ovarian suppression than with tamoxifen alone (hazard ratio, 0.78; 95% CI, 0.62 to 0.98). Most recurrences occurred in patients who had received prior chemotherapy, among whom the rate of freedom from breast cancer at 5 years was 82.5% in the tamoxifen-ovarian suppression group and 78.0% in the tamoxifen group (hazard ratio for recurrence, 0.78; 95% CI, 0.60 to 1.02). At 5 years, the rate of freedom from breast cancer was 85.7% in the exemestane-ovarian suppression group (hazard ratio for recurrence vs. tamoxifen, 0.65; 95% CI, 0.49 to 0.87). CONCLUSIONS: Adding ovarian suppression to tamoxifen did not provide a significant benefit in the overall study population. However, for women who were at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remained premenopausal, the addition of ovarian suppression improved disease outcomes. Further improvement was seen with the use of exemestane plus ovarian suppression. (Funded by Pfizer and others; SOFT ClinicalTrials.gov number, NCT00066690.)..
Harman, N.L.
Conroy, E.J.
Lewis, S.C.
Murray, G.
Norrie, J.
Sydes, M.R.
Lane, J.A.
Altman, D.G.
Baigent, C.
Bliss, J.M.
Campbell, M.K.
Elbourne, D.
Evans, S.
Sandercock, P.
Gamble, C.
(2015). Exploring the role and function of trial steering committees: results of an expert panel meeting. Trials,
Vol.16,
p. 597.
show abstract
BACKGROUND: The independent oversight of clinical trials, which is recommended by the Medical Research Council (MRC) Guidelines for Good Clinical Practice, is typically provided by an independent advisory Data Monitoring Committee (DMC) and an independent executive committee, to whom the DMC makes recommendations. The detailed roles and function of this executive committee, known as the Trial Steering Committee (TSC), have not previously been studied or reviewed since those originally proposed by the MRC in 1998. METHODS: An expert panel (n = 7) was convened comprising statisticians, clinicians and trial methodologists with prior TSC experience. Twelve questions about the role and responsibilities of the TSC were discussed by the panel at two full-day meetings. Each meeting was transcribed in full and the discussions were summarised. RESULTS: The expert panel reached agreement on the role of the TSC, to which it was accountable, the membership, the definition of independence, and the experience and training needed. The management of ethical issues, difficult/complex situations and issues the TSC should not ask the DMC to make recommendations on were more difficult to discuss without specific examples, but support existed for further work to help share issues and to provide appropriate training for TSC members. Additional topics discussed, which had not been identified by previous work relating to the DMCs but were pertinent to the role of the TSC, included the following: review of data sharing requests, indemnity, lifespan of the TSC, general TSC administration, and the roles of both the Funder and the Sponsor. CONCLUSIONS: This paper presents recommendations that will contribute to the revision and update of the MRC TSC terms of reference. Uncertainty remains in some areas due to the absence of real-life examples; future guidance on these issues would benefit from a repository of case studies. Notably, the role of a patient and public involvement (PPI) contributor was not discussed, and further work is warranted to explore the role of a PPI contributor in independent trial oversight..
Tsang, Y.
Ciurlionis, L.
Kirby, A.M.
Locke, I.
Venables, K.
Yarnold, J.R.
Titley, J.
Bliss, J.
Coles, C.E.
IMPORT Trial Management Group,
(2015). Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom. Br j radiol,
Vol.88
(1056),
p. 20150453.
show abstract
full text
OBJECTIVE: IMPORT HIGH is a multicentre randomized UK trial testing dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision in females with early breast cancer and higher than average local recurrence risk. A survey was carried out to investigate the impact of this trial on the adoption of advanced breast radiotherapy (RT) techniques in the UK. METHODS: A questionnaire was sent to all 26 IMPORT HIGH recruiting RT centres to determine whether the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification. In order to compare the clinical practice of breast RT between IMPORT HIGH and non-IMPORT HIGH centres, parts of the Royal College of Radiologists (RCR) breast RT audit result were used in this study. RESULTS: 26/26 participating centres completed the questionnaire. After joining the trial, the number of centres routinely using tumour bed clips to guide whole-breast RT rose from 5 (19%) to 21 (81%). 20/26 (77%) centres now contour target volumes and organs at risk (OARs) in some or all patients compared with 14 (54%) before the trial. 14/26 (54%) centres offer inverse-planned IMRT for selected non-trial patients with breast cancer, and 10/14 (71%) have adopted the IMPORT HIGH trial protocol for target volume and OARs dose constraints. Only 2/26 (8%) centres used clip information routinely for breast treatment verification prior to IMPORT HIGH, a minority that has since risen to 7/26 (27%). Data on 1386 patients was included from the RCR audit. This suggested that more cases from IMPORT HIGH centres had surgical clips implanted (83 vs 67%), were treated using CT guided planning with full three-dimensional dose compensation (100 vs 75%), and were treated with photon boost RT (30 vs 8%). CONCLUSION: The study suggests that participation in the IMPORT HIGH trial has played an important part in providing the guidance and support networks needed for the safe integration of advanced RT techniques, where appropriate, as a standard of care for breast cancer patients treated at participating cancer centres. ADVANCES IN KNOWLEDGE: We investigated the impact of the IMPORT HIGH trial on the adoption of advanced breast RT techniques in the UK and the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification..
Irshad, S.
Gillett, C.
Pinder, S.E.
A'hern, R.P.
Dowsett, M.
Ellis, I.O.
Bartlett, J.M.
Bliss, J.M.
Hanby, A.
Johnston, S.
Barrett-Lee, P.
Ellis, P.
Tutt, A.
(2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast cancer res treat,
Vol.144
(2),
pp. 331-341.
show abstract
The TACT trial is the largest study assessing the benefit of taxanes as part of adjuvant therapy for early breast cancer. The goal of this translational study was to clarify the predictive and prognostic value of Tau within the TACT trial. Tissue microarrays (TMA) were available from 3,610 patients. ER, PR, HER2 from the TACT trial and Tau protein expression was determined by immunohistochemistry on duplicate TMAs. Two parallel scoring systems were generated for Tau expression ('dichotomised' vs. 'combined' score). The positivity rate of Tau expression was 50 % in the trial population (n = 2,483). Tau expression correlated positively with ER (p < 0.001) and PR status (p < 0.001); but negatively with histological grade (p < 0.001) and HER2 status (p < 0.001). Analyses with either scoring systems for Tau expression demonstrated no significant interaction between Tau expression and efficacy of docetaxel. Contrary to the hypothesis that taxane benefit would be enriched in Tau negative/low patients, the only groups with a suggestion of a reduced event rate in the taxane group were the HER2-positive, Tau positive subgroups. Tau expression was seen to be a prognostic factor on univariate analysis associated with an improved DFS, independent of the treatment group (p < 0.001). It had no prognostic value in ER-negative tumours and the weak prognostic effect of Tau in ER-positive tumours (p = 0.02) diminished, when considering ER as an ordinal variable. On multivariable analyses, Tau had no prognostic value in either group. In addition, no significant interaction between Tau expression and benefit from docetaxel in patients within the PR-positive and negative subsets was seen. This is now the second large adjuvant study, and the first with quantitative analysis of ER and Tau expression, failing to show an association between Tau and taxane benefit with limited utility as a prognostic marker for Tau in ER-positive early breast cancer patients..
Horwich, A.
Fossa, S.D.
Huddart, R.
Dearnaley, D.P.
Stenning, S.
Aresu, M.
Bliss, J.M.
Hall, E.
(2014). Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br j cancer,
Vol.110
(1),
pp. 256-263.
show abstract
full text
BACKGROUND: Patients with stage I testicular seminoma are typically diagnosed at a young age and treatment is associated with low relapse and mortality rates. The long-term risks of adjuvant radiotherapy in this patient group are therefore particularly relevant. METHODS: We identified patients and obtained treatment details from 12 cancer centres (11 United Kingdom, 1 Norway) and ascertained second cancers and mortality through national registries. Data from 2629 seminoma patients treated with radiotherapy between 1960 and 1992 were available, contributing 51,151 person-years of follow-up. RESULTS: Four hundred and sixty-eight second cancers (excluding non-melanoma skin cancers) were identified. The standardised incidence ratio (SIR) was 1.61 (95% confidence interval (CI): 1.47-1.76, P<0.0001). The SIR was 1.53 (95% CI: 1.39-1.68, P<0.0001) when the 32 second testicular cancers were also excluded. This increase was largely due to an excess risk to organs in the radiation field; for pelvic-abdominal sites the SIR was 1.62 (95% CI: 1.43-1.83), with no significant elevated risk of cancers in organs elsewhere. There was no overall increase in mortality with a standardised mortality ratio (SMR) of 1.06 (95% CI: 0.98-1.14), despite an increase in the cancer-specific mortality (excluding testicular cancer deaths) SMR of 1.46 (95% CI: 1.30-1.65, P<0.0001). CONCLUSION: The prognosis of stage I seminoma is excellent and it is important to avoid conferring long-term increased risk of iatrogenic disease such as radiation-associated second cancers..
Hall, E.
Cameron, D.
Waters, R.
Barrett-Lee, P.
Ellis, P.
Russell, S.
Bliss, J.M.
Hopwood, P.
TACT Trial Investigators,
(2014). Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). Eur j cancer,
Vol.50
(14),
pp. 2375-2389.
show abstract
full text
BACKGROUND: The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5 years suggested no improvement in disease-free survival with FEC-D. Given differing toxicity profiles of the regimens, the impact on quality of life (QL) was explored. METHODS: Patients from 44 centres completed standardised QL questionnaires before chemotherapy, after cycles 4 and 8, at 9, 12, 18 and 24 months and at 6 years follow-up. Patient diaries assessed frequency, associated distress and impact on daily activity of 15 treatment related side effects. FINDINGS: 830 patients (415 FEC-D; 415 controls) contributed assessments during 0-24 months; 362 of whom participated again at 6 years. During chemotherapy, FEC-D impaired global health/QL and depression rates and significantly more QL domains than standard regimens. Novel diary card ratings highlighted significantly more distress and interference with daily activities due to FEC-D side effects compared with standard treatment. In both groups, most QL parameters returned to baseline levels by 2 years and were unchanged at 6 years. INTERPRETATION: Within expected negative effects of chemotherapy on wide ranging QL domains FEC-D patients reported greater toxicity, disruption and distress during treatment with no improvement in disease outcome at 5 years than patients receiving standard anthracycline-based chemotherapy. Findings should inform future patients of relative costs and benefits of adjuvant chemotherapy..
Pagani, O.
Regan, M.M.
Walley, B.A.
Fleming, G.F.
Colleoni, M.
Láng, I.
Gomez, H.L.
Tondini, C.
Burstein, H.J.
Perez, E.A.
Ciruelos, E.
Stearns, V.
Bonnefoi, H.R.
Martino, S.
Geyer, C.E.
Pinotti, G.
Puglisi, F.
Crivellari, D.
Ruhstaller, T.
Winer, E.P.
Rabaglio-Poretti, M.
Maibach, R.
Ruepp, B.
Giobbie-Hurder, A.
Price, K.N.
Bernhard, J.
Luo, W.
Ribi, K.
Viale, G.
Coates, A.S.
Gelber, R.D.
Goldhirsch, A.
Francis, P.A.
TEXT and SOFT Investigators,
International Breast Cancer Study Group,
(2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N engl j med,
Vol.371
(2),
pp. 107-118.
show abstract
full text
BACKGROUND: Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer. METHODS: In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials. RESULTS: After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane-ovarian suppression group and 87.3% in the tamoxifen-ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval [CI], 0.60 to 0.85; P<0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane-ovarian suppression group, as compared with 88.8% in the tamoxifen-ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P<0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane-ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P=0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane-ovarian suppression group and 29.4% of those in the tamoxifen-ovarian suppression group, with profiles similar to those for postmenopausal women. CONCLUSIONS: In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence. (Funded by Pfizer and others; TEXT and SOFT ClinicalTrials.gov numbers, NCT00066703 and NCT00066690, respectively.)..
Palmieri, C.
Cleator, S.
Kilburn, L.S.
Kim, S.B.
Ahn, S.-.
Beresford, M.
Gong, G.
Mansi, J.
Mallon, E.
Reed, S.
Mousa, K.
Fallowfield, L.
Cheang, M.
Morden, J.
Page, K.
Guttery, D.S.
Rghebi, B.
Primrose, L.
Shaw, J.A.
Thompson, A.M.
Bliss, J.M.
Coombes, R.C.
(2014). NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast cancer res treat,
Vol.148
(3),
pp. 581-590.
show abstract
Neoadjuvant endocrine therapy is an alternative to chemotherapy for women with oestrogen receptor (ER)-positive early breast cancer (BC). We aimed to assess feasibility of recruiting patients to a study comparing chemotherapy versus endocrine therapy in postmenopausal women with ER-rich primary BC, and response as well as translational endpoints were assessed. Patients requiring neoadjuvant therapy were randomised to chemotherapy: 6 × 3-weekly cycles FE₁₀₀C or endocrine therapy: letrozole 2.5 mg, daily for 18-23 weeks. Primary endpoints were recruitment feasibility and tissue collection. Secondary endpoints included clinical, radiological and pathological response rates, quality of life and translational endpoints. 63/80 patients approached were eligible, of those 44 (70, 95% CI 57-81) were randomised. 12 (54.5, 95% CI 32.2-75.6) chemotherapy patients showed radiological objective response compared with 13 (59.1, 95% CI 36.4-79.3) letrozole patients. Compared with baseline, mean Ki-67 levels fell in both groups at days 2-4 and at surgery [fold change: 0.24 (95% CI 0.12-0.51) and 0.24; (95% CI 0.15-0.37), respectively]. Plasma total cfDNA levels rose from baseline to week 8 [fold change: chemotherapy 2.10 (95% CI 1.47-3.00), letrozole 1.47(95% CI 0.98-2.20)], and were maintained at surgery in the chemotherapy group [chemotherapy 2.63; 95% CI 1.56-4.41), letrozole 0.95 (95% CI 0.71-1.26)]. An increase in plasma let-7a miRNA was seen at surgery for patients with objective radiological response to chemotherapy. Recruitment and tissue collection endpoints were met; however, a larger trial was deemed unfeasible due to slow accrual. Both regimens were equally efficacious. Dynamic changes were seen in Ki-67 and circulating biomarkers in both groups with increases in cfDNA and let-7a miRNA persisting until surgery for chemotherapy patients..
EBCTCG (Early Breast Cancer Trialists' Collaborative Group),
McGale, P.
Taylor, C.
Correa, C.
Cutter, D.
Duane, F.
Ewertz, M.
Gray, R.
Mannu, G.
Peto, R.
Whelan, T.
Wang, Y.
Wang, Z.
Darby, S.
(2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet,
Vol.383
(9935),
pp. 2127-2135.
show abstract
BACKGROUND: Postmastectomy radiotherapy was shown in previous meta-analyses to reduce the risks of both recurrence and breast cancer mortality in all women with node-positive disease considered together. However, the benefit in women with only one to three positive lymph nodes is uncertain. We aimed to assess the effect of radiotherapy in these women after mastectomy and axillary dissection. METHODS: We did a meta-analysis of individual data for 8135 women randomly assigned to treatment groups during 1964-86 in 22 trials of radiotherapy to the chest wall and regional lymph nodes after mastectomy and axillary surgery versus the same surgery but no radiotherapy. Follow-up lasted 10 years for recurrence and to Jan 1, 2009, for mortality. Analyses were stratified by trial, individual follow-up year, age at entry, and pathological nodal status. FINDINGS: 3786 women had axillary dissection to at least level II and had zero, one to three, or four or more positive nodes. All were in trials in which radiotherapy included the chest wall, supraclavicular or axillary fossa (or both), and internal mammary chain. For 700 women with axillary dissection and no positive nodes, radiotherapy had no significant effect on locoregional recurrence (two-sided significance level [2p]>0·1), overall recurrence (rate ratio [RR], irradiated vs not, 1·06, 95% CI 0·76-1·48, 2p>0·1), or breast cancer mortality (RR 1·18, 95% CI 0·89-1·55, 2p>0·1). For 1314 women with axillary dissection and one to three positive nodes, radiotherapy reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·68, 95% CI 0·57-0·82, 2p=0·00006), and breast cancer mortality (RR 0·80, 95% CI 0·67-0·95, 2p=0·01). 1133 of these 1314 women were in trials in which systemic therapy (cyclophosphamide, methotrexate, and fluorouracil, or tamoxifen) was given in both trial groups and, for them, radiotherapy again reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·67, 95% CI 0·55-0·82, 2p=0·00009), and breast cancer mortality (RR 0·78, 95% CI 0·64-0·94, 2p=0·01). For 1772 women with axillary dissection and four or more positive nodes, radiotherapy reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·79, 95% CI 0·69-0·90, 2p=0·0003), and breast cancer mortality (RR 0·87, 95% CI 0·77-0·99, 2p=0·04). INTERPRETATION: After mastectomy and axillary dissection, radiotherapy reduced both recurrence and breast cancer mortality in the women with one to three positive lymph nodes in these trials even when systemic therapy was given. For today's women, who in many countries are at lower risk of recurrence, absolute gains might be smaller but proportional gains might be larger because of more effective radiotherapy. FUNDING: Cancer Research UK, British Heart Foundation, UK Medical Research Council..
Kilburn, L.S.
Banerji, J.
Bliss, J.M.
NCRI Breast Clinical Studies Group,
(2014). The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective. Trials,
Vol.15,
p. 379.
show abstract
BACKGROUND: Improved survival rates in early breast cancer and the chronic nature of disease relapse result in a large cohort of patients being available for long-term follow-up (LTFUP) in randomised controlled trials. Whilst of recognised scientific value to assess long-term treatment-related sequelae, the volume of this activity can be challenging for trialists and participating sites, and comes at a considerable cost to research funders and the National Health Service (NHS). A National Cancer Research Institute Breast Clinical Studies Group supported project aimed to characterise UK LTFUP data collection procedures in order to propose improvements. METHODS: Protocols and case report forms for UK non-commercial National Institute for Health Research portfolio early breast cancer randomised controlled trials were reviewed and a questionnaire sent to associated participating NHS sites. Responders were asked to give opinions on issues with follow-up and LTFUP data collection procedures and to suggest potential improvements to practice. Results were used to inform design of a proposed standard LTFUP case report form. RESULTS: Thirty-four trials, involving eight Clinical Trials Units were eligible for inclusion in the review. All trials requested follow-up at least annually up to 5 years, with two-thirds requesting LTFUP after that time point. Information relating to efficacy endpoints was captured for all trials via case report forms; however, precise detail on recording of recurrence, second malignancies and death varied. Separately, questionnaires were returned from 66 NHS sites. Main concerns identified included difficulties in identifying all adverse events from hospital notes, volume of work, bureaucratic data management practices in Clinical Trials Units and perceptions of prioritisation of recruitment over follow-up. CONCLUSION: Variation has existed with respect to detail of LTFUP information requested for UK trials. Improved communication, simplification and standardisation of data and associated collection methods are possible without compromising data requirements for efficient and effective trial reporting. Future use of routinely collected data, captured via electronic means, could transform practices and alleviate resource usage..
Copson, E.
Eccles, B.
Maishman, T.
Gerty, S.
Stanton, L.
Cutress, R.I.
Altman, D.G.
Durcan, L.
Simmonds, P.
Lawrence, G.
Jones, L.
Bliss, J.
Eccles, D.
POSH Study Steering Group,
(2013). Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. J natl cancer inst,
Vol.105
(13),
pp. 978-988.
show abstract
BACKGROUND: Breast cancer at a young age is associated with poor prognosis. The Prospective Study of Outcomes in Sporadic and Hereditary Breast Cancer (POSH) was designed to investigate factors affecting prognosis in this patient group. METHODS: Between 2000 and 2008, 2956 patients aged 40 years or younger were recruited to a UK multicenter prospective observational cohort study (POSH). Details of tumor pathology, disease stage, treatment received, and outcome were recorded. Overall survival (OS) and distant disease-free interval (DDFI) were assessed using Kaplan-Meier curves. All statistical tests were two-sided. RESULTS: Median age of patients was 36 years. Median tumor diameter was 22 mm, and 50% of patients had positive lymph nodes; 59% of tumors were grade 3, 33.7% were estrogen receptor (ER) negative, and 24% were human epidermal growth factor receptor 2 (HER2) positive. Five-year OS was higher for patients with ER-positive than ER-negative tumors (85.0%, 95% confidence interval [CI] = 83.2% to 86.7% vs 75.7%, 95% CI = 72.8% to 78.4%; P < .001), but by eight years, survival was almost equal. The eight-year OS of patients with ER-positive tumors was similar to that of patients with ER-negative tumors in both HER2-positive and HER2-negative subgroups. The flexible parametric survival model for OS shows that the risk of death increases steadily over time for patients with ER-positive tumors in contrast to patients with ER-negative tumors, where risk of death peaked at two years. CONCLUSIONS: These results confirm the increased frequency of ER-negative tumors and early relapse in young patients and also demonstrate the equally poor longer-term outlook of young patients who have ER-positive tumors with HER2-negative or -positive disease..
Bartlett, J.M.
A'hern, R.
Piper, T.
Ellis, I.O.
Dowsett, M.
Mallon, E.A.
Cameron, D.A.
Johnston, S.
Bliss, J.M.
Ellis, P.
Barrett-Lee, P.J.
(2013). Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast cancer res treat,
Vol.138
(3),
pp. 773-781.
show abstract
Results from the NSABP B-28 trial suggest AKT activation may predict reduced benefit from taxanes following standard anthracycline therapy. Pre-clinical data support a link between PI3 K/AKT signalling and taxane resistance. Using the UK taxotere as adjuvant chemotherapy trial (TACT), we tested the hypothesis that activation of AKT or downstream markers, p70S6K or p90RSK, identifies patients with reduced benefit from taxane chemotherapy. TACT is a multi-centre open-label phase III trial comparing four cycles of standard FEC (fluorouracil, epirubicin, cyclophosphamide) followed by four cycles of docetaxel versus eight cycles of anthracycline-based chemotherapy. Samples from 3,596 patients were available for the current study. We performed immunohistochemical analysis of activation of AKT, p70S6 K and p90RSK. Using a training set with multiple cut-offs for predictive values (10 % increments in expression), we found no evidence for a treatment by marker interaction for pAKT473, pS6 or p90RSK. pAKT473, pS6 and p90RSK expression levels were weakly correlated. A robust, preplanned statistical analysis in the TACT trial found no evidence that pAKT473, pS6 or p90RSK identifies patients deriving reduced benefit from adjuvant docetaxel. This result is consistent with the recent NASBP B28 study where the pAKT473 effect is not statistically significant for the treatment interaction test. Therefore, neither TACT nor NASBP-B28 provides statistically robust evidence of a treatment by marker interaction between pAKT473 and taxane treatment. Alternative methods for selecting patients benefitting from taxanes should be explored..
Johnston, S.R.
Kilburn, L.S.
Ellis, P.
Dodwell, D.
Cameron, D.
Hayward, L.
Im, Y.-.
Braybrooke, J.P.
Brunt, A.M.
Cheung, K.-.
Jyothirmayi, R.
Robinson, A.
Wardley, A.M.
Wheatley, D.
Howell, A.
Coombes, G.
Sergenson, N.
Sin, H.-.
Folkerd, E.
Dowsett, M.
Bliss, J.M.
SoFEA investigators,
(2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet oncol,
Vol.14
(10),
pp. 989-998.
show abstract
BACKGROUND: The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation. METHODS: In a composite, multicentre, phase 3 randomised controlled trial done in the UK and South Korea, postmenopausal women with hormone-receptor-positive breast cancer (oestrogen receptor [ER] positive, progesterone receptor [PR] positive, or both) were eligible if they had relapsed or progressed with locally advanced or metastatic disease on an NSAI (given as adjuvant for at least 12 months or as first-line treatment for at least 6 months). Additionally, patients had to have adequate organ function and a WHO performance status of 0-2. Participants were randomly assigned (1:1:1) to receive fulvestrant (500 mg intramuscular injection on day 1, followed by 250 mg doses on days 15 and 29, and then every 28 days) plus daily oral anastrozole (1 mg); fulvestrant plus anastrozole-matched placebo; or daily oral exemestane (25 mg). Randomisation was done with computer-generated permuted blocks, and stratification was by centre and previous use of an NSAI as adjuvant treatment or for locally advanced or metastatic disease. Participants and investigators were aware of assignment to fulvestrant or exemestane, but not of assignment to anastrozole or placebo. The primary endpoint was progression-free survival (PFS). Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, numbers NCT00253422 (UK) and NCT00944918 (South Korea). FINDINGS: Between March 26, 2004, and Aug 6, 2010, 723 patients underwent randomisation: 243 were assigned to receive fulvestrant plus anastrozole, 231 to fulvestrant plus placebo, and 249 to exemestane. Median PFS was 4·4 months (95% CI 3·4-5·4) in patients assigned to fulvestrant plus anastrozole, 4·8 months (3·6-5·5) in those assigned to fulvestrant plus placebo, and 3·4 months (3·0-4·6) in those assigned to exemestane. No difference was recorded between the patients assigned to fulvestrant plus anastrozole and fulvestrant plus placebo (hazard ratio 1·00, 95% CI 0·83-1·21; log-rank p=0·98), or between those assigned to fulvestrant plus placebo and exemestane (0·95, 0·79-1·14; log-rank p=0·56). 87 serious adverse events were reported: 36 in patients assigned to fulvestrant plus anastrozole, 22 in those assigned to fulvestrant plus placebo, and 29 in those assigned to exemestane. Grade 3-4 adverse events were rare; the most frequent were arthralgia (three in the group assigned to fulvestrant plus anastrozole; seven in that assigned to fulvestrant plus placebo; eight in that assigned to exemestane), lethargy (three; 11; 11), and nausea or vomiting (five; two; eight). INTERPRETATION: After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane..
Haviland, J.S.
Owen, J.R.
Dewar, J.A.
Agrawal, R.K.
Barrett, J.
Barrett-Lee, P.J.
Dobbs, H.J.
Hopwood, P.
Lawton, P.A.
Magee, B.J.
Mills, J.
Simmons, S.
Sydenham, M.A.
Venables, K.
Bliss, J.M.
Yarnold, J.R.
START Trialists' Group,
(2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet oncol,
Vol.14
(11),
pp. 1086-1094.
show abstract
BACKGROUND: 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer. In this prespecified analysis, we report the 10-year follow-up of the START trials testing 13 fraction and 15 fraction regimens. METHODS: From 1999 to 2002, women with completely excised invasive breast cancer (pT1-3a, pN0-1, M0) were enrolled from 35 UK radiotherapy centres. Patients were randomly assigned to a treatment regimen after primary surgery followed by chemotherapy and endocrine treatment (where prescribed). Randomisation was computer-generated and stratified by centre, type of primary surgery (breast-conservation surgery or mastectomy), and tumour bed boost radiotherapy. In START-A, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 41·6 Gy or 39 Gy in 13 fractions over 5 weeks. In START-B, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 40 Gy in 15 fractions over 3 weeks. Eligibility criteria included age older than 18 years and no immediate surgical reconstruction. Primary endpoints were local-regional tumour relapse and late normal tissue effects. Analysis was by intention to treat. Follow-up data are still being collected. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. FINDINGS: START-A enrolled 2236 women. Median follow-up was 9·3 years (IQR 8·0-10·0), after which 139 local-regional relapses had occurred. 10-year rates of local-regional relapse did not differ significantly between the 41·6 Gy and 50 Gy regimen groups (6·3%, 95% CI 4·7-8·5 vs 7·4%, 5·5-10·0; hazard ratio [HR] 0·91, 95% CI 0·59-1·38; p=0·65) or the 39 Gy (8·8%, 95% CI 6·7-11·4) and 50 Gy regimen groups (HR 1·18, 95% CI 0·79-1·76; p=0·41). In START-A, moderate or marked breast induration, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 39 Gy group than in the 50 Gy group. Normal tissue effects did not differ significantly between 41·6 Gy and 50 Gy groups. START-B enrolled 2215 women. Median follow-up was 9·9 years (IQR 7·5-10·1), after which 95 local-regional relapses had occurred. The proportion of patients with local-regional relapse at 10 years did not differ significantly between the 40 Gy group (4·3%, 95% CI 3·2-5·9) and the 50 Gy group (5·5%, 95% CI 4·2-7·2; HR 0·77, 95% CI 0·51-1·16; p=0·21). In START-B, breast shrinkage, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 40 Gy group than in the 50 Gy group. INTERPRETATION: Long-term follow-up confirms that appropriately dosed hypofractionated radiotherapy is safe and effective for patients with early breast cancer. The results support the continued use of 40 Gy in 15 fractions, which has already been adopted by most UK centres as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer. FUNDING: Cancer Research UK, UK Medical Research Council, UK Department of Health..
Bliss, J.M.
Kilburn, L.S.
Coleman, R.E.
Forbes, J.F.
Coates, A.S.
Jones, S.E.
Jassem, J.
Delozier, T.
Andersen, J.
Paridaens, R.
van de Velde, C.J.
Lønning, P.E.
Morden, J.
Reise, J.
Cisar, L.
Menschik, T.
Coombes, R.C.
(2012). Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J clin oncol,
Vol.30
(7),
pp. 709-717.
show abstract
PURPOSE: Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. PATIENTS AND METHODS: Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. RESULTS: In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). CONCLUSION: The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival..
Mieog, J.S.
Morden, J.P.
Bliss, J.M.
Coombes, R.C.
van de Velde, C.J.
IES Steering Committee,
(2012). Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet oncol,
Vol.13
(4),
pp. 420-432.
show abstract
BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p<0·0001). More events occurred during treatment in the exemestane group than in the tamoxifen group (66 [2·8%] vs seven [0·3%], adjusted OR 9·90, 99% CI 3·52-27·82; p<0·0001). There was no significant difference between groups in events in the post-treatment period (ten with exemestane [0·4%] vs seven with tamoxifen [0·3%]; p=0·46). More patients in the exemestane group (1082 of 2319 patients, 46·7%) had musculoskeletal symptoms than in the tamoxifen group (901 of 2338, 38·5%; OR 1·48, 99% CI 1·32-1·67, p<0·0001). More events occurred during treatment in the exemestane group than in the tamoxifen group (984 [42·4%] vs 776 [33·2%], adjusted OR 1·59, 99% CI 1·32-1·91; p<0·0001), with this difference persisting to some extent in the post-treatment period (449 [19·4%] vs 390 [16·7%]; p=0·017). Of 73 on-treatment cases of carpal tunnel syndrome, 58 (79·5%) completed questionnaires were available. 27 patients (46·6%) had bilateral carpal tunnel syndrome and 31 (53·4%) had unilateral disease; 40 (69·0%) underwent surgical release. The disorder greatly affected daily-life activities in 21 (36·2%) cases. Occurrence of musculoskeletal symptoms, including carpal tunnel syndrome, was associated with improved disease-free survival in unadjusted analysis (p=0·023), but not with overall survival (p=0·36). However, after adjustment for possible confounding factors, musculoskeletal symptoms were not associated with disease-free survival (hazard ratio [HR] 0·96, 95% CI 0·82-1·14, p=0·67) or overall survival (HR 1·02, 95% CI 0·84-1·25, p=0·82). INTERPRETATION: Occurrence of carpal tunnel syndrome is higher in patients with breast cancer given exemestane than in those treated with tamoxifen, and surgical release might be necessary in most cases. Development of musculoskeletal symptoms in the first 6 months of treatment is not an independent biomarker of improved disease outcome. Further investigation is warranted into the relation between treatment-emergent musculoskeletal symptoms and clinical outcome in patients with breast cancer receiving hormonal therapy. FUNDING: Pfizer..
Albain, K.
Anderson, S.
Arriagada, R.
Barlow, W.
Bergh, J.
Bliss, J.
Buyse, M.
Cameron, D.
Carrasco, E.
Clarke, M.
Correa, C.
Coates, A.
Collins, R.
Costantino, J.
Cutter, D.
Cuzick, J.
Darby, S.
Davidson, N.
Davies, C.
Davies, K.
Delmestri, A.
Di Leo, A.
Dowsett, M.
Elphinstone, P.
Evans, V.
Ewertz, M.
Gelber, R.
Gettins, L.
Geyer, C.
Goldhirsch, A.
Godwin, J.
Gray, R.
Gregory, C.
Hayes, D.
Hill, C.
Ingle, J.
Jakesz, R.
James, S.
Kaufmann, M.
Kerr, A.
MacKinnon, E.
McGale, P.
McHugh, T.
Norton, L.
Ohashi, Y.
Paik, S.
Pan, H.C.
Perez, E.
Peto, R.
Piccart, M.
Pierce, L.
Pritchard, K.
Pruneri, G.
Raina, V.
Ravdin, P.
Robertson, J.
Rutgers, E.
Shao, Y.F.
Swain, S.
Taylor, C.
Valagussa, P.
Viale, G.
Whelan, T.
Winer, E.
Wang, Y.
Wood, W.
EBCTCG,
(2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet,
Vol.379
(9814),
pp. 432-444.
Tsang, Y.
Haviland, J.
Venables, K.
Yarnold, J.
FAST Trial Management Group,
(2012). The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiother oncol,
Vol.104
(2),
pp. 143-147.
show abstract
BACKGROUND AND PURPOSE: Linear quadratic models predict that hypofractionation increases the biological effect of physical dose inhomogeneity. The clinical significance of this effect was tested retrospectively in a trial of adjuvant breast hypofractionation. METHODS: The UK FAST trial randomised 915 women after breast conservation surgery between standard fractionation and two dose levels of a 5-fraction regimen delivering 5.7 or 6.0 Gy fractions in 5 weeks, using 3D dosimetry. Logistic regression tested for association between the absolute volumes receiving different isodose level >100% of prescribed dose (hotspots) and the risk of change in 2-year photographic breast appearance. The strength of this association was compared between control and hypofractionated groups. RESULTS: Three hundred and ninety datasets from 11 participating centres were available for analysis. At 2 years post-randomisation, 81 (20.8%) had mild change and 24 (6.2%) had marked change in photographic breast appearance. After adjusting for breast size and surgical deficit, there was no statistically significant association between the risk of 2-year change in breast appearance and dose inhomogeneity in either the control or hypofractionated schedules, according to the various definitions of hotspots analysed. The magnitude of the effect of dosimetry on 2-year change in breast appearance did not vary significantly between control and hypofractionated schedules for any of the dosimetry parameters (p>0.05 for all heterogeneity tests). CONCLUSION: Dose inhomogeneity had no greater impact on the risk of 2-year change in photographic breast appearance after hypofractionated breast radiotherapy than after standard fractionation..
Fallowfield, L.J.
Kilburn, L.S.
Langridge, C.
Snowdon, C.F.
Bliss, J.M.
Coombes, R.C.
IES Trial Steering Committee,
(2012). Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br j cancer,
Vol.106
(6),
pp. 1062-1067.
show abstract
full text
BACKGROUND: The Intergroup Exemestane Study (IES) (ISRCTN11883920) demonstrated improved survival for postmenopausal women with ER-positive/unknown primary breast cancer who switched to exemestane after 2-3 years tamoxifen, compared with those continuing on tamoxifen to complete 5 years therapy. This was achieved without detriment to on-treatment quality-of-life (QoL). We report on- and post-treatment QoL impact in IES. METHODS: A total of 582 patients from 8 countries participated in the QoL substudy. Functional Assessment of Cancer Therapy-Breast (FACT-B) and endocrine symptom subscale (ES) were completed at baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 months. The primary endpoint was FACT-B Trial Outcome Index (TOI); secondary endpoints included severity of individual endocrine symptoms. RESULTS: Both the groups showed gradual improvement in overall QoL and lessening of total endocrine symptoms post treatment compared with baseline (P<0.002). There was no evidence of any between-group differences in TOI. Vasomotor complaints remained high on treatment. Vaginal discharge was more frequent (P<0.01) with tamoxifen up to 24 months from baseline. In both the groups, post-treatment libido did not recover to baseline levels. CONCLUSION: Clinical benefits of switching to exemestane are accompanied by good overall QoL. Although some symptoms persist, the majority of endocrine symptoms improve after treatment completion..
Pinhel, I.
Hills, M.
Drury, S.
Salter, J.
Sumo, G.
A'Hern, R.
Bliss, J.M.
Sestak, I.
Cuzick, J.
Barrett-Lee, P.
Harris, A.
Dowsett, M.
NCRI Adjuvant Breast Cancer Trial Management Group,
(2012). ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast cancer res,
Vol.14
(2),
p. R46.
show abstract
INTRODUCTION: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas. METHODS: ER and HER2 levels were assessed with immunohistochemistry (IHC) and (for HER2) fluorescent in situ hybridization (FISH) and by quantitative reverse transcription-polymerase chain reaction (q-RT-PCR) in formalin-fixed primary breast cancers from 448 patients in the National Cancer Research Institute (NCRI) Adjuvant Breast Cancer Trial (ABC) tamoxifen-only arm. Relations at the RNA level were assessed in 1,139 TransATAC tumors. RESULTS: ER and HER2 RNA levels were negatively correlated as expected in HER2+ve (IHC 3+ and/or FISH-amplified) tumors (r = -0.45; P = 0.0028). However, in HER2-ve tumors (ER+ve and ER-ve combined), a significant positive correlation was found (r = 0.43; P < 0.0001), HER2 RNA levels being 1.74-fold higher in ER+ve versus ER-ve tumors. This correlation was maintained in the ER+veHER2-ve subgroup (r = 0.24; P = 0.0023) and confirmed in this subgroup in 1,139 TransATAC tumours (r = 0.25; P < 0.0001). The positive relation extended to IHC-detected ER in ABC: mean ± 95% confidence interval (CI) H-scores were 90 ± 19 and 134 ± 19 for 0 and 1+ HER2 IHC categories, respectively (P = 0.0013). A trend toward lower relapse-free survival (RFS) was observed in patients with the lowest levels of ER and HER2 RNA levels within the ER+veHER2-ve subgroup both for ABC and TransATAC cohorts. CONCLUSIONS: ER and HER2 expression is positively correlated in HER2-ve tumors. The distinction between HER2+ve and HER2-ve is greater in ER-ve than in ER+ve tumors. These findings are important to consider in clinical trials of anti-HER2 and anti-endocrine therapy in HER2-ve disease. TRIAL REGISTRATION: Clinical trial identifier: ISRCTN31514446..
Metzger-Filho, O.
Tutt, A.
de Azambuja, E.
Saini, K.S.
Viale, G.
Loi, S.
Bradbury, I.
Bliss, J.M.
Azim, H.A.
Ellis, P.
Di Leo, A.
Baselga, J.
Sotiriou, C.
Piccart-Gebhart, M.
(2012). Dissecting the heterogeneity of triple-negative breast cancer. J clin oncol,
Vol.30
(15),
pp. 1879-1887.
show abstract
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes. This is observed despite its usual high sensitivity to chemotherapy. In the advanced setting, responses observed with chemotherapy lack durability. Early-stage clinical studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction. The molecular complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies. In this review, we discuss the biology of TNBC at the pathologic and the molecular levels. We also elaborate on the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC..
Yarnold, J.R.
Agrawal, R.K.
Alhasso, A.
Barrett-Lee, P.J.
Bliss, J.M.
Bliss, P.
Bloomfield, D.
Bowen, J.
Brunt, A.M.
Donovan, E.
Emson, M.
Goodman, A.
Harnett, A.
Haviland, J.S.
Kaggwa, R.
Morden, J.P.
Robinson, A.
Simmons, S.
Stewart, A.
Sydenham, M.A.
Syndikus, I.
Tremlett, J.
Tsang, Y.
Wheatley, D.
Venables, K.
(2011). First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiotherapy and oncology,
Vol.100
(1),
pp. 93-8.
Treasure, T.
Lang-Lazdunski, L.
Waller, D.
Bliss, J.M.
Tan, C.
Entwisle, J.
Snee, M.
O'Brien, M.
Thomas, G.
Senan, S.
O'Byrne, K.
Kilburn, L.S.
Spicer, J.
Landau, D.
Edwards, J.
Coombes, G.
Darlison, L.
Peto, J.
(2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet oncology,
Vol.12
(8),
pp. 763-10.
Campbell, H.E.
Epstein, D.
Bloomfield, D.
Griffin, S.
Manca, A.
Yarnold, J.
Bliss, J.
Johnson, L.
Earl, H.
Poole, C.
Hiller, L.
Dunn, J.
Hopwood, P.
Barrett-Lee, P.
Ellis, P.
Cameron, D.
Harris, A.L.
Gray, A.M.
Sculpher, M.J.
(2011). The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur j cancer,
Vol.47
(17),
pp. 2517-2530.
show abstract
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depending upon prognostic factors. Adjuvant chemotherapy reduces this risk; however, increasingly effective regimens are associated with higher costs and toxicity profiles, making it likely that different regimens may be cost-effective for women with differing prognoses. To investigate this we performed a cost-effectiveness analysis of four treatment strategies: (1) no chemotherapy, (2) chemotherapy using cyclophosphamide, methotrexate, and fluorouracil (CMF) (a first generation regimen), (3) chemotherapy using Epirubicin-CMF (E-CMF) or fluorouracil, epirubicin, and cyclophosphamide (FEC60) (a second generation regimens), and (4) chemotherapy with FEC60 followed by docetaxel (FEC-D) (a third generation regimen). These adjuvant chemotherapy regimens were used in three large UK-led randomised controlled trials (RCTs). METHODS: A Markov model was used to simulate the natural progression of early breast cancer and the impact of chemotherapy on modifying this process. The probability of a first recurrent event within the model was estimated for women with different prognostic risk profiles using a parametric regression-based survival model incorporating established prognostic factors. Other probabilities, treatment effects, costs and quality of life weights were estimated primarily using data from the three UK-led RCTs, a meta-analysis of all relevant RCTs, and other published literature. The model predicted the lifetime costs, quality adjusted life years (QALYs) and cost-effectiveness of the four strategies for women with differing prognoses. Sensitivity analyses investigated the impact of uncertain parameters and model assumptions. FINDINGS: For women with an average to high risk of recurrence (based upon prognostic factors and any other adjuvant therapies received), FEC-D appeared most cost-effective assuming a threshold of £20,000 per QALY for the National Health Service (NHS). For younger low risk women, E-CMF/FEC60 tended to be the optimal strategy and, for some older low risk women, the model suggested a policy of no chemotherapy was cost-effective. For no patient group was CMF chemotherapy the preferred option. Sensitivity analyses demonstrated cost-effectiveness results to be particularly sensitive to the treatment effect estimate for FEC-D and the future price of docetaxel. INTERPRETATION: To our knowledge, this analysis is the first cost-effectiveness comparison of no chemotherapy, and first, second, and third generation adjuvant chemotherapy regimens for early breast cancer patients with differing prognoses. The results demonstrate the potential for different treatment strategies to be cost-effective for different types of patients. These findings may prove useful for policy makers attempting to formulate cost-effective treatment guidelines in the field of early breast cancer..
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
Darby, S.
McGale, P.
Correa, C.
Taylor, C.
Arriagada, R.
Clarke, M.
Cutter, D.
Davies, C.
Ewertz, M.
Godwin, J.
Gray, R.
Pierce, L.
Whelan, T.
Wang, Y.
Peto, R.
(2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet,
Vol.378
(9804),
pp. 1707-1716.
show abstract
BACKGROUND: After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may do so more for some groups of women than for others. We describe the absolute magnitude of these reductions according to various prognostic and other patient characteristics, and relate the absolute reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk. METHODS: We undertook a meta-analysis of individual patient data for 10,801 women in 17 randomised trials of radiotherapy versus no radiotherapy after breast-conserving surgery, 8337 of whom had pathologically confirmed node-negative (pN0) or node-positive (pN+) disease. FINDINGS: Overall, radiotherapy reduced the 10-year risk of any (ie, locoregional or distant) first recurrence from 35·0% to 19·3% (absolute reduction 15·7%, 95% CI 13·7-17·7, 2p<0·00001) and reduced the 15-year risk of breast cancer death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6-6·0, 2p=0·00005). In women with pN0 disease (n=7287), radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence reduction 15·4%, 13·2-17·6, 2p<0·00001) and from 20·5% to 17·2% (absolute mortality reduction 3·3%, 0·8-5·8, 2p=0·005), respectively. In these women with pN0 disease, the absolute recurrence reduction varied according to age, grade, oestrogen-receptor status, tamoxifen use, and extent of surgery, and these characteristics were used to predict large (≥20%), intermediate (10-19%), or lower (<10%) absolute reductions in the 10-year recurrence risk. Absolute reductions in 15-year risk of breast cancer death in these three prediction categories were 7·8% (95% CI 3·1-12·5), 1·1% (-2·0 to 4·2), and 0·1% (-7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03). In the few women with pN+ disease (n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute reduction 21·2%, 95% CI 14·5-27·9, 2p<0·00001) and the 15-year risk of breast cancer death from 51·3% to 42·8% (absolute reduction 8·5%, 1·8-15·2, 2p=0·01). Overall, about one breast cancer death was avoided by year 15 for every four recurrences avoided by year 10, and the mortality reduction did not differ significantly from this overall relationship in any of the three prediction categories for pN0 disease or for pN+ disease. INTERPRETATION: After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth. These proportional benefits vary little between different groups of women. By contrast, the absolute benefits from radiotherapy vary substantially according to the characteristics of the patient and they can be predicted at the time when treatment decisions need to be made. FUNDING: Cancer Research UK, British Heart Foundation, and UK Medical Research Council..
Coombes, R.C.
Bliss, J.M.
Espie, M.
Erdkamp, F.
Wals, J.
Tres, A.
Marty, M.
Coleman, R.E.
Tubiana-Mathieu, N.
den Boer, M.O.
Wardley, A.
Kilburn, L.S.
Cooper, D.
Thomas, M.W.
Reise, J.A.
Wilkinson, K.
Hupperets, P.
(2011). Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer. Journal of clinical oncology,
Vol.29
(24),
pp. 3247-8.
Larkin, J.M.
Turajlic, S.
Nathan, P.D.
Lorigan, P.
Stamp, G.
Gonzalez de Castro, D.
Martin, N.
Griffiths, J.
Edmonds, K.
Sarker, S.
James, M.G.
A'Hern, R.
Coombes, G.
Snowdon, C.
Bliss, J.M.
Gore, M.E.
Marais, R.
(2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). J clin oncol,
Vol.29
(15_suppl),
p. TPS229.
show abstract
TPS229 Background: Recent studies have indicated that KIT mutations occur in approximately 20% of acral and mucosal melanomas (Curtin, al. 2006; Beadling, et al. 2008). Several case reports have shown that KIT mutated melanomas can respond to treatment with KIT inhibitors (Hodi et al. 2008; Lutzky et al. 2008; Quintas-Cardama et al. 2008; Handolias et al. 2010; Itoh, et al. 2010; Satzger et al. 2010; Terheyden et al. 2010; Woodman and Davies 2010) suggesting that such tumours critically depend on upregulated KIT signalling. Nilotinib, which potently inhibits the tyrosine kinase activity of BCR-ABL and KIT, has been evaluated in patients with advanced KIT mutated GIST and has shown clinical efficacy at well tolerated doses (Demetri et al. 2009; Montemurro et al. 2009; Schlemmer et al. 2010). METHODS: NICAM is a single arm 2-stage open label phase II study of nilotinib in KIT mutated advanced mucosal or acral melanoma. Patients with KIT mutations known to confer resistance to nilotinib are excluded. The primary objective in this feasibility study is to evaluate the efficacy of nilotinib in KIT mutated advanced mucosal and acral melanoma with a primary endpoint of progression free survival at 6 months. Secondary endpoints include response rate at 12 weeks; overall survival; toxicity of treatment; correlation between the response to nilotinib and KIT genotype, KIT gene copy number and KIT expression. In addition, the following will be explored: 1. Suppression of phosphorylation of KIT and downstream pathways on day 15 tumour biopsies; 2. Possible mechanisms of resistance by analysis of biopsies obtained at disease progression; 3. The use of circulating tumour DNA for non-invasive KIT mutational testing; 4. Genetic lesions that potentially cooperate with oncogenic KIT in melanoma (using Next Generation Sequencing). All patients are treated until disease progression or unacceptable toxicity. If 2 or more of the first 9 patients are progression free at 6 months, patient entry will continue into the second stage until a total of 24 patients have been recruited. To date, 45 patients have been registered and screened for KIT mutation and 5 patients have entered the study..
Coombes, R.C.
Von Minckwitz, G.
Hicks, J.
Klare, P.
Evans, A.A.
Schmidt, M.
Makris, A.
Grieve, R.
Loibl, S.
Maher, L.
Mousa, K.
Buchsenscuhtz, K.
A'Hern, R.
Bliss, J.M.
(2011). A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). J clin oncol,
Vol.29
(15_suppl),
p. TPS115.
show abstract
TPS115 Background: Celecoxib is a selective COX-2 inhibitor licensed for the treatment of chronic arthritis. However, an association between non-steroidal anti-inflammatory drug (NSAID) use and decreased breast cancer risk in women has also been demonstrated (Harris et al, Epidemiology, 1996), believed to be due to inhibition of the COX-2 enzyme. Preclinical data has shown that COX-2 inhibitors can prevent mammary tumour formation (Harris et al, Can Res, 2000), inhibit angiogenesis (Rozic et al, Int J Cancer, 2001) and reverse resistance to apoptosis (Tsujii et al, Cell, 1995). A review of treatment with aromatase inhibitors and COX-2 inhibitors concluded that interactions between aromatase and COX pathways are involved in tumour formation and progression in breast cancer (Falandry et al, Ann Oncol, 2009). REACT is designed to assess the adjuvant benefit of COX-2 inhibition on treatment of primary breast cancer. METHODS: This is an academic study coordinated by the ICCG (UK) and GBG (DE), under the auspices of BIG and with Pfizer funding. To date 1,074 subjects have been recruited from 131 sites. Women with completely resected, unilateral breast cancer +/- chemotherapy and +/- radiotherapy are randomised to either 400mg celecoxib p.o. or placebo daily for 2 years in a 2:1 ratio in favour of celecoxib; stratification is by centre and hormone receptor status (pos. vs. neg.). Eligible patients must have a normal baseline ECG and normal clinical cardiovascular assessment. Patients with HER2 +++ disease and patients with a history of an adverse reaction or hypersensitivity to NSAIDs and sulphonamides are excluded. All ER+ and/or PgR+ patients receive endocrine therapy according to local practice. The primary endpoint is disease free survival (DFS). To detect a 20% reduction in risk of recurrence in the 5 year DFS, 2,590 patients (709 events) are required (HR = 0.8) with 80% power and α=0.05. Secondary endpoints include overall survival, safety and incidence of second primaries. A pathology sub-study is being carried out to investigate modulators of celecoxib response with 907 consented patients..
Smith, I.E.
Johnson, L.
Dowsett, M.
Robertson, J.F.
Robison, L.E.
Kokan, J.S.
Evans, A.A.
Holcombe, C.
Horgan, K.
Skene, A.
Prasad, R.
Absar, M.S.
Vidya, R.
Bundred, N.J.
Harding-Mackean, C.
Wheatley, D.A.
Kissin, M.W.
Pinhel, I.F.
Kilburn, L.S.
Bliss, J.M.
POETIC Trialists,
(2011). Trial of perioperative endocrine therapy: Individualizing care (POETIC). J clin oncol,
Vol.29
(15_suppl),
p. TPS117.
show abstract
TPS117 Background: The neoadjuvant IMPACT trial suggested Ki67 levels after 2 weeks endocrine therapy predicts long-term outcome. Major changes in gene expression have also been seen in ER+ breast cancer after aromatase inhibitor (AI) treatment. POETIC evaluates whether changes in Ki67 level after 2 weeks treatment predicts for relapse-free survival (RFS) more effectively than the baseline value. It also tests whether gene expression profile at this timepoint provides more accurate prognostic and predictive information than the pre-treatment profile. Experimental evidence suggests peri-operative endocrine therapy may improve disease outcome. This hypothesis is also addressed in POETIC. ( ISRCTN63882543 ) With a sample size of 4000, an improvement in 5 year relapse from 10% to 7% could be detected with 91% power (two sided alpha of 5%), as would a 1.3 fold difference in the ability of Ki67 to predict RFS (90% power, two sided 5% significance level). Target recruitment is 4000 patients from 100 UK hospitals over 3-4 years. METHODS: Patients are randomised in the ratio of 2:1 to perioperative AI (letrozole 2.5mg or anastrozole 1mg daily) starting 2 weeks before planned surgery until 2 weeks after surgery. FFPE and RNA-later samples are taken prior to trial entry (baseline) and at surgery. Eligible patients are postmenopausal with ER+ invasive breast cancer. Consent to take additional research tissue is sought from patients undergoing diagnostic biopsy. Consenting patients donate tumour tissue in RNA-later and/or a FFPE research sample and enter POETIC following diagnosis of ER+ breast cancer. Matching tumour tissue is taken at surgery. Where an RNA-later sample at baseline is unavailable, consenting patients may undergo a further biopsy for research tissue immediately before study entry. Where consent procedures at diagnosis present logistical challenges, sites may provide FFPE tissue left over from diagnosis only. The 1(st) patient was entered in September 2008, and by January 2011 102 UK hospitals open and 1200 patients were entered. 182 optional RNA-later samples at both timepoints are available. Current success is due to a flexible approach to tissue sample collection and overcoming local and national logistical challenges..
Leonard, R.
Ballinger, R.
Cameron, D.
Ellis, P.
Fallowfield, L.
Gosney, M.
Johnson, L.
Kilburn, L.S.
Makris, A.
Mansi, J.
Reed, M.
Ring, A.
Robinson, A.
Simmonds, P.
Thomas, G.
Bliss, J.M.
(2011). Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?. British journal of cancer,
Vol.105
(9),
pp. 1260-7.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
Davies, C.
Godwin, J.
Gray, R.
Clarke, M.
Cutter, D.
Darby, S.
McGale, P.
Pan, H.C.
Taylor, C.
Wang, Y.C.
Dowsett, M.
Ingle, J.
Peto, R.
(2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet,
Vol.378
(9793),
pp. 771-784.
show abstract
BACKGROUND: As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen. METHODS: We undertook a collaborative meta-analysis of individual patient data from 20 trials (n=21,457) in early breast cancer of about 5 years of tamoxifen versus no adjuvant tamoxifen, with about 80% compliance. Recurrence and death rate ratios (RRs) were from log-rank analyses by allocated treatment. FINDINGS: In oestrogen receptor (ER)-positive disease (n=10,645), allocation to about 5 years of tamoxifen substantially reduced recurrence rates throughout the first 10 years (RR 0·53 [SE 0·03] during years 0-4 and RR 0·68 [0·06] during years 5-9 [both 2p<0·00001]; but RR 0·97 [0·10] during years 10-14, suggesting no further gain or loss after year 10). Even in marginally ER-positive disease (10-19 fmol/mg cytosol protein) the recurrence reduction was substantial (RR 0·67 [0·08]). In ER-positive disease, the RR was approximately independent of progesterone receptor status (or level), age, nodal status, or use of chemotherapy. Breast cancer mortality was reduced by about a third throughout the first 15 years (RR 0·71 [0·05] during years 0-4, 0·66 [0·05] during years 5-9, and 0·68 [0·08] during years 10-14; p<0·0001 for extra mortality reduction during each separate time period). Overall non-breast-cancer mortality was little affected, despite small absolute increases in thromboembolic and uterine cancer mortality (both only in women older than 55 years), so all-cause mortality was substantially reduced. In ER-negative disease, tamoxifen had little or no effect on breast cancer recurrence or mortality. INTERPRETATION: 5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen. FUNDING: Cancer Research UK, British Heart Foundation, and Medical Research Council..
Dowsett, M.
Smith, I.
Robertson, J.
Robison, L.
Pinhel, I.
Johnson, L.
Salter, J.
Dunbier, A.
Anderson, H.
Ghazoui, Z.
Skene, T.
Evans, A.
A'Hern, R.
Iskender, A.
Wilcox, M.
Bliss, J.
(2011). Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J natl cancer inst monogr,
Vol.2011
(43),
pp. 120-123.
show abstract
The preoperative setting is increasingly popular for the clinical investigation of hormonal agents and new biological drugs. The effectiveness of endocrine agents is well established for estrogen receptor-positive disease, and the emphasis in preoperative studies is on their combination with agents targeted at resistance mechanisms over 3 or more months. New agents are also being assessed for early evidence of clinical efficacy in shorter-term window-of-opportunity studies. The establishment of Ki67 as an intermediate marker of treatment benefit and of long-term outcome, with endocrine drugs, provides the opportunity for new trial designs with Ki67 as the primary endpoint. The PeriOperative Endocrine Therapy for Individualizing Care (POETIC) trial is randomizing (2:1) 4000 estrogen receptor-positive patients to 2 weeks presurgical treatment with a nonsteroidal aromatase inhibitor or no presurgical treatment. It provides a unique opportunity for detailed study of the determinants of response and resistance to estrogen deprivation as well as testing the role of presurgical therapy for improved biomarker-based estimates of prognosis..
Martin, S.
Sydenham, M.
Haviland, J.
A'Hern, R.
Owen, R.
Bliss, J.
Yarnold, J.
(2010). Test of association between variant tg beta 1 alleles and late adverse effects of breast radiotherapy. Radiotherapy and oncology,
Vol.97
(1),
pp. 15-4.
Hopwood, P.
Haviland, J.S.
Sumo, G.
Mills, J.
Bliss, J.M.
Yarnold, J.R.
(2010). Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet oncology,
Vol.11
(3),
pp. 231-10.
Bertelli, G.
Hall, E.
Ireland, E.
Snowdon, C.F.
Jassem, J.
Drosik, K.
Karnicka-Mlodkowska, H.
Coombes, R.C.
Bliss, J.M.
(2010). Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Annals of oncology,
Vol.21
(3),
pp. 498-8.
Hopwood, P.
Sumo, G.
Mills, J.
Haviland, J.
Bliss, J.M.
(2010). The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: Results from the UK Standardisation of Radiotherapy Trials (START). Breast,
Vol.19
(2),
pp. 84-8.
Sirohi, B.
A'Hern, R.
Coombes, G.
Bliss, J.M.
Hickish, T.
Perren, T.
Crawford, M.
O'Brien, M.
Iveson, T.
Ebbs, S.
Skene, A.
Laing, R.
Smith, I.E.
(2010). A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of oncology,
Vol.21
(8),
pp. 1623-7.
Coleman, R.E.
Banks, L.M.
Girgis, S.I.
Vrdoljak, E.
Fox, J.
Cawthorn, S.J.
Patel, A.
Bliss, J.M.
Coombes, R.C.
Kilburn, L.S.
(2010). Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast cancer research and treatment,
Vol.124
(1),
pp. 153-9.
Dowsett, M.
Cuzick, J.
Ingle, J.
Coates, A.
Forbes, J.
Bliss, J.
Buyse, M.
Baum, M.
Buzdar, A.
Colleoni, M.
Coombes, C.
Snowdon, C.
Gnant, M.
Jakesz, R.
Kaufmann, M.
Boccardo, F.
Godwin, J.
Davies, C.
Peto, R.
(2010). Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of clinical oncology,
Vol.28
(3),
pp. 509-10.
Treasure, T.
Waller, D.
Tan, C.
Entwisle, J.
O'Brien, M.
O'Byrne, K.
Thomas, G.
Snee, M.
Spicer, J.
Landau, D.
Lang-Lazdunski, L.
Bliss, J.
Peckitt, C.
Rogers, S.
Marriage (nee Denholm), E.
Coombes, G.
Webster-Smith, M.
Peto, J.
(2009). The Mesothelioma and Radical Surgery Randomized Controlled Trial The MARS Feasibility Study. Journal of thoracic oncology,
Vol.4
(10),
pp. 1254-5.
Reed, M.W.
Wyld, L.
Ellis, P.
Bliss, J.
Leonard, R.
(2009). Breast Cancer in Older Women: Trials and Tribulations. Clinical oncology,
Vol.21
(2),
pp. 99-4.
Ellis, P.
Barrett-Lee, P.
Johnson, L.
Cameron, D.
Wardley, A.
O'Reilly, S.
Verrill, M.
Smith, I.
Yarnold, J.
Coleman, R.
Earl, H.
Canney, P.
Twelves, C.
Poole, C.
Bloomfield, D.
Hopwood, P.
Johnston, S.
Dowsett, M.
Bartlett, J.M.
Ellis, I.
Peckitt, C.
Hall, E.
Bliss, J.M.
TACT Trial Management Group,
TACT Trialists,
(2009). Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet,
Vol.373
(9676),
pp. 1681-1692.
show abstract
BACKGROUND: Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration. METHODS: In this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated permuted block randomisation to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m(2) at 3-weekly intervals) for four cycles (n=2073) or control (n=2089). For the control regimen, centres chose either FEC for eight cycles (n=1265) or epirubicin (100 mg/m(2) at 3-weekly intervals) for four cycles followed by CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) at 4-weekly intervals) for four cycles (n=824). The primary endpoint was disease-free survival. Analysis was by intention to treat (ITT). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN79718493. FINDINGS: All randomised patients were included in the ITT population. With a median follow-up of 62 months, disease-free survival events were seen in 517 of 2073 patients in the experimental group compared with 539 of 2089 controls (hazard ratio [HR] 0.95, 95% CI 0.85-1.08; p=0.44). 75.6% (95% CI 73.7-77.5) of patients in the experimental group and 74.3% (72.3-76.2) of controls were alive and disease-free at 5 years. The proportion of patients who reported any acute grade 3 or 4 adverse event was significantly greater in the experimental group than in the control group (p<0.0001); the most frequent events were neutropenia (937 events vs 797 events), leucopenia (507 vs 362), and lethargy (456 vs 272). INTERPRETATION: This study did not show any overall gain from the addition of docetaxel to standard anthracycline chemotherapy. Exploration of predictive biomarker-defined subgroups might have the potential to better target the use of taxane-based therapy. FUNDING: Cancer Research UK (CRUK 01/001), Sanofi-Aventis, Pfizer, and Roche..
Gibson, L.
Lawrence, D.
Dawson, C.
Bliss, J.
(2009). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane database of systematic reviews,
(4),
p. 122.
Kilburn, L.S.
TNT Trial Management Group,
(2008). 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin oncol (r coll radiol),
Vol.20
(1),
pp. 35-39.
START Trialists' Group,
Bentzen, S.M.
Agrawal, R.K.
Aird, E.G.
Barrett, J.M.
Barrett-Lee, P.J.
Bliss, J.M.
Brown, J.
Dewar, J.A.
Dobbs, H.J.
Haviland, J.S.
Hoskin, P.J.
Hopwood, P.
Lawton, P.A.
Magee, B.J.
Mills, J.
Morgan, D.A.
Owen, J.R.
Simmons, S.
Sumo, G.
Sydenham, M.A.
Venables, K.
Yarnold, J.R.
(2008). The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet oncol,
Vol.9
(4),
pp. 331-341.
show abstract
BACKGROUND: The international standard radiotherapy schedule for breast cancer treatment delivers a high total dose in 25 small daily doses (fractions). However, a lower total dose delivered in fewer, larger fractions (hypofractionation) is hypothesised to be at least as safe and effective as the standard treatment. We tested two dose levels of a 13-fraction schedule against the standard regimen with the aim of measuring the sensitivity of normal and malignant tissues to fraction size. METHODS: Between 1998 and 2002, 2236 women with early breast cancer (pT1-3a pN0-1 M0) at 17 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy versus 41.6 Gy or 39 Gy in 13 fractions of 3.2 Gy or 3.0 Gy over 5 weeks. Women were eligible if they were aged over 18 years, did not have an immediate surgical reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. FINDINGS: 749 women were assigned to the 50 Gy group, 750 to the 41.6 Gy group, and 737 to the 39 Gy group. After a median follow up of 5.1 years (IQR 4.4-6.0) the rate of local-regional tumour relapse at 5 years was 3.6% (95% CI 2.2-5.1) after 50 Gy, 3.5% (95% CI 2.1-4.3) after 41.6 Gy, and 5.2% (95% CI 3.5-6.9) after 39 Gy. The estimated absolute differences in 5-year local-regional relapse rates compared with 50 Gy were 0.2% (95% CI -1.3% to 2.6%) after 41.6 Gy and 0.9% (95% CI -0.8% to 3.7%) after 39 Gy. Photographic and patient self-assessments suggested lower rates of late adverse effects after 39 Gy than with 50 Gy, with an HR for late change in breast appearance (photographic) of 0.69 (95% CI 0.52-0.91, p=0.01). From a planned meta-analysis with the pilot trial, the adjusted estimates of alpha/beta value for tumour control was 4.6 Gy (95% CI 1.1-8.1) and for late change in breast appearance (photographic) was 3.4 Gy (95% CI 2.3-4.5). INTERPRETATION: The data are consistent with the hypothesis that breast cancer and the dose-limiting normal tissues respond similarly to change in radiotherapy fraction size. 41.6 Gy in 13 fractions was similar to the control regimen of 50 Gy in 25 fractions in terms of local-regional tumour control and late normal tissue effects, a result consistent with the result of START Trial B. A lower total dose in a smaller number of fractions could offer similar rates of tumour control and normal tissue damage as the international standard fractionation schedule of 50 Gy in 25 fractions..
Haviland, J.S.
Ashton, A.
Broad, B.
Gothard, L.
Owen, J.R.
Tait, D.
Sydenham, M.A.
Yarnold, J.R.
Bliss, J.M.
(2008). Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clin oncol (r coll radiol),
Vol.20
(7),
pp. 497-501.
show abstract
AIMS: Serial photographs have been collected prospectively to evaluate the effect of radiotherapy on normal tissues in the breast. The aim of this study was to compare two methods of scoring radiation-induced changes. MATERIALS AND METHODS: Five-year photographs of 400 patients randomised to receive either 42.9 or 39 Gy in 13 fractions to the whole breast after tumour excision of early breast cancer were compared with a post-surgery baseline and scored for change in breast appearance on a three-point graded scale. Two alternative methods of scoring using three observers were compared: (a) scores allocated independently, with independent resolution of discrepancies, and (b) scores allocated by consensus. RESULTS: Treatment effects estimated from the consensus and independent scores were very similar (odds ratio 1.89, 95% confidence interval 1.21-2.96 vs 2.28, 95% confidence interval 1.50-3.47, respectively). Agreement between the scores obtained from each method was reasonable, and the repeatability of the consensus method was good. CONCLUSIONS: The consensus method of scoring photographic change in breast appearance seems to be no less sensitive to randomised dose as the independent method of assessment, but is much quicker to administer. The consensus method has been used to score over 3000 sets of photographs in the National Cancer Research Institute Standardisation of Breast Radiotherapy trial..
Johnson, L.
Barrett-Lee, P.
Ellis, P.
Bliss, J.M.
TACT Trial Management Group,
(2008). How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patients. Br j cancer,
Vol.98
(1),
pp. 34-38.
show abstract
Questionnaires were circulated to UK patients and health care professionals (HCPs) participating in the Taxotere as Adjuvant ChemoTherapy (TACT) trial in autumn 2004 asking if and how trial results, when available, should be conveyed to patients. A total of 1431 (37% of surviving UK TACT patients) returned questionnaires. In all, 30 (2%) patients did not want results. In all, 554 (40%) patients preferred to receive them via their hospital; 664 (47%) preferred results posted directly to their home, 177 (13%) preferred a letter providing a telephone number to request results. Six hundred and twelve patients thought results should come directly from the trials office. One hundred and seventy-six HCPs from 89 UK centres (86%) returned questionnaires. In all, 169 out of 176 patients (96%) thought results should be written in lay terms for patients. Seventy (41%) preferred patients to receive results via their hospital; 64 (38%) preferred a letter providing a telephone number to request results, and 32 (19%) preferred results posted directly to patients. Thirty-one HCPs (18%) thought results to patients should come directly from the trials office. A total of 868 (61%) patients thought next of kin of deceased patients should receive results, 543 (38%) did not; 47 (27%) HCPs thought they should; 118 (68%) did not..
START Trialists' Group,
Bentzen, S.M.
Agrawal, R.K.
Aird, E.G.
Barrett, J.M.
Barrett-Lee, P.J.
Bentzen, S.M.
Bliss, J.M.
Brown, J.
Dewar, J.A.
Dobbs, H.J.
Haviland, J.S.
Hoskin, P.J.
Hopwood, P.
Lawton, P.A.
Magee, B.J.
Mills, J.
Morgan, D.A.
Owen, J.R.
Simmons, S.
Sumo, G.
Sydenham, M.A.
Venables, K.
Yarnold, J.R.
(2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet,
Vol.371
(9618),
pp. 1098-1107.
show abstract
BACKGROUND: The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2.0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefits of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy. METHODS: Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. FINDINGS: 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)--ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy. INTERPRETATION: A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions..
Bartlett, J.M.
Ellis, I.O.
Dowsett, M.
Mallon, E.A.
Cameron, D.A.
Johnston, S.
Hall, E.
A'Hern, R.
Peckitt, C.
Bliss, J.M.
Johnson, L.
Barrett-Lee, P.
Ellis, P.
(2007). Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J clin oncol,
Vol.25
(28),
pp. 4423-4430.
show abstract
PURPOSE: Human epidermal growth factor receptor 2 (HER-2) expression is associated with increased risk of high-grade disease, nodal metastasis, and absence of estrogen receptors (ERs) in early breast cancer. We tested interactions between ER and HER-2 to determine if they may modulate breast cancer nodal metastasis and proliferation. PATIENTS AND METHODS: Tumors from the Cancer Research UK Taxotere as Adjuvant Chemotherapy phase III trial were tested for HER-2 using current diagnostic procedures. ER status, progesterone status, clinicopathologic characteristics, and patient age were included in a logistic regression analysis to identify associations with HER-2 status (positive v negative). RESULTS: A total of 841 (23.6%) of 3,565 samples were HER-2 positive (3+ by immunohistochemistry or positive by fluorescent in situ hybridization). ER-negative tumors were more likely to be HER-2 positive than were ER-positive tumors (odds ratio [OR] = 1.87, ER negative v ER positive; P < .001). For ER-positive tumors, risk of HER-2 positivity increased by grade (OR = 7.6, grade 3 v grade 1; P < .001) but not nodal status (OR = 1.3, four or more positive nodes v node negative; P = .08). Conversely, ER negative node-positive tumors were markedly more frequently HER-2 positive than node-negative cases (OR = 3.05, four or more positive nodes v node negative; P < .001) but independent of grade (OR = 0.82, grade 3 v grade 1; P = .76). CONCLUSION: In early breast cancer patients selected for cytotoxic chemotherapy, we identified significant interactions between HER-2 and ER expression that correlate with tumor pathology. In ER-positive breast cancers, HER-2 expression correlates with grade, not nodal metastasis. In ER-negative breast cancers, HER-2 expression correlates with increased nodal positivity, not grade. ER and HER-2 expression may modify tumor pathology via ER/HER-2-mediated cross talk..
Coleman, R.E.
Banks, L.M.
Girgis, S.I.
Kilburn, L.S.
Vrdoljak, E.
Fox, J.
Cawthorn, S.J.
Patel, A.
Snowdon, C.F.
Hall, E.
Bliss, J.M.
Coombes, R.C.
(2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet oncology,
Vol.8
(2),
pp. 119-9.
Bliss, J.M.
Johnson, L.
Lawrence, D.
Peto, J.
Price, D.
Yarnold, J.
Barrett-Lee, P.
Brunt, A.M.
Dodwell, D.
Earl, H.
Fernando, I.
Foster, L.
George, W.D.
Harnett, A.M.
Perren, T.
Poole, C.
Raina, V.
Robinson, A.
(2007). Ovarian ablation or suppression in premenopausal early breast cancer: Results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. Jnci-journal of the national cancer institute,
Vol.99
(7),
pp. 516-10.
Adjuvant Breast Cancer Trialists Collaborative Group,
Collaborator: J Bliss,
(2007). Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J natl cancer inst,
Vol.99
(7),
pp. 506-515.
Hopwood, P.
Haviland, J.
Mills, J.
Sumo, G.
Bliss, J.M.
(2007). The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UKSTART Trial (Standardisation of Breast Radiotherapy Trial). Breast,
Vol.16
(3),
pp. 241-11.
Johnson, L.
Cameron, D.
Barrett-Lee, P.
Canney, P.
Bliss, J.M.
and on behalf of the TACT2 Trial Management Group,
(2007). Improving adjuvant chemotherapy in breast cancer – can we get more for less with TACT2? 19:593-595. Clin oncol (r coll. radiol),
Vol.19,
pp. 593-595.
Coombes, R.C.
Kilburn, L.S.
Snowdon, C.F.
Paridaens, R.
Coleman, R.E.
Jones, S.E.
Jassem, J.
Van de Velde, C.J.
Delozier, T.
Alvarez, I.
Del Mastro, L.
Ortmann, O.
Diedrich, K.
Coates, A.S.
Bajetta, E.
Holmberg, S.B.
Dodwell, D.
Mickiewicz, E.
Andersen, J.
Lonning, P.E.
Cocconi, G.
Forbes, J.
Castiglione, M.
Stuart, N.
Stewart, A.
Fallowfield, L.J.
Bertelli, G.
Hall, E.
Bogle, R.G.
Carpentieri, M.
Colajori, E.
Subar, M.
Ireland, E.
Bliss, J.M.
(2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet,
Vol.369
(9561),
pp. 559-12.
Gibson, L.J.
Dawson, C.L.
Lawrence, D.J.
Bliss, J.M.
(2007). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane database of systematic reviews,
(1),
p. 92.
Nitti, D.
Wils, J.
Dos Santos, J.G.
Fountzilas, G.
Conte, P.F.
Sava, C.
Tres, A.
Coombes, R.C.
Crivellari, D.
Marchet, A.
Sanchez, E.
Bliss, J.M.
Homewood, J.
Couvreur, M.L.
Hall, E.
Baron, B.
Woods, E.
Emson, M.
Van Cutsem, E.
Lise, M.
(2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer A combined analysis of the EORTC GI Group and the ICCG. Annals of oncology,
Vol.17
(2),
pp. 262-8.
Owen, J.R.
Ashton, A.
Bliss, J.M.
Homewood, J.
Harper, C.
Hanson, J.
Haviland, J.
Bentzen, S.M.
Yarnold, J.R.
(2006). Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet oncol,
Vol.7
(6),
pp. 467-471.
show abstract
BACKGROUND: Standard curative schedules of radiotherapy to the breast deliver 25 fractions of 2.0 Gy over 5 weeks. In a randomised trial, we tested whether fewer, larger fractions were at least as safe and as effective as standard regimens. In this analysis, we assessed the long-term results of tumour control in the same population. METHODS: In 1986-98, we randomly assigned 1410 women with invasive breast cancer (tumour stage 1-3 with a maximum of one positive node and no metastasis) who had had local tumour excision of early stage breast cancer to receive 50 Gy radiotherapy given in 25 fractions, 39 Gy given in 13 fractions, or 42.9 Gy given in 13 fractions, all given over 5 weeks. The primary endpoint was late change in breast appearance, which has been reported elsewhere. Here, we report ipsilateral tumour relapse, one of the secondary endpoints. Relapse was defined as any appearance of cancer in the irradiated breast. Analysis was by intention to treat. FINDINGS: After a median follow-up of 9.7 years (IQR 7.8-11.8) for the 838 (95%) patients who survived, the risk of ipsilateral tumour relapse after 10 years was 12.1% (95% CI 8.8-15.5) in the 50 Gy group, 14.8% (11.2-18.3) in the 39 Gy group, and 9.6% (6.7-12.6) in the 42.9 Gy group (difference between 39 Gy and 42.9 Gy groups, chi2 test, p=0.027). The sensitivity of breast cancer to dose per fraction was estimated to be 4.0 Gy (95% CI 1.0-7.8), similar to that estimated for the late adverse effects in healthy tissue from breast radiotherapy. INTERPRETATION: Breast cancer tissue is probably just as sensitive to fraction size as dose-limiting healthy tissues. If this finding is confirmed, radiotherapy schedules can be greatly simplified by the delivery of fewer, larger fractions without compromising effectiveness or safety, and possibly improving both..
Venables, K.
Miles, E.A.
Aird, E.G.
Hoskin, P.J.
on behalf of START Trial Management Group,
Member: Bliss, J.M.
(2006). What is the optimum breast plan: a study based on the START trial plans. Br j radiol,
Vol.79,
pp. 734-739.
Smith, I.E.
(2006). Trastuzumab for early breast cancer. Lancet,
Vol.367
(9505),
p. 107.
Rayman, M.
Thompson, A.
Warren-Perry, M.
Galassini, R.
Catterick, J.
Hall, E.
Lawrence, D.
Bliss, J.
(2006). Impact of selenium on mood and quality of life: A randomized, controlled trial. Biological psychiatry,
Vol.59
(2),
pp. 147-8.
Coombes, R.C.
Paridaens, R.
Jassem, J.
Van de Velde, C.J.
Delozier, T.
Jones, S.E.
Hall, E.
Kilburn, L.S.
Snowdon, C.F.
Bliss, J.M.
(2006). First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. Journal of clinical oncology,
Vol.24
(18),
pp. 9S-1.
Coombes, R.C.
Paridaens, R.
Jassem, J.
Van de Velde, C.J.
Delozier, T.
Jones, S.E.
Hall, E.
Kilburn, L.S.
Snowdon, C.F.
Bliss, J.M.
Intergroup Exemestane Study (IES),
(2006). First mature analysis of the Intergroup Exemestane Study. J clin oncol,
Vol.24
(18_suppl),
p. LBA527.
show abstract
LBA527 Background: We have previously shown that switching to exemestane (E) after 2-3 years tamoxifen (T) improves disease free survival (DFS) in postmenopausal (PM) women with early breast cancer (BC). We report results with 95% of patients (pts) having ≥3 years follow-up. METHODS: 4724 PM pts (2352 E vs 2372 T) with ER +ve/unknown unilateral BC, disease-free after 2-3 years T, were randomized to continue T or switch to E to complete a total of 5 years adjuvant endocrine therapy. 122 pts (56 E vs 66 T) originally reported as ER unknown were later found to be ER -ve. In addition to intention to treat (ITT), we repeated analyses excluding ER -ve pts. Adverse events (pre relapse) by treatment received were analysed on treatment (TRT) and also including follow-up (TRTFU). In safety analyses P < 0.01 was taken as significant due to multiple testing. RESULTS: With median follow up of 58 months there were 808 first events (disease relapse, contralateral breast cancer (CLBC), intercurrent death) and 483 deaths. See table for unadjusted hazard ratios (HR). In ER +ve/unknown pts, adjusting for pre-specified prognostic factors of nodal status, chemo use, HRT use, gave HR for DFS of 0.74 (0.64, 0.85); p < 0.0001 and for overall survival (OS) of 0.83 (0.69, 0.99); P = 0.04. There were 145 intercurrent deaths (65 E vs 80 T), including deaths from cardiac (14 E vs 13 T), vascular (17 E vs 11 T) and other cancers (20 E vs 35 T). No statistically significant differences in myocardial infarctions, angina, or cerebrovascular accidents were observed. In T pts there were more thromboembolic (TRT p = 0.006, TRTFU p = NS) and serious gynaecologic events (TRT p < 0.001, TRTFU p < 0.001) and less fractures (TRT p = NS, TRTFU p = 0.003). CONCLUSIONS: Switching to E following 2-3 years of T significantly improves DFS, reducing chance of first event, CLBC and distant recurrence. In ER +ve/unknown pts, the switching strategy with E significantly reduces the risk of dying. [Table: see text] [Table: see text]..
Chua, S.
Smith, I.E.
A'Hern, R.P.
Coombes, G.A.
Hickish, T.F.
Robinson, A.C.
Laing, R.W.
O'Brien, M.E.
Ebbs, S.R.
Hong, A.
Wardley, A.
Mughal, T.
Verrill, M.
Dubois, D.
Bliss, J.M.
(2005). Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of oncology,
Vol.16
(9),
pp. 1435-7.
Horwich, A.
Dearnaley, D.
Huddart, R.
Graham, J.
Bessell, E.
Mason, M.
Bliss, J.
(2005). A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother oncol,
Vol.75
(1),
pp. 34-43.
show abstract
BACKGROUND AND PURPOSE: To evaluate the efficacy and toxicity of an accelerated fractionation regimen to treat localised muscle invasive bladder cancer. PATIENTS AND METHODS: A prospective randomised trial was undertaken in 229 patients randomised between 1988 and 1998 comparing accelerated fractionation (AF) to a dose of 60.8 Gy in 32 fractions over 26 days with conventional fractionation (CF) treating to 64 Gy in 32 fractions over 45 days. Accelerated fractionation was delivered using two fractions per day with a 6h gap between fractions and with the first daily fraction size being 1.8 Gy and the second daily fraction size being 2.0 Gy. There was a 1 week treatment gap after the first 12 fractions. Conventional fractionation was one fraction per day, 5 days per week. Eligible patients had clinical stage T2 or T3, N0 or N1, M0 transitional cell carcinoma. The primary endpoint of the trial was local control and the trial was powered to detect a 20% difference (alpha 0.05, power 90%). Secondary endpoints were toxicity and survival. RESULTS: In the initial phase of the trial, randomisation was unequal such that in total 129 patients were randomised to accelerated fractionation and 100 to conventional fractionation. Acute toxicity was evaluable in 121 patients treated with AF and 96 patients treated with CF. RTOG grade 2 or 3 bowel toxicity was noted in 44% of AF patients compared to 26% of CF patients (P trend =0.001). Acute grade 2 or 3 bladder toxicity was seen in 35% of AF patients compared to 36% of CF patients (P=0.99). Late radiation toxicity was evaluated in patients surviving free from local recurrence at 2 years post treatment. Late radiation toxicity equivalent to RTOG grade 2 or more had occurred in 44% (95% CI 34-55%) of AF patients and in 38% (95% CI 26-49%) of CF patients (logrank over 5 years follow-up P=0.23). There was no significant difference in analysis of time to loss of local tumour control comparing the two treatment arms; local recurrence was recorded in 29 of the 100 patients treated with CF and in 41 of 129 patients treated with AF (logrank P=0.86). There was also no significant difference between the treatment arms comparing disease-free survival and overall survival. The overall survival figures at 3 years were for AF 54% (95% CI 45-63%) and for CF 47% (95% CI 36-57%). By 5 years the overall survival was 37% for AF and 40% for CF. There were two treatment related deaths, both on the AF arm of the trial. CONCLUSIONS: This accelerated fractionation schedule did not improve on the efficacy of conventional fractionation for patients with T2 and T3 bladder cancer and accelerated fractionation was associated with increased acute bowel reactions..
Andreassen, C.N.
Alsner, J.
Overgaard, J.
Herskind, C.
Haviland, J.
Owen, R.
Homewood, J.
Bliss, J.
Yarnold, J.
(2005). TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiotherapy and oncology,
Vol.75
(1),
pp. 18-4.
Yarnold, J.
Ashton, A.
Bliss, J.
Homewood, J.
Harper, C.
Hanson, J.
Haviland, J.
Bentzen, S.
Owen, R.
(2005). Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiotherapy and oncology,
Vol.75
(1),
pp. 9-9.
Lowe, L.C.
Guy, M.
Mansi, J.L.
Peckitt, C.
Bliss, J.
Wilson, R.G.
Colston, K.W.
(2005). Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. European journal of cancer,
Vol.41
(8),
pp. 1164-6.
Coombes, R.C.
Howell, A.
Emson, M.
Peckitt, C.
Gallagher, C.
Bengala, C.
Tres, A.
Welch, R.
Lawton, P.
Rubens, R.
Woods, E.
Haviland, J.
Vigushin, D.
Kanfer, E.
Bliss, J.M.
on behalf of the International Collaborative Cancer Group,
(2005). High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann oncol,
Vol.16,
pp. 726-734.
Watson, M.
Homewood, J.
Haviland, J.
Bliss, J.M.
(2005). Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. European journal of cancer,
Vol.41
(12),
pp. 1710-5.
Venables, K.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2005). Verification films: a study of the daily and weekly reproducibility of breast patient set-up in the START Trial. Clin oncol (r coll. radiol),
Vol.17,
pp. 337-342.
Johnson, L.
Ellis, P.
Bliss, J.M.
(2005). Fast recruiting clinical trials--a utopian dream or logistical nightmare?. Br j cancer,
Vol.92
(9),
pp. 1679-1683.
show abstract
Randomised clinical trials that exceed anticipated recruitment rates will by definition have the necessary precision to answer the research question within the expected time, thus ensuring the timely release of data that will inform future clinical practice. In addition, the national or international momentum generated brings with it a collective sense of achievement. Such trials, however, may also identify logistical and scientific problems that researchers should be aware of and for which provision needs to be made. The logistical problems relate to the rapid identification of the extra resources required to allow continued excellence in day-to-day management and monitoring of trial governance (both in participating centres and in coordinating trials units). The scientific/clinical problems include managing issues such as unexpected toxicities and suboptimal compliance, and the lack of time available in a rapidly recruiting trial to address them. A related issue concerns the lack of time available to initiate substudies (e.g. biological substudies), the relevance of which may only become apparent as the trial progresses. Many of these challenges were highlighted by recent experience with the Cancer Research UK Taxotere as Adjuvant Chemotherapy trial..
Abe, O.
Abe, R.
Enomoto, K.
Kikuchi, K.
Koyama, H.
Masuda, H.
Nomura, Y.
Sakai, K.
Sugimachi, K.
Tominaga, T.
Uchino, J.
Yoshida, M.
Haybittle, J.L.
Davies, C.
Harvey, V.J.
Holdaway, T.M.
Kay, R.G.
Mason, B.H.
Forbes, J.F.
Wilcken, N.
Gnant, M.
Jakesz, R.
Ploner, M.
Yosef, H.M.
Focan, C.
Lobelle, J.P.
Peek, U.
Oates, G.D.
Powell, J.
Durand, M.
Mauriac, L.
Di Leo, A.
Dolci, S.
Piccart, M.J.
Masood, M.B.
Parker, D.
Price, J.J.
Hupperets, P.S.
Jackson, S.
Ragaz, J.
Berry, D.
Broadwater, G.
Cirrincione, C.
Muss, H.
Norton, L.
Weiss, R.B.
Abu-Zahra, H.T.
Portnoj, S.M.
Baum, M.
Cuzick, J.
Houghton, J.
Riley, D.
Gordon, N.H.
Davis, H.L.
Beatrice, A.
Mihura, J.
Naja, A.
Lehingue, Y.
Romestaing, P.
Dubois, J.B.
Delozier, T.
Mace-Lesec'h, J.
Rambert, P.
Andrysek, O.
Barkmanova, J.
Owen, J.R.
Meier, P.
Howell, A.
Ribeiro, G.C.
Swindell, R.
Alison, R.
Boreham, J.
Clarke, M.
Collins, R.
Darby, S.
Davies, C.
Elphinstone, P.
Evans, V.
Godwin, J.
Gray, R.
Harwood, C.
Hicks, C.
James, S.
MacKinnon, E.
McGale, P.
McHugh, T.
Mead, G.
Peto, R.
Wang, Y.
Albano, J.
de Oliveira, C.F.
Gervásio, H.
Gordilho, J.
Johansen, H.
Mouridsen, H.T.
Gelman, R.S.
Harris, J.R.
Henderson, I.C.
Shapiro, C.L.
Andersen, K.W.
Axelsson, C.K.
Blichert-Toft, M.
Moller, S.
Mouridsen, H.T.
Overgaard, J.
Overgaard, M.
Rose, C.
Cartensen, B.
Palshof, T.
Trampisch, H.J.
Dalesio, O.
de Vries, E.G.
Rodenhuis, S.
van Tinteren, H.
Comis, R.L.
Davidson, N.E.
Gray, R.
Robert, N.
Sledge, G.
Tormey, D.C.
Wood, W.
Cameron, D.
Chetty, U.
Forrest, P.
Jack, W.
Rossbach, J.
Klijn, J.G.
Treurniet-Donker, A.D.
van Putten, W.L.
Costa, A.
Veronesi, U.
Bartelink, H.
Duchateau, L.
Legrand, C.
Sylvester, R.
van der Hage, J.A.
van de Velde, C.J.
Cunningham, M.P.
Catalano, R.
Creech, R.H.
Bonneterre, J.
Fargeot, P.
Fumoleau, P.
Kerbrat, P.
Namer, M.
Jonat, W.
Kaufmann, M.
Schumacher, M.
von Minckwitz, G.
Bastert, G.
Rauschecker, H.
Sauer, R.
Sauerbrei, W.
Schauer, A.
Schumacher, M.
de Schryver, A.
Vakaet, L.
Belfiglio, M.
Nicolucci, A.
Pellegrini, F.
Sacco, M.
Valentini, M.
McArdle, C.S.
Smith, D.C.
Galligioni, E.
Boccardo, F.
Rubagotti, A.
Dent, D.M.
Gudgeon, C.A.
Hacking, A.
Erazo, A.
Medina, J.Y.
Izuo, M.
Morishita, Y.
Takei, H.
Fentiman, I.S.
Hayward, J.L.
Rubens, R.D.
Skilton, D.
Graeff, H.
Jänicke, F.
Meisner, C.
Scheurlen, H.
Kaufmann, M.
von Fournier, D.
Dafni, U.
Fountzilas, G.
Klefstrom, P.
Blomqvist, C.
Saarto, T.
Margreiter, R.
Asselain, B.
Salmon, R.J.
Vilcoq, J.R.
Arriagada, R.
Hill, C.
Laplanche, A.
Lê, M.G.
Spielmann, M.
Bruzzi, P.
Montanaro, E.
Rosso, R.
Sertoli, M.R.
Venturini, M.
Amadori, D.
Benraadt, J.
Kooi, M.
van de Velde, A.O.
van Dongen, J.A.
Vermorken, J.B.
Castiglione, M.
Cavalli, F.
Coates, A.
Collins, J.
Forbes, J.
Gelber, R.D.
Goldhirsch, A.
Lindtner, J.
Price, K.N.
Rudenstam, C.M.
Senn, H.J.
Bliss, J.M.
Chilvers, C.E.
Coombes, R.C.
Hall, E.
Marty, M.
Borovik, R.
Brufman, G.
Hayat, H.
Robinson, E.
Wigler, N.
Bonadonna, G.
Camerini, T.
De Palo, G.
Del Vecchio, M.
Formelli, F.
Valagussa, P.
Martoni, A.
Pannuti, F.
Cocconi, G.
Colozza, A.
Camisa, R.
Aogi, K.
Takashima, S.
Abe, O.
Ikeda, T.
Inokuchi, K.
Kikuchi, K.
Sawa, K.
Sonoo, H.
Korzeniowski, S.
Skolyszewski, J.
Ogawa, M.
Yamashita, J.
Bonte, J.
Christiaens, R.
Paridaens, R.
Van den Boegart, W.
Martin, P.
Romain, S.
Hakes, T.
Hudis, C.A.
Norton, L.
Wittes, R.
Giokas, G.
Kondylis, D.
Lissaios, B.
de la Huerta, R.
Sainz, M.G.
Altemus, R.
Cowan, K.
Danforth, D.
Lichter, A.
Lippman, M.
O'Shaughnessy, J.
Pierce, L.J.
Steinberg, S.
Venzon, D.
Zujewski, J.
Paradiso, A.
De Lena, M.
Schittulli, F.
Myles, J.D.
Pater, J.L.
Pritchard, K.I.
Nomura, Y.
Anderson, S.
Bass, G.
Brown, A.
Bryant, J.
Costantino, J.
Dignam, J.
Fisher, B.
Redmond, C.
Wieand, S.
Wolmark, N.
Baum, M.
Jackson, I.M.
Palmer, M.K.
Ingle, J.N.
Suman, V.J.
Bengtsson, N.O.
Jonsson, H.
Larsson, L.G.
Lythgoe, J.P.
Swindell, R.
Kissin, M.
Erikstein, B.
Hannisdal, E.
Jacobsen, A.B.
Varhaug, J.E.
Erikstein, B.
Gundersen, S.
Hauer-Jensen, M.
Host, H.
Jacobsen, A.B.
Nissen-Meyer, R.
Blamey, R.W.
Mitchell, A.K.
Morgan, D.A.
Robertson, J.F.
Di Palma, M.
Mathé, G.
Misset, J.L.
Clark, R.M.
Levine, M.
Morimoto, K.
Sawa, K.
Takatsuka, Y.
Crossley, E.
Harris, A.
Talbot, D.
Taylor, M.
Cocconi, G.
di Blasio, B.
Ivanov, V.
Semiglazov, V.
Brockschmidt, J.
Cooper, M.R.
Ueo, H.
Falkson, C.I.
A'Hern, R.
Ashley, S.
Powles, T.J.
Smith, I.E.
Yarnold, J.R.
Gazet, J.C.
Cocoran, N.
Deshpande, N.
di Martino, L.
Douglas, P.
Hacking, A.
Host, H.
Lindtner, A.
Notter, G.
Bryant, A.J.
Ewing, G.H.
Firth, L.A.
Krushen-Kosloski, J.L.
Nissen-Meyer, R.
Foster, L.
George, W.D.
Stewart, H.J.
Stroner, P.
Malmström, P.
Möller, T.R.
Rydén, S.
Tengrup, I.
Tennvall-Nittby, L.
Carstenssen, J.
Dufmats, M.
Hatschek, T.
Nordenskjöld, B.
Söderberg, M.
Carpenter, J.T.
Albain, K.
Crowley, J.
Green, S.
Martino, S.
Osborne, C.K.
Ravdin, P.M.
Glas, U.
Johansson, U.
Rutqvist, L.E.
Singnomklao, T.
Wallgren, A.
Castiglione, M.
Goldhirsch, A.
Maibach, R.
Senn, H.J.
Thürlimann, B.
Brenner, H.
Hercbergs, A.
Yoshimoto, M.
DeBoer, G.
Paterson, A.H.
Pritchard, K.I.
Meakin, J.W.
Panzarella, T.
Pritchard, K.I.
Shan, Y.
Shao, Y.F.
Wang, X.
Zhao, D.B.
Boreham, J.
Chen, Z.M.
Pan, H.C.
Peto, R.
Bahi, J.
Reid, M.
Spittle, M.
Deutsch, G.P.
Senanayake, F.
Kwong, D.L.
Bianco, A.R.
Carlomagno, C.
De Laurentiis, M.
De Placido, S.
Buzdar, A.U.
Smith, T.
Bergh, J.
Holmberg, L.
Liljegren, G.
Nilsson, J.
Seifert, M.
Sevelda, P.
Zielinsky, C.C.
Buchanan, R.B.
Cross, M.
Royle, G.T.
Dunn, J.A.
Hills, R.K.
Lee, M.
Morrison, J.M.
Spooner, D.
Litton, A.
Chlebowski, R.T.
Caffier, H.
(2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials. Lancet,
Vol.365
(9472),
pp. 1687-31.
Praga, C.
Bergh, J.
Bliss, J.
Bonneterre, J.
Cesana, B.
Coombes, R.C.
Fargeot, P.
Folin, A.
Fumoleau, P.
Giuliani, R.
Kerbrat, P.
Hery, M.
Nilsson, J.
Onida, F.
Piccart, M.
Shepherd, L.
Therasse, P.
Wils, J.
Rogers, D.
(2005). Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. Journal of clinical oncology,
Vol.23
(18),
pp. 4179-13.
Braun, S.
Vogl, F.D.
Naume, B.
Janni, W.
Osborne, M.P.
Coombes, R.C.
Schlimok, G.
Diel, I.J.
Gerber, B.
Gebauer, G.
Pierga, J.Y.
Marth, C.
Oruzio, D.
Wiedswang, G.
Solomayer, E.F.
Kundt, G.
Strobl, B.
Fehm, T.
Wong, G.Y.
Bliss, J.
Vincent-Salomon, A.
Pantel, K.
(2005). A pooled analysis of bone marrow micrometastasis in breast cancer. New england journal of medicine,
Vol.353
(8),
pp. 793-10.
Smith, I.E.
A'Hern, R.P.
Coombes, G.A.
Howell, A.
Ebbs, S.R.
Hickish, T.F.
O'Brien, M.E.
Mansi, J.L.
Wilson, C.B.
Robinson, A.C.
Murray, P.A.
Price, C.G.
Perren, T.J.
Laing, R.W.
Bliss, J.M.
(2004). A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of oncology,
Vol.15
(5),
pp. 751-8.
Venables, K.
Miles, E.A.
Deighton, A.
Aird, E.G.
Hoskin, P.J.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2004). Irradiation of the heart during tangential breast treatment: a study within the START Trial. Br j radiol,
Vol.77,
pp. 137-142.
Venables, K.
Miles, E.A.
Aird, E.
Hoskin, P.
on behalf of the START Trial Management Group: Member J Bliss,
(2004). The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother oncol,
Vol.71,
pp. 303-310.
Guy, M.
Lowe, L.C.
Bretherton-Watt, D.
Mansi, J.
Peckitt, C.
Bliss, J.M.
Wilson, R.G.
Thomas, V.
Colston, K.W.
(2004). Vitamin D receptor gene polymorphisms and breast cancer risk. Clin cancer res,
Vol.10,
pp. 5472-5481.
Coombes, R.C.
Hall, E.
Gibson, L.J.
Paridaens, R.
Jassem, J.
Delozier, T.
Jones, S.E.
Alvarez, I.
Bertelli, G.
Ortmann, O.
Coates, A.S.
Bajetta, E.
Dodwell, D.
Coleman, R.E.
Fallowfield, L.J.
Mickiewicz, E.
Andersen, J.
Lonning, P.E.
Cocconi, G.
Stewart, A.
Stuart, N.
Snowdon, C.F.
Carpentieri, M.
Massimini, G.
Bliss, J.M.
(2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New england journal of medicine,
Vol.350
(11),
pp. 1081-12.
Barrett-Lee, P.J.
Bliss, J.M.
Brunt, A.M.
Dehshiri, K.
Harnett, A.N.
Johnson, L.
Lawrence, D.
Robinson, A.
Weerasekera, K.
ABC Trial Management Group,
(2004). Polychemotherapy (CT) in pre- and post-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) -results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial in 1991 patients. J clin oncol,
Vol.22
(14_suppl),
p. 656.
show abstract
656 Background: EBCTCG 2000 systematic overview confirmed overall survival advantage of CT in early breast cancer (BC), but doubts remain over these benefits in presence of concomitant prolonged tamoxifen (T) and ovarian ablation (OA) in premenopausal women. METHODS: The ABC trial is a pragmatic, randomised phase III trial. One aspect of ABC compared CT (any type but CMF recommended) vs. none in patients with early (1-3a) BC. All patients prescribed 20mg T for 5 years. Patients could receive OA or not as elective treatment. Main endpoints: relapse-free survival (RFS) and overall survival (OS). RESULTS: During 1993 to 2000, 1991 (987 CT, 1004 no CT) patients were randomised from 106 UK and 16 non-UK centres. Pre-treatment patient characteristics were well-balanced. In total 62% patients were age >50 years, 56% node positive, and 64% oestrogen receptor (ER) positive. 92% patients received CT as allocated. Type of CT was CMF (87%), anthracycline containing (11%). 244 patients received OA. Results based on median follow-up of 5.0 years, 601 relapses and 485 deaths. CT suggested an improvement in RFS (HR 0.86 [95%CI 0.73-1.01] p=0.061) and OS (HR 0.87 [95%CI 0.73-1.04] p=0.12) but unadjusted results did not reach conventional levels of statistical significance. Adjusting for nodal status, ER, age, OA slightly increases magnitude of benefit of CT (RFS: HR 0.83 (0.71-0.97) p=0.024, OS: HR0.84 (0.70-1.00) p=0.051). Results (RFS) were independent of ER status. Impact appeared greater for women aged <50 (<50 HR 0.76 [0.57-1.01], ≥50 HR 0.89 [0.73-1.09]), for those (pre-menopausal) not receiving OA (without OA HR 0.71 [0.47-1.08], with OA HR 0.94 [0.56-1.56]) and for those from centres with good CT compliance (good CT HR 0.83 [0.68-1.01], poor CT HR 0.95 [0.71-1.25]). CONCLUSION: This is the first report of CT in women with early BC receiving concomitant and 5-year duration T, showing that benefits of CT are retained in this context. No significant financial relationships to disclose..
Yarnold, J.R.
Bliss, J.M.
Earl, H.
George, D.
Lawrence, D.
Mortazavi, S.H.
Perren, T.J.
Raina, V.
Spooner, D.
(2004). Ovarian ablation (DA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T+ chemotherapy (CT)- results from the UKNCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients. Journal of clinical oncology,
Vol.22
(14),
pp. 11S-1.
Harnett, A.N.
Bliss, J.M.
Johnson, L.
Lawrence, D.
Raina, V.
Robinson, A.
ABC Trial Management Group,
(2004). Thromboembolic events (TEE) in UK NCRI Adjuvant Breast Cancer (ABC) international trial -retrospective and prospective audits. J clin oncol,
Vol.22
(14_suppl),
p. 666.
show abstract
666 Background: In 1996, NCIC (Pritchard et al JCO 1996:14;2731) reported a high incidence of TEEs in postmenopausal breast cancer (BC) patients receiving concurrent tamoxifen (T) and chemotherapy (CT) compared with T alone (13.6% vs. 2.6%). For trials open to recruitment at that time, including the ABC Trial, this triggered a need for urgent review. METHODS: The ABC trial is a pragmatic, randomised phase III trial which accrued 3854 patients between 1993 and 2000. One aspect of ABC compares CT (any type but CMF recommended) vs. none in patients with early BC. All patients were prescribed 20mg T for 5 years. In Oct '97 a retrospective audit of TEEs was carried out on UK patients randomised before 30 Sept '96 and a prospective audit initiated for all patients entered after 1 Jul '97. Time period of interest was date of surgery to 18 months. Analyses focused on TEE before BC relapse. RESULTS: Retrospectively, 59/1222 (4.8%) patients had TEE (16 with more than 1 TEE, 51 within 12 months, 8 after BC relapse/2(nd) primary, 14 superficial phlebitis). A higher rate of TEEs occurred in CT patients, significant only in postmenopausal patients, (7.7% vs 1.8%; difference 5.9% (95%CI 2.0-9.8%)). 2 patients died due to PE (1 with CT). Prospectively, 46/1420 (3.2%) patients had TEE (4 with more than 1 TEE, 39 within 12 months, 4 after BC relapse/2(nd) primary, 8 superficial phlebitis). Again, a higher rate of TEEs occurred in CT patients, significant in both pre (5.5% vs. 0%; difference 5.5% (95%CI 0.2-10.8%)) and postmenopausal patients (7.2% vs. 0.4%; difference 6.8% (95%CI 3.5-10.2%)). 4 patients died - 3 due to PE and 1 MI (4 with CT). Rates of TEE were similar according to type of CT (CMF 5.0%, anthracycline containing 5.0%). CONCLUSIONS: Incidence of TEEs is increased by concurrent CT and T compared with T alone, but rates are lower than NCIC trial. No evidence of excess TEEs in patients treated with anthracyclines. In our opinion it is unlikely that the number of TEEs will differ following recent changes in practice to sequential chemo-endocrine therapy. No significant financial relationships to disclose..
Brunt, A.M.
Bliss, J.M.
Benghiat, A.
Dawson, C.
Dewar, J.
Harnett, A.N.
Hopwood, P.
Lawrence, D.
Trask, C.
ABC Trial Management Group,
(2004). The impact on quality of life of adding chemotherapy (CT) or ovarian suppression (OS) to adjuvant tamoxifen (TAM): Outcomes from the UK NCRI Adjuvant Breast Cancer (ABC) trial. J clin oncol,
Vol.22
(14_suppl),
p. 8015.
show abstract
8015 Background: To assess quality of life (QL) in a multicentre phase III randomised trial evaluating the benefit of adding CT and/or OS to adjuvant TAM in pre/perimenopausal women, and of adding CT to TAM in postmenopausal women. Key QL outcomes included systemic and menopausal symptoms, mood, sexual functioning, body image, role functioning and global QL. METHODS: Patients reported QL using the EORTC QLQ-C30, BR23 breast cancer module, Hospital Anxiety and Depression Scale (HADS) and Menopausal Symptom Scale (MSS), before randomisation and at 3, 6, 9, 18, 30, 48 and 72 months. RESULTS: From 1997-2000, 436/3854 patients in the ABC trial were recruited to the QL study (247 in +/-CT comparison, 199 in +/-OS comparison), median age 49 (range 28-79). Compliance with QL forms was high; 99.8% at baseline ranging to 86.3% at 30 months. The addition of CT was associated with worse QL during the first 9 months for depression (p=0.007), role function (p=0.003) and global QL (p=0.001) and a trend to worse QL for body image concerns (p=0.02), and sexual enjoyment (p=0.08). Systemic side effects (p=0.001) and menopausal problems (p=0.02) were worse over 30 months. The addition of OS resulted in increased menopausal symptoms (p<0.0001), depression (p=0.05) and anxiety (p=0.04) over 30 months but no deterioration in role function, global QL, body image or sexual function. CONCLUSIONS: Adverse QL counters the potential benefits of additional CT; therefore treatment choice should consider possible health gains and QL losses. The negative QL effect of OS is paralleled by a lack of clinical benefit in the ABC trial. No significant financial relationships to disclose..
Marty, M.E.
Coombes, R.C.
Peckitt, C.
Pérez López, F.R.
Tres, A.
Morvan, F.
Tubiana-Mathieu, N.
Espié, M.
Bliss, J.M.
International Collaborative Cancer Group (ICCG),
(2004). Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer. J clin oncol,
Vol.22
(14_suppl),
p. 592.
show abstract
592 Background: Our previous study of node positive (N+) patients (Coombes: JCO 1996 14:35-45) compared FEC1/2 vs. CMF1/2 (see table below). At 4.5 years there was no difference in disease free survival (DFS), p=0.61; or overall survival (OS), p=0.31. However, subset analysis suggested that FEC2 was better than CMF2 (DFS:p=0.03;OS:p=0.02). Concurrently a study in node negative (N-) patients was conducted comparing FEC2 with CMF2. This paper updates the previous N+ study, reports N- study outcome, and a combined meta analysis (MA). METHODS: Prospective MA of two international randomised trials of CMF vs. FEC chemotherapy in early breast cancer: 1) N+ premenopausal trial, 2 regime options (CMF1/FEC1, CMF2/FEC2). and 2) N- trial (CMF2/FEC2). Main endpoints are OS and DFS. Sample sizes are small by today's standards, hence the prospective MA. RESULTS: N+ recruited 759 (180 CMF1, 180 FEC1, 199 CMF2, 200 FEC2) patients between 1984-1992, median follow-up 100 months. N- recruited 950 (477 CMF2, 473 FEC2) patients between 1990-2000, median follow-up 70 months. Median age was 44 (N+) and 48 (N-) years. Grade 3/4 toxicity (sore mouth, vomiting/nausea, diarrhoea, anorexia, alopecia) occurred twice as often with FEC (54%) than CMF (24%), p<0.001. Grade 3/4 toxicity in N+ (56%) was twice that of N- (25%) patients, p<0.001. MA hazard ratios showed that for OS, CMF was better 1.08 (95% CI 0.87 -1.35, p=0.49) but for DFS, FEC was better 0.97 (95% CI 0.82-1.16, p=0.76). Tests showed OS trial results were heterogeneous (p=0.04) with FEC1 better than CMF1 (p=0.04), and CMF2 better than FEC2 (p=0.06) for N+ but no difference for N- (p=0.87). CONCLUSIONS: MA showed no difference between the treatments in terms of OS or DFS. Individual trial results for OS were not homogeneous. [Figure: see text] [Table: see text]..
Thomas, J.M.
Newton-Bishop, J.
A'Hern, R.
Coombes, G.
Timmons, M.
Evans, J.
Cook, M.
Theaker, J.
Fallowfield, M.
O'Neill, T.
Ruka, W.
Bliss, J.M.
(2004). Excision margins in high-risk malignant melanoma. New england journal of medicine,
Vol.350
(8),
pp. 757-10.
Coombes, R.C.
Gibson, L.
Hall, E.
Emson, M.
Bliss, J.
(2003). Aromatase inhibitors as adjuvant therapies in patients with breast cancer. Journal of steroid biochemistry and molecular biology,
Vol.86
(3-5),
pp. 309-3.
Venables, K.
Winfield, E.A.
Aird, E.G.
Hoskin, P.J.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2003). Three-dimensional distribution of radiation within the breast: an intercomparison of departments participating in the START Trial of breast radiotherapy fractionation. Int j radiat onc biol phys,
Vol.55,
pp. 271-279.
Barrett-Lee, P.
Ellis, P.
Bliss, J.
(2002). Duration of adjuvant chemotherapy; Anthracyclines, taxanes and novel agents - More or less. Clinical oncology,
Vol.14
(4),
pp. 263-4.
Winfield, E.
Deighton, A.
Venables, K.
Aird, E.
Hoskin, P.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2002). Survey of UK Breast Radiotherapy Techniques: Background prior to the introduction of the quality assurance programme for the START (standardisation of radiotherapy) trial in breast cancer. Clin oncol (r coll. radiol),
Vol.14,
pp. 267-271.
Venables, K.
Winfield, E.
Deighton, A.
Aird, E.
Hoskin, P.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2001). The START trial-measurements in semi-anatomical breast and chest wall phantoms. Physics in med & biol,
Vol.46,
pp. 1937-1948.
Venables, K.
Winfield, E.
Deighton, A.
Aird, E.
Hoskin, P.
on behalf of the START Trial Management Group,
Member: Bliss, J.M.
(2001). A survey of radiotherapy quality of control practice in the United Kingdom for the START Trial. Radiother & onc,
Vol.60,
pp. 311-318.
Williamson, P.
Hutton, J.L.
Bliss, J.
Blunt, J.
Campbell, M.J.
Nicholson, R.
(2000). Statistical review by research ethics committees. Journal of the royal statistical society series a-statistics in society,
Vol.163,
pp. 5-9.
Peacock, J.
Ashton, A.
Bliss, J.
Bush, C.
Eady, J.
Jackson, C.
Owen, R.
Regan, J.
Yarnold, J.
(2000). Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother oncol,
Vol.55
(2),
pp. 173-178.
show abstract
PURPOSE: To test for an association between in vitro fibroblast radiosensitivity and complication risk in a case-control study of breast cancer patients treated under standard conditions in a clinical trial of radiotherapy dose fractionation. PATIENTS AND METHODS: A cohort of patients participating in a randomised clinical trial of radiotherapy dose fractionation was selected on the basis of treatment-induced changes in the breast several years later. Thirty-nine cases with marked normal tissue changes were matched on several variables with 65 controls with no changes attributable to radiotherapy. Dermal fibroblast strains were established from duplicate skin biopsies, and clonogenic cell survival assays performed in triplicate after both high ( approximately 1.6 Gy/min) and low ( approximately 1 cGy/min) dose-rate irradiation. Laboratory studies were blind to patient identity, treatment outcome and radiotherapy schedule. RESULTS: Analysis of 1128 clonogenic survival curves confirmed significant inter-patient variation in fibroblast radiosensitivity as measured by clonogenic survival. However, no association between fibroblast radiosensitivity and the development of late radiotherapy normal tissue effects was detected. CONCLUSIONS: Inter-individual variation in cellular radiosensitivity may not be the main determinant of complication risk in patients undergoing radiotherapy for breast cancer. Other biological and technical factors may be more important in explaining the marked inter-patient differences in normal tissue damage evident several years after curative radiotherapy..
Early Breast Cancer Collaborative Group,
Collaborator: Bliss, J.M.
(2000). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet,
Vol.355,
pp. 1757-1770.
Wils, J.A.
Bliss, J.M.
Marty, M.
Coombes, G.
Fontaine, C.
Morvan, F.
Olmos, T.
Perez-Lopez, F.R.
Vassilopoulos, P.
Woods, E.
Coombes, R.C.
(1999). Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. Journal of clinical oncology,
Vol.17
(7),
pp. 1988-11.
START Trial Management Group,
Member: Bliss, J.M.
(1999). Standardization of Breast Radiotherapy (START) Trial 11:145-147. Clin oncol (r coll. radiol),
Vol.11,
pp. 145-147.
The Bone Pain Trial Working Group,
Member: Bliss, J.M.
(1999). 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radioth & onc,
Vol.52,
pp. 111-121.
Brown, J.
Karnon, J.
Eldabi, T.
Paul, R.J.
with and on behalf of the ABC Trial Member: Judith Bliss,
(1999). Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. Onco hematology,
Vol.32,
pp. 95-103.
Watson, M.
Haviland, J.S.
Greer, S.
Davidson, J.
Bliss, J.M.
(1999). Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet,
Vol.354
(9187),
pp. 1331-6.
Mansi, J.L.
Gogas, H.
Bliss, J.M.
Gazet, J.C.
Berger, U.
Coombes, R.C.
(1999). Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet,
Vol.354
(9174),
pp. 197-6.
Loong, S.
Wilkins, M.
Bliss, J.M.
Davidson, J.
Ebbs, S.R.
Regan, J.
Yarnold, J.R.
(1998). The effectiveness of the routine clinic visit in the follow-up of breast cancer patients: analysis of a defined patient cohort. Clin oncol (r coll. radiol),
Vol.10,
pp. 103-106.
Moynihan, C.
Bliss, J.M.
Davidson, J.
Burchell, L.
Horwich, A.
(1998). Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial. Bmj,
Vol.316
(7129),
pp. 429-435.
show abstract
OBJECTIVE: To determine the efficacy of adjuvant psychological therapy in patients with testicular cancer and to compare the characteristics and psychosocial outcomes of men who agreed to participate with those who declined to participate in a randomised trial of psychological intervention. DESIGN: Newly diagnosed patients were asked to participate in a randomised trial of psychological support compared with standard medical care. Participants and non-participants completed self assessment questionnaires at baseline and at 2, 4 and 12 months. SETTING: Testicular Tumour Unit of the Royal Marsden Hospital. SUBJECTS: 73 of 184 (40%) eligible patients agreed to enter the randomised trial (participants) and 81 (44%) declined to participate but agreed to complete further assessments (non-participants). 30 patients wanted no further contact with the researchers. OUTCOME MEASURES: Hospital anxiety and depression scale, psychosocial adjustment to illness scale, Rotterdam symptom checklist, mental adjustment to cancer scale. Only scores on the hospital anxiety and depression scale are reported for evaluating treatment efficacy. RESULTS: 111 of 184 (60%) eligible men declined to participate in the trial. Patients with stage I disease were most likely to refuse to participate. A patient was less likely to participate if he had low volume disease and was receiving no further treatment. Likelihood of participation was associated with stage of disease and with type of primary treatment (P < 0.001 for heterogeneity). Patients with early stage disease (P < 0.001) and fewer physical symptoms (P < 0.001) were less likely to participate. Psychosocial factors associated with participation included anxious preoccupation regarding disease (P = 0.01). There were no differences in outcome between participants and non-participants during follow up. Patients seemed to gain little benefit from adjuvant psychological therapy. At 2 months change from baseline favoured the treated group in the anxiety subscale (mean difference between groups -1.41 (95% confidence interval -2.86 to 0.03)). This was not sustained when adjusted for factors related to the disease. By 12 months change from baseline seemed to favour the control group (mean difference between groups 1.66 (-0.18 to 3.50)). CONCLUSIONS: Patients with testicular cancer seem to have considerable coping abilities. Those who declined to participate in the trial differed from those who participated. Those who agreed to participate may comprise the clinical group who perceive a need for psychological support. No evidence was found to indicate a need for routinely offering adjuvant psychological therapy..
Shayeghi, M.
Seal, S.
Regan, J.
Collins, N.
Barfoot, R.
Rahman, N.
Ashton, A.
Moohan, M.
Wooster, R.
Owen, R.
Bliss, J.M.
Stratton, M.R.
Yarnold, J.
(1998). Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br j cancer,
Vol.78
(7),
pp. 922-927.
show abstract
Of patients being treated by radiotherapy for cancer, a small proportion develop marked long-term radiation damage. It is believed that this is due, at least in part, to intrinsic individual differences in radiosensitivity, but the underlying mechanism is unknown. Individuals affected by the recessive disease ataxia telangiectasia (AT) exhibit extreme sensitivity to ionizing radiation. Cells from such individuals are also radiosensitive in in vitro assays, and cells from AT heterozygotes are reported to show in vitro radiosensitivity at an intermediate level between homozygotes and control subjects. In order to examine the possibility that a defect in the ATM gene may account for a proportion of radiotherapy complications, 41 breast cancer patients developing marked changes in breast appearance after radiotherapy and 39 control subjects who showed no clinically detectable reaction after radiotherapy were screened for mutations in the ATM gene. One out of 41 cases showing adverse reactions was heterozygous for a mutation (insertion A at NT 898) that is predicted to generate a truncated protein of 251 amino acids. No truncating mutations were detected in the control subjects. On the basis of this result, the estimated percentage (95% confidence interval) of AT heterozygous patients in radiosensitive cases was 2.4% (0.1-12.9%) and in control subjects (0-9.0%). We conclude that ATM gene defects are not the major cause of radiotherapy complications in women with breast cancer..
Hardy, J.
Ling, J.
Mansi, J.
Isaacs, R.
Bliss, J.
A'Hern, R.
Blake, P.
Gore, M.
Shepherd, J.
Hanks, G.
(1998). Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. Palliat med,
Vol.12
(6),
pp. 437-442.
show abstract
To determine the effect of dexamethasone when treating malignant bowel obstruction, 35 patients were randomized to receive intravenous dexamethasone or a placebo, crossing over to the alternate treatment arm if there had been no resolution of obstruction by day 5. This was done in two consecutive studies. Patients were stratified according to whether or not they had received specific anticancer therapy within 28 days of study. In trial 1, 15 out of 22 patients 'responded' (resolution of obstruction by day 5; 10 on dexamethasone, five on placebo). Eleven out of 15 patients were 'on treatment'. In trial 2, six out of 13 responded (three on dexamethasone, three on placebo); three out of six were 'on treatment'. When both studies are combined, 60% (21/35) patients responded (13 on dexamethasone, eight on placebo). Poor patient accrual terminated both studies. Numbers are too small to allow a combination of studies or formal statistical analysis. We are unable to make any conclusion as to the effectiveness of dexamethasone in the palliation of malignant bowel disease..
Early Breast Cancer Trialists' Collaborative Group,
Collaborator: Bliss, J.M.
(1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet,
Vol.351,
pp. 1451-1467.
Abe, O.
Abe, R.
Enomoto, K.
Kikuchi, K.
Koyama, H.
Nomura, Y.
Sakai, K.
Sugimachi, K.
Tominaga, T.
Uchino, J.
Yoshida, M.
Benraadt, J.
van de Velde, A.O.
van Dongen, J.A.
Vermorken, J.B.
Giokas, G.
Lissaios, B.
Harvey, V.J.
Holdaway, T.M.
Kay, R.G.
Mason, B.H.
Coates, A.
Forbes, J.F.
Focan, C.
Lobelle, J.P.
Gates, G.D.
Powell, J.
Durand, M.
Mauriac, L.
Bartholomeus, S.
Piccart, M.J.
Gelman, R.S.
Henderson, I.C.
Shapiro, C.L.
Hancock, A.K.
Masood, M.B.
Parker, D.
Price, J.J.
Jackson, S.
Ragaz, J.
Delozier, T.
Mace-Lesec'h, J.
Haybittle, J.L.
Berry, D.
Broadwater, G.
Cirrincione, C.
Muss, H.
Norton, L.
Baum, M.
Houghton, J.
Riley, D.
Dent, D.M.
Gudgeon, C.A.
Hacking, A.
Gordon, N.H.
Davis, H.L.
Romestaing, P.
Lehingue, Y.
Owen, J.R.
Meier, P.
Howell, A.
Ribeiro, G.C.
Swindell, R.
Albano, J.
de Oliveira, C.F.
Gervasio, H.
Gordilho, J.
Carstensen, B.
Palshof, T.
Johansen, H.
Korzeniowski, S.
Skolyszewski, J.
Portnoj, S.M.
Andersen, K.W.
Axelsson, C.K.
Blichert-Toft, M.
Mouridsen, H.T.
Overgaard, M.
Rose, C.
Corcoran, N.
Trampisch, H.J.
Comis, R.L.
Davidson, N.E.
Gray, R.
Robert, N.
Tormey, D.C.
Wood, W.
Chetty, U.
Forrest, P.
Jack, W.
Rossbach, J.
Sylvester, R.J.
van de Velde, C.J.
Cunningham, M.P.
Bonneterre, J.
Fumoleau, P.
Namer, M.
Bastert, G.
Rauschecker, H.
Sauer, R.
Sauerbrei, W.
Schauer, A.
Schumacher, M.
de Schryver, A.
Belfiglio, M.
Mari, E.
Nicolucci, A.
Scorpiglione, N.
Yosef, H.M.
McArdle, C.S.
Smith, D.C.
Lara, P.C.
Boccardo, F.
Rubagotti, A.
Erazo, A.
Medina, J.Y.
Izuo, M.
Morishita, Y.
Bentley, A.
Doran, Z.
Fentiman, I.S.
Hayward, J.L.
Rubens, R.D.
Kaufmann, M.
Jonat, W.
Scheurlen, H.
von Fournier, D.
Fountzilas, G.
Klafstrom, P.
Blomqvist, C.
Cuzick, J.
Margreiter, R.
Castiglione, M.
Cavilli, F.
Collins, J.
Forbes, J.
Gelber, R.D.
Goldhirsch, A.
Lindtner, J.
Price, K.N.
Rudenstam, C.M.
Senn, H.J.
Bliss, J.M.
Chilvers, C.E.
Coombes, R.C.
Marty, M.
Borovik, R.
Brufman, G.
Hayat, H.
Robinson, E.
Wigler, N.
Pannuti, F.
Takashima, S.
Yasutomi, T.
Sonoo, H.
Yamashita, J.
Ogawa, M.
Welvaart, K.
Hupperets, P.S.
Bonte, J.
Tengrup, I.
Tennvall-Nittby, L.
Martin, P.
Romain, S.
Ingle, J.N.
Suman, V.J.
Buzdar, A.U.
Smith, T.
Hakes, T.
Wittes, R.
de la Huerta, R.
Sainz, M.G.
Bonadonna, G.
del Vecchio, M.
Valagussa, P.
Veronesi, U.
Dubois, J.B.
Bianco, A.R.
Lippman, M.E.
Pierce, L.J.
Simon, R.
Steinberg, S.M.
Myles, J.D.
Pater, J.L.
Pritchard, K.I.
Anderson, S.
Brown, A.
Bryant, J.
Costantino, J.
Dignam, J.
Fisher, B.
Redmond, C.
Wieand, S.
Wolmark, N.
Jackson, I.M.
Palmer, M.K.
Bengtsson, N.O.
Larsson, L.G.
Lythgoe, J.P.
Kissin, M.
Hannisdal, E.
Varhaug, J.E.
Nissen-Meyer, R.
Blamey, R.W.
Mitchell, A.K.
Robertson, J.F.
Ueo, H.
Mathe, G.
Misset, J.L.
Abu-Zahra, H.T.
Clarke, E.A.
McLaughlin, J.R.
Clark, R.M.
Levine, M.
Morimoto, K.
Sawa, K.
Takatsuka, Y.
Gundersen, S.
Hauer-Jensen, M.
Host, H.
Crossley, E.
Harris, A.
Beighton, A.
Clarke, M.
Collins, R.
Davies, C.
Evans, V.
Godwin, J.
Greaves, E.
Harwood, C.
Jackson, D.
James, S.
Lau, E.
Mead, G.
Naughten, A.
Peto, R.
Tooth, A.
Rambert, P.
Asselain, B.
Salmon, R.J.
Vilcoq, J.R.
Arriagada, R.
Hill, C.
Laplanche, A.
Le, M.G.
Spielmann, M.
Cocconi, G.
di Blasio, B.
Catalano, R.
Creech, R.H.
Brockschmidt, J.
Cooper, M.R.
Andrysek, O.
Barkmanova, J.
Falkson, C.I.
Abraham, M.
Klijn, J.G.
Treurniet-Donker, A.D.
van Putten, W.L.
Easton, D.
Powles, T.J.
Gazet, J.C.
Semiglazov, V.
Deshpande, N.
di Martino, L.
Douglas, P.
Lindtner, A.
Notter, G.
Bryant, A.J.
Ewing, G.H.
Krushen-Kosloski, J.L.
George, W.D.
Gould, A.
Stewart, H.J.
Stroner, P.
Moller, T.R.
Ryden, S.
Carstensen, J.
Hatschek, T.
Soderberg, M.
Carpenter, J.T.
Albain, K.
Crowley, J.
Green, S.
Martino, S.
Osborne, C.K.
Ravdin, P.M.
Rutqvist, L.E.
Wallgren, A.
Holm, L.E.
Thurlimann, B.
Brenner, H.
Hercbergs, A.
Yoshimoto, M.
DeBoer, G.
Paterson, A.H.
Meakin, J.W.
Panzarella, T.
Naja, A.
Bahi, J.
Reid, M.
Spittle, M.
Senanayake, F.
Bergh, J.
Holmberg, L.
Sevelda, P.
Zielinsky, C.C.
Gnant, M.
Jakesz, R.
Buchanan, R.B.
Cross, M.
Dunn, J.A.
Gillespie, W.M.
Kelly, K.
Morrison, J.M.
Litton, A.
Chlebowski, R.T.
Bezwoda, W.R.
Caffier, H.
Gr, E.B.
(1998). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet,
Vol.352
(9132),
pp. 930-942.
Moorey, S.
Greer, S.
Bliss, J.
Law, M.
(1998). A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer. Psychooncology,
Vol.7
(3),
pp. 218-228.
show abstract
This study compared the effectiveness of two psychological treatments in a group of 57 patients with various types of cancer attending the Royal Marsden Hospital. Patients referred for psychiatric assessment who met criteria for an abnormal adjustment reaction were randomly allocated to either 8 weeks of Adjuvant Psychological Therapy (APT), a problem-focused, cognitive behavioural treatment programme, or 8 weeks of a comparison treatment of supportive counselling. At 8 weeks from the baseline assessment, APT had produced a significantly greater change than the counselling intervention on fighting spirit, helplessness, coping with cancer, anxiety, and self-defined problems. At 4 months from baseline, APT had produced a significantly greater change than counselling on fighting spirit, coping with cancer, anxiety and self defined problems. It is concluded that APT produces greater change in anxiety, adjustment to cancer and use of coping strategies than a non-directive, supportive intervention over an 8 week period of treatment. This difference persists at follow up 4 months after baseline assessment..
Pace, P.
Jarman, M.
Phillips, D.
Hewer, A.
Bliss, J.
Coombes, R.C.
(1997). Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. British journal of cancer,
Vol.76
(6),
pp. 700-5.
Fox, S.B.
Leek, R.D.
Bliss, J.
Mansi, J.L.
Gusterson, B.
Gatter, K.C.
Harris, A.L.
(1997). Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. Jnci-journal of the national cancer institute,
Vol.89
(14),
pp. 1044-6.
Burnet, N.G.
Bliss, J.M.
Harmer, C.L.
(1997). The Impact of Radiotherapy Dose on Local Control of Ewing's Sarcoma of Bone. Sarcoma,
Vol.1
(1),
pp. 31-38.
show abstract
Purpose. Improvements in the systemic management of Ewing's sarcoma of bone over the last 20 years have led to a dramatic improvement in survival. The corollary is that treatment of the primary disease requires re-evaluation, since a significant number of patients still suffer local relapse.Patients. The effect of radiation dose on local control was reviewed in a series of 96 patients treated between 1967 and 1986. Seventy-four had no metastases at presentation (M0), 22 had metastases (M1). The 5-year survival of all patients was 28%, and of M0 patients alone 37%. Although these figures are poor by today's standards, they are consistent with published studies whose patients were enrolled during the same calendar period. Although most deaths occurred by 5 years, survival continued to fall beyond 10 years, which has implications for follow-up in future studies.Results. The local control (LC) rate at 5 years was 56% for all patients and for M0 patients analyzed separately. There was no difference in either LC or survival between the first and second decades of the study. Primary site was a significant determinant of survival and local control, with better outcome for limb tumours compared to pelvic primaries. Chemotherapy also had a major effect on LC. Radiotherapy improved the probability of LC. Omission of radiotherapy, or a dose <40 Gy, was ineffective. In the dose range 40-66 Gy, there was no evidence of a dose-response relationship..
Coombes, R.C.
Bliss, J.M.
Wils, J.
Morvan, F.
Espie, M.
Amadori, D.
Gambrosier, P.
Richards, M.
Aapro, M.
VillarGrimalt, A.
McArdle, C.
PerezLopez, F.R.
Vassilopoulos, P.
Ferreira, E.P.
Chilvers, C.E.
Coombes, G.
Woods, E.M.
Marty, M.
(1996). Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. Journal of clinical oncology,
Vol.14
(1),
pp. 35-11.
Clarke, M.
Collins, R.
Davies, C.
Godwin, J.
Gray, R.
Peto, R.
Abe, O.
Abe, R.
Enomoto, K.
Kikuchi, K.
Koyama, H.
Nomura, Y.
Sakai, K.
Sugimachi, K.
Tominaga, T.
Uchino, J.
Yoshida, M.
vandeVelde, A.O.
vanDongen, J.A.
Vermorken, J.B.
Arvelakis, A.
Giokas, G.
Lissaios, B.
Harvey, V.J.
Holdaway, T.M.
Kay, R.G.
Mason, B.H.
Coates, A.
Forbes, J.F.
Focan, C.
Lobelle, J.P.
Peek, U.
Oates, G.D.
Powell, J.
Bastert, G.
Rauschecker, H.
Sauer, R.
Sauerbrei, W.
Schauer, A.
Schumacher, M.
Durand, M.
Mauriac, L.
Bartholomeus, S.
Piccart, M.J.
Gelman, R.S.
Henderson, I.C.
Shapiro, C.L.
Hancock, A.K.
Masood, M.B.
Parker, D.
Price, J.J.
Jackson, S.
Ragaz, J.
Delozier, T.
MaceLesech, J.
Haybittle, J.L.
Cirrincione, C.
Korzun, A.
Weiss, R.B.
Wood, W.C.
Baum, M.
Houghton, J.
Riley, D.
Dent, D.M.
Gudgeon, C.A.
Hacking, A.
Horgan, K.
Hughes, L.
Stewart, H.J.
Gordon, N.H.
Davis, H.L.
Lehingue, Y.
Owen, J.R.
Meier, P.
Howell, A.
Ribeiro, G.C.
Swindell, R.
Albano, J.
deOliveira, C.F.
Gervasio, H.
Gordilho, J.
Carstensen, B.
Palshof, T.
Johansen, H.
Korzeniowski, S.
Skolyszewski, J.
Andersen, K.W.
Axelsson, C.K.
BlichertToft, M.
Mouridsen, H.T.
Overgaard, M.
Rose, C.
Corcoran, N.
Trampisch, H.J.
Abeloff, M.D.
Carbone, P.C.
Glick, J.
Tormey, D.C.
Rossbach, J.
Scanlon, E.F.
Schurman, S.
deSchryver, A.
Yosef, H.M.
McArdle, C.S.
Smith, D.C.
Lara, P.C.
Boccardo, F.
Erazo, A.
Medina, J.Y.
Izuo, M.
Morishita, Y.
Bentley, A.
Doran, Z.
Fentiman, I.S.
Hayward, J.L.
Rubens, R.D.
Kaufmann, M.
Jonat, W.
Scheurlen, H.
vonFournier, D.
Fountzilas, G.
Klefstrom, P.
Blomqvist, C.
Cuzick, J.
Margreiter, R.
Castiglione, M.
Cavalli, F.
Collins, J.
Forbes, J.
Gelber, R.D.
Goldhirsch, A.
Lindtner, J.
Price, K.N.
Rudenstam, C.M.
Senn, H.J.
Bliss, J.M.
Chilvers, C.E.
Coombes, R.C.
Marty, M.
Borovik, R.
Brufman, G.
Hayat, H.
Robinson, E.
Wigler, N.
Pannuti, F.
Takashima, S.
Tasutomi, T.
Sonoo, H.
Yamashita, J.
Ogawa, M.
Hupperets, P.S.
Bonte, J.
Tengrup, I.
TennvallNittby, L.
Martin, P.
Romain, S.
Ahmann, D.
Schaid, D.J.
Buzdar, A.U.
Smith, T.
Hakes, T.
Norton, L.
Wittes, R.
delaHuerta, R.
Sainz, M.G.
Bonadonna, G.
delVecchio, M.
Valagussa, P.
Veronesi, U.
Dubois, J.B.
Bianco, A.R.
Lippman, M.E.
Pierce, L.J.
Simon, R.
Steinberg, S.M.
Brown, A.
Fisher, B.
Redmond, C.
Wolmark, N.
Jackson, I.M.
Palmer, M.K.
Ingle, J.N.
Suman, V.J.
Bengtsson, N.O.
Larsson, L.G.
Lythgoe, J.P.
Kissin, M.
Hannisdal, E.
Varhaug, J.E.
NissenMeyer, R.
Blamey, R.W.
Mitchell, A.K.
Robertson, J.F.
Nakamura, Y.
Mathe, G.
Misset, J.L.
AbuZahra, H.T.
Clarke, E.A.
McLaughlin, J.R.
Clark, R.M.
Levine, M.
Myles, J.D.
Pater, J.L.
Pritchard, K.I.
Morimoto, K.
Sawa, K.
Takatsuka, Y.
Gundersen, S.
HauerJensen, M.
Host, A.
Crossley, E.
Durrant, K.
Harris, A.
Beighton, A.
Collins, R.
Evans, V.
Greaves, E.
Harwood, C.
James, S.
Lau, E.
Mead, G.
Muldal, A.
Naughton, A.
Tooth, A.
Wheatley, K.
Rambert, P.
Asselain, B.
Salmon, R.J.
Vilcoq, J.R.
Arriagada, R.
Hill, C.
Laplanche, A.
Le, M.G.
Speilmann, M.
Cocconi, G.
diBlasio, B.
Catalano, R.
Creech, R.H.
Brockschmidt, J.
Cooper, M.R.
Andrysek, O.
Barkmanova, J.
Falkson, C.J.
Abraham, M.
Klijn, J.G.
TreurnietDonker, A.D.
vanPutten, W.L.
Easton, D.
Powles, T.J.
Gazet, J.C.
Semiglazov, V.
Deshpande, N.
diMartino, L.
Douglas, P.
Host, H.
Bryant, A.J.
Ewing, G.H.
KrushenKosloski, J.L.
Forrest, A.P.
Jack, W.
McDonald, C.
Moller, T.R.
Ryden, S.
Carstensen, J.
Hatschek, T.
Soderberg, M.
Carpenter, J.T.
Albain, K.
Crowley, J.
Green, S.
Martino, S.
Osborne, C.K.
Ravdin, P.M.
Rutqvist, L.E.
Wallgren, A.
Holm, L.E.
Yoshimoto, M.
DeBoer, G.
Paterson, A.H.
Meakin, J.W.
Panzarella, T.
Naja, A.
Bahi, J.
Reid, M.
Spittle, M.
Senanayake, F.
Bergh, J.
Holmberg, L.
Sevelda, P.
Zielinsky, C.C.
Jakesz, R.
Gnant, M.
Buchanan, R.B.
Cross, M.
Dunn, J.A.
Gillespie, W.M.
Kelly, K.
Morrison, J.M.
Litton, A.
Chlebowski, R.T.
Bezwoda, W.R.
Caffier, H.
(1996). Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet,
Vol.348
(9036),
pp. 1189-8.
Horwich, A.
Bliss, J.
(1996). Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours. Ann oncol,
Vol.7
(10),
pp. 989-991.
BLISS, J.M.
FORD, D.
SWERDLOW, A.J.
ARMSTRONG, B.K.
CRISTOFOLINI, M.
ELWOOD, J.M.
GREEN, A.
HOLLY, E.A.
MACK, T.
MACKIE, R.M.
OSTERLIND, A.
WALTER, S.D.
PETO, J.
EASTON, D.F.
(1995). RISK OF CUTANEOUS MELANOMA-ASSOCIATED WITH PIGMENTATION CHARACTERISTICS AND FRECKLING - SYSTEMATIC OVERVIEW OF 10 CASE-CONTROL STUDIES. International journal of cancer,
Vol.62
(4),
pp. 367-10.
FORD, D.
BLISS, J.M.
SWERDLOW, A.J.
ARMSTRONG, B.K.
FRANCESCHI, S.
GREEN, A.
HOLLY, E.A.
MACK, T.
MACKIE, R.M.
OSTERLIND, A.
WALTER, S.D.
PETO, J.
EASTON, D.F.
(1995). RISK OF CUTANEOUS MELANOMA-ASSOCIATED WITH A FAMILY HISTORY OF THE DISEASE. International journal of cancer,
Vol.62
(4),
pp. 377-5.
ABE, O.
ABE, R.
ASAISHI, K.
ENOMOTO, K.
HATTORI, T.
IINO, Y.
KIKUCHI, K.
KOYAMA, H.
SAWA, K.
UCHINO, J.
YOSHIDA, M.
VANDEVELDE, A.O.
VERMORKEN, J.B.
FOROGLOU, P.
GIOKAS, G.
LISSAIOS, B.
HARVEY, V.J.
HOLDAWAY, T.M.
KAY, R.G.
MASON, B.H.
FORBES, J.F.
FOCAN, C.
LOBELLE, J.P.
PEEK, U.
OATES, G.D.
POWELL, J.
BASTERT, G.
RAUSCHECKER, H.
SAUER, R.
SAUERBREI, W.
SCHAUER, A.
SCHUMACHER, M.
GELMAN, R.S.
HENDERSON, I.C.
SHAPIRO, C.L.
HANCOCK, A.K.
JACKSON, S.
RAGAZ, J.
DELOZIER, T.
MACELESECH, J.
HAYBITTLE, J.L.
CIRRINCIONE, C.
KORZUN, A.
WEISS, R.B.
WOOD, W.C.
BAUM, M.
HOUGHTON, J.
RILEY, D.
DENT, D.M.
GUDGEON, C.A.
HACKING, A.
HORGAN, K.
HUGHES, L.
STEWART, H.J.
GORDON, N.H.
DAVIS, H.L.
OWEN, J.R.
MEIER, P.
HOWELL, A.
RIBEIRO, G.C.
SWINDELL, R.
ALBANO, J.
DEOLIVEIRA, C.F.
GERVASIO, H.
GORDILHO, J.
CARSTENSEN, B.
PALSHOF, T.
JOHANSEN, H.
KORZENIOWSKI, S.
SKOLYSZEWSKI, J.
ANDERSEN, K.W.
AXELSSON, C.K.
BLICHERTTOFT, M.
MOURIDSEN, H.T.
OVERGAARD, M.
ROSE, C.
CORCORAN, N.
TRAMPISCH, H.J.
ABELOFF, M.D.
CARBONE, P.C.
GLICK, J.
GRAY, R.
TORMEY, D.C.
BARTELINK, H.
FENTIMAN, I.S.
PARIDAENS, R.
VANDRIEL, O.J.
SYLVESTER, R.J.
VANDEVELDE, C.J.
VANDERSCHUEREN, E.
VANDONGEN, J.A.
WELVAART, K.
SCANLON, E.F.
SCHURMAN, S.
DESCHRYVER, A.
YOSEF, H.M.
MCARDLE, C.S.
SMITH, D.C.
LARA, P.C.
BOCCARDO, F.
IZUO, M.
MORISHITA, Y.
BENTLEY, A.
DORAN, Z.
HAYWARD, J.L.
RUBENS, R.D.
KAUFMANN, M.
JONAT, W.
SCHEURLEN, H.
VONFOURNIER, D.
KAUFMANN, M.
KLEFSTROM, P.
CUZICK, J.
MARGREITER, R.
CAVALLI, F.
COLLINS, J.
GELBER, R.D.
GOLDHIRSCH, A.
ISLEY, M.R.
LINDTNER, J.
PRICE, K.N.
RUDENSTAM, C.M.
BLISS, J.M.
CHILVERS, C.E.
COOMBES, R.C.
MARTY, M.
BRUFMAN, G.
HAYAT, H.
BOROVIK, R.
ROBINSON, E.
PANNUTI, F.
TAKASHIMA, S.
YASUTOMI, T.
SONOO, H.
YAMASHITA, J.
OGAWA, M.
NOMURA, Y.
BONTE, J.
TENGRUP, I.
TENNVALLNITTBY, L.
MARTIN, P.
ROMAIN, S.
AHMANN, D.
SCHAID, D.J.
BUZDAR, A.U.
SMITH, T.
HAKES, T.
NORTON, L.
WITTES, R.
DELAHUERTA, R.
SAINZ, M.G.
BONADONNA, G.
DELVECCHIO, M.
VALAGUSSA, P.
VERONESI, U.
DUBOIS, J.B.
BIANCO, A.R.
LIPPMAN, M.E.
PIERCE, L.J.
SIMON, R.
STEINBERG, S.M.
BROWN, A.
FISHER, B.
REDMOND, C.
WOLMARK, N.
JACKSON, I.M.
PALMER, M.K.
INGLE, J.N.
BENGTSSON, N.O.
LARSSON, L.G.
LYTHGOE, J.P.
KISSIN, M.
HANNISDAL, E.
VARHAUG, J.E.
BLAMEY, R.W.
MITCHELL, A.K.
ROBERTSON, J.F.
NAKAMURA, Y.
MATHE, G.
MISSET, J.L.
CLARKE, E.A.
MCLAUGHLIN, J.R.
CLARK, R.M.
LEVINE, M.
MORIMOTO, K.
GUNDERSEN, S.
HAUERJENSEN, M.
HOST, H.
CROSSLEY, E.
DURRANT, K.
HARRIS, A.
BEIGHTON, A.
CHADBON, D.
CLARKE, M.
COLLINS, R.
DAVIES, C.
EVANS, V.
GODWIN, J.
GREAVES, E.
HARWOOD, C.
JAMES, S.
MEAD, G.
MULDAHL, A.
PETO, R.
TOOTH, A.
WHEATLEY, K.
RAMBERT, P.
ASSELAIN, B.
SALMON, R.J.
VILCOQ, J.R.
ARRIAGADA, R.
HILL, C.
LAPLANCHE, A.
LE, M.G.
SPIELMANN, M.
COCCONI, G.
DIBLASIO, B.
CATALANO, R.
CREECH, R.H.
BROCKSCHMIDT, J.
COOPER, M.R.
ANDRYSEK, O.
BARKMANOVA, J.
TREURNIETDONKER, A.D.
VANPUTTEN, W.L.
EASTON, D.
POWLES, T.J.
GAZET, J.C.
SEMIGLAZOV, V.
DESHPANDE, N.
DIMARTINO, L.
DOUGLAS, P.
LINDTNER, A.
NOTTER, G.
NISSENMEYER, R.
FORREST, A.P.
JACK, W.
MCDONALD, C.
MOLLER, T.R.
RYDEN, S.
CARSTENSEN, J.
HATSCHEK, T.
SODERBERG, M.
CARPENTER, J.T.
ALBAIN, K.
CROWLEY, J.
GREEN, S.
OSBORNE, C.K.
RUTQUIST, L.E.
WALLGREN, A.
HOLM, L.E.
CASTIGLIONE, M.
FLUCKIGER, H.
THURLIMANN, B.
BRENNER, H.
HERCBERGS, A.
YOSHIMOTO, M.
DEBOER, G.
PATERSON, A.H.
PRITCHARD, K.I.
MEAKIN, J.W.
PANZARELLA, T.
NAJA, A.
BAHI, J.
REID, M.
SPITTLER, M.
SENANAYAKE, F.
HOLMBERG, L.
SEVELDA, P.
ZIELINSKY, C.C.
JAKESZ, R.
BUCHANAN, R.B.
CROSS, M.
DUNN, J.A.
GILLESPIE, W.M.
KELLY, K.
MORRISON, J.M.
LITTON, A.
CHLEBOWSKI, R.T.
BEZWODA, W.R.
CAFFIER, H.
(1995). EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS. New england journal of medicine,
Vol.333
(22),
pp. 1444-12.
Wils, J.A.
Coombes, R.C.
Bliss, J.M.
Law, M.
Fountzilas, G.
Amadori, D.
Abad-Esteve, A.
Klein, H.O.
Pinto-Ferreira, E.
Reis, H.
Vassilopoulos, P.
Tres, A.
Woods, E.
(1995). Phase I - II study of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX) at different dose levels in advanced gastric cancer. Gi cancer,
Vol.1,
pp. 55-59.
COOMBES, R.C.
CHILVERS, C.E.
AMADORI, D.
MEDI, F.
FOUNTZILAS, G.
RAUSCHECKER, H.
VASSILOPOULOS, P.
FERREIRA, E.P.
VANNOZZI, G.
BLISS, J.M.
WOODS, E.
WILS, J.
(1994). RANDOMIZED TRIAL OF EPIRUBICIN VERSUS FLUOROURACIL IN ADVANCED GASTRIC-CANCER - AN INTERNATIONAL-COLLABORATIVE-CANCER-GROUP (ICCG) STUDY. Annals of oncology,
Vol.5
(1),
pp. 33-4.
Moody, A.M.
Mayles, W.P.
Bliss, J.M.
A'Hern, R.P.
Owen, J.R.
Regan, J.
Broad, B.
Yarnold, J.R.
(1994). The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother oncol,
Vol.33
(2),
pp. 106-112.
show abstract
A prospective assessment of late changes in breast appearance in 559 patients after tumour excision and radiotherapy for early breast cancer noted a strong association with breast size. Only 3/48 (6%) patients with small breasts developed moderate or severe late changes compared with 94/423 (22%) with medium sized breasts and 34/88 (39%) patients with large breasts (p < 0.001). One possibility is that greater radiation changes are related to greater dose inhomogeneity in women with large breasts. To explore this hypothesis, radiation dose distributions were assessed in a separate group of 37 women in whom three-level transverse computer tomographic images of the breast in the treatment position were available. A significant correlation was found between breast size and dose inhomogeneity which may account for the marked changes in breast appearance reported in women with large breasts..
WATSON, M.
LAW, M.
DOSSANTOS, M.
GREER, S.
BARUCH, J.
BLISS, J.
(1994). THE MINI-MAC - FURTHER DEVELOPMENT OF THE MENTAL ADJUSTMENT TO CANCER SCALE. Journal of psychosocial oncology,
Vol.12
(3),
pp. 33-14.
Moorey, S.
Greer, S.
Watson, M.
Baruch, J.D.
Robertson, B.M.
Mason, A.
Rowden, L.
Tunmore, R.
Law, M.
Bliss, J.M.
(1994). Adjuvant Psychological therapy for patients with cancer: outcome at one year. Psyco oncol,
Vol.3,
pp. 39-46.
Wils, J.
Coombes, R.C.
Marty, M.
Bliss, J.M.
Woods, E.
(1993). Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer A trial of the International Collaborative Cancer Group (ICCG). Drugs,
Vol.45,
pp. 46-50.
STEIN, R.C.
BOWER, M.
LAW, M.
BLISS, J.M.
BARTON, C.
GAZET, J.C.
FORD, H.T.
COOMBES, R.C.
(1992). MITOXANTRONE AND METHOTREXATE CHEMOTHERAPY WITH AND WITHOUT MITOMYCIN-C IN THE TREATMENT OF ADVANCED BREAST-CANCER - A RANDOMIZED CLINICAL-TRIAL. European journal of cancer,
Vol.28A
(12),
pp. 1963-3.
BLISS, J.M.
SELBY, P.J.
ROBERTSON, B.
POWLES, T.J.
(1992). A METHOD FOR ASSESSING THE QUALITY-OF-LIFE OF CANCER-PATIENTS - REPLICATION OF THE FACTOR STRUCTURE. British journal of cancer,
Vol.65
(6),
pp. 961-6.
Watson, M.
Law, M.
Maguire, G.P.
Robertson, B.
Greer, S.
Bliss, J.M.
Ibbotson, T.
(1992). Further development of a quality of life measure for cancer patients: the Rotterdam Symptom Checklist (revised). Psyco-oncol,
Vol.1,
pp. 35-44.
ABE, O.
ABE, R.
ASAISHI, K.
ENOMOTO, K.
HATTORI, T.
INO, Y.
KIKUCHI, K.
KOYAMA, H.
SAWA, K.
UCHINO, J.
YOSHIDA, M.
HAYBITTLE, J.L.
VANDEVELDE, T.
VERMORKEN, J.B.
HARVEY, V.J.
HOLDAWAY, T.M.
KAY, R.G.
MASON, B.H.
FORBES, J.F.
BASTERT, G.
SAUERBREI, W.
SCHEURLEN, H.
SCHUMACHER, M.
FOCAN, C.
LOBELLE, J.P.
PEEK, U.
OATES, G.D.
POWELL, J.
DURAND, M.
MAURIAC, L.
GELMAN, R.S.
HENDERSON, I.C.
SHAPIRO, C.L.
HANCOCK, A.K.
JACKSON, S.
RAGAZ, J.
HENDERSON, I.C.
KORZUN, A.
WOOD, W.C.
YOSHIMOTO, M.
BAUM, M.
HOUGHTON, J.
HORGAN, K.
HUGHES, L.
STEWART, H.J.
GORDON, N.H.
DAVIS, H.L.
DELOZIER, T.
MACELESECH, J.
RAMBERT, P.
ANDRYSEK, O.
BARKMANOVA, J.
OWEN, J.R.
HOWELL, A.
RIBEIRO, G.C.
SWINDELL, R.
DEOLIVEIRA, C.F.
CARSTENSEN, B.
PALSHOF, T.
JOHANSEN, H.
KORZENIOWSKI, S.
SKOLYSZEWSKI, J.
ANDERSEN, K.W.
DOMBERNOWSKY, P.
MOURIDSEN, H.T.
ROSE, C.
CORCORAN, N.
TRAMPISCH, H.J.
ABELOFF, M.D.
CARBONE, P.C.
GLICK, J.
GRAY, R.
TORMEY, D.C.
BUYSE, M.
MIGNOLET, F.
PARIDAENS, R.
VANDRIEL, O.J.
SYLVESTER, R.J.
VANDEVELDE, C.J.
VANDONGEN, J.A.
WELVAART, K.
SCANLON, E.F.
SCHURMAN, S.
CATALANO, R.
CREECH, R.H.
DESCHRYVER, A.
MCGREGOR, K.
YOSEF, H.M.
MCARDLE, C.S.
SMITH, D.C.
LARA, P.C.
DENT, D.M.
GUDGEON, C.A.
HACKING, A.
BOCCARDO, F.
IZUO, M.
BENTLEY, A.
DORAN, Z.
FENTIMAN, I.S.
HAYWARD, J.L.
RUBENS, R.D.
KAUFMANN, M.
JONAT, W.
SCHEURLEN, H.
VONFOURNIER, D.
KAUFMANN, M.
KLEFSTROM, P.
CUZICK, J.
MARGREITER, R.
ASSELAIN, B.
POUILLARD, P.
BAHI, J.
MILLA, A.
SANCHIZ, F.
CASTIGLIONE, M.
CAVALLI, F.
COLLINS, J.
GELBER, R.D.
GOLDHIRSCH, A.
ISLEY, M.R.
LINDTNER, J.
PRICE, K.N.
RUDENSTAM, C.M.
SENN, H.J.
BLISS, J.M.
CHILVERS, C.E.
COOMBES, R.C.
MARTY, M.
BOROVIK, R.
BRUFMAN, G.
ROBINSON, E.
PANNUTI, F.
TAKASHIMA, S.
YASUTOMI, T.
HOLM, L.E.
SONOO, H.
YAMASHITA, J.
BONTE, J.
BUZDAR, A.U.
SMITH, T.
MARTIN, P.
ROMAIN, S.
AHMANN, D.
SCHAID, D.J.
HAKES, T.
NORTON, L.
WITTES, R.
FOROGLOU, P.
LISSAIOS, B.
BONADONNA, G.
DELVECCHIO, M.
VALAGUSSA, P.
VERONESI, U.
DUBOIS, J.B.
BRUFMAN, G.
HAYAT, H.
BIANCO, A.R.
LIPPMAN, M.E.
PIERCE, L.J.
SIMON, R.
STEINBERG, S.M.
NOMURA, Y.
DELAHUERTA, R.
SAINZ, M.G.
BROWN, A.
FISHER, B.
REDMOND, C.
WOLMARK, N.
BAUM, M.
JACKSON, I.M.
PALMER, M.K.
INGLE, J.N.
SCHAID, D.J.
BENGTSSON, N.O.
LARSSON, L.G.
LYTHGOE, J.P.
SWINDELL, R.
KISSIN, M.
BLAMEY, R.W.
MITCHELL, A.K.
ROBERTSON, J.F.
CASTIGLIONE, M.
FLUCKIGER, H.
SENN, H.J.
NAKAMURA, Y.
MATHE, G.
MISSET, J.L.
DESHPANDE, N.
DIMARTINO, L.
CLARKE, E.A.
MCLAUGHLIN, J.R.
CLARK, R.M.
LEVINE, M.
MORIMOTO, K.
GUNDERSEN, S.
HAUERJENSEN, M.
HOST, H.
CROSSLEY, E.
DURRANT, K.
HARRIS, A.
CLARKE, M.
COLLINS, R.
GODWIN, J.
GRAY, R.
GREAVES, E.
HARWOOD, C.
MEAD, G.
PETO, R.
WHEATLEY, K.
HILL, C.
LACOUR, J.
LAPLANCHE, A.
LE, M.
SARRAZIN, D.
SEMIGLAZOV, V.
BROCKSCHMIDT, J.
COOPER, M.R.
MEAKIN, J.W.
PANZARELLA, T.
PRITCHARD, K.I.
TREURNIETDONKER, A.D.
VANPUTTEN, W.L.
EASTON, D.
POWLES, T.J.
GAZET, J.C.
DOUGLAS, P.
HACKING, A.
HOST, H.
LINDTNER, A.
NOTTER, G.
BRYANT, A.J.
EWING, G.H.
KRUSHEN, J.L.
NISSENMEYER, R.
FORREST, A.P.
MCDONALD, C.
STEWART, H.J.
MOLLER, T.R.
RYDEN, S.
CARSTENSEN, J.
HATSCHEK, T.
SODERBERG, M.
CARPENTER, J.T.
CRAWLEY, J.
GREEN, S.
OSBORNE, C.K.
RUTQVIST, L.E.
WALLGREN, A.
BRENNER, H.
HERCBERGS, A.
DEBOER, G.
PATERSON, A.H.
PRITCHARD, K.I.
NAJA, A.
REID, M.
SPITTLE, M.
SENANAYAKE, F.
MEIER, P.
TENGRUP, I.
TENNVALLNITTBY, L.
CAFFIER, H.
BEZWODA, W.R.
HOLMBERG, L.
SEVELDA, P.
ZIELINSKY, C.C.
JAKESZ, R.
BUCHANAN, R.B.
CROSS, M.
DUNN, J.A.
GILLESPIE,
KELLY, K.
MORRISON, J.M.
LITTON, A.
CHLEBOWSKI, R.T.
(1992). SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN 2. Lancet,
Vol.339
(8785),
pp. 71-15.
GREER, S.
MOOREY, S.
BARUCH, J.D.
WATSON, M.
ROBERTSON, B.M.
MASON, A.
ROWDEN, L.
LAW, M.G.
BLISS, J.M.
(1992). ADJUVANT PSYCHOLOGICAL THERAPY FOR PATIENTS WITH CANCER - A PROSPECTIVE RANDOMIZED TRIAL. British medical journal,
Vol.304
(6828),
pp. 675-6.
Brada, M.
Ford, D.
Ashley, S.
Bliss, J.M.
Crowley, S.
Mason, M.
Rajan, B.
Traish, D.
(1992). Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Bmj,
Vol.304
(6838),
pp. 1343-1346.
show abstract
OBJECTIVE: To assess the risk of second brain tumour in patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. DESIGN: Long term follow up of a cohort of patients with pituitary adenoma and comparison of tumour occurrence with population incidence rates. SETTING: The Royal Marsden Hospital. SUBJECTS: 334 patients with pituitary adenoma treated with conservative surgery and radiotherapy (median dose 45 Gy) and followed up for 3760 person years. MAIN OUTCOME MEASURES: Second intracranial tumour and systemic malignancy. RESULTS: Five patients developed a second brain tumour: two had astrocytoma, two meningioma, and one meningeal sarcoma. The cumulative risk of developing a second brain tumour over the first 10 years after treatment was 1.3% (95% confidence interval 0.4% to 3.9%) and over 20 years 1.9% (0.7% to 5.0%). The relative risk of a second brain tumour compared with the incidence in the normal population was 9.38 (3.05 to 21.89). There was no excess risk of any other type of second primary malignancy. CONCLUSIONS: There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Although radiation is likely to be the most important factor contributing to the excess risk, further study is required in a cohort of similar patients not receiving radiation..
WHITE, I.D.
HOSKIN, P.J.
HANKS, G.W.
BLISS, J.M.
(1991). ANALGESICS IN CANCER PAIN - CURRENT PRACTICE AND BELIEFS. British journal of cancer,
Vol.63
(2),
pp. 271-4.
full text
BLISS, J.M.
(1991). IMPROVING THE QUALITY OF DATA IN CLINICAL-TRIALS IN CANCER. British journal of cancer,
Vol.63
(3),
pp. 412-4.
full text
WATSON, M.
GREER, S.
ROWDEN, L.
GORMAN, C.
ROBERTSON, B.
BLISS, J.M.
TUNMORE, R.
(1991). RELATIONSHIPS BETWEEN EMOTIONAL CONTROL, ADJUSTMENT TO CANCER AND DEPRESSION AND ANXIETY IN BREAST-CANCER PATIENTS. Psychological medicine,
Vol.21
(1),
pp. 51-7.
MOOREY, S.
GREER, S.
WATSON, M.
GORMAN, C.
ROWDEN, L.
TUNMORE, R.
ROBERTSON, B.
BLISS, J.
(1991). THE FACTOR STRUCTURE AND FACTOR STABILITY OF THE HOSPITAL ANXIETY AND DEPRESSION SCALE IN PATIENTS WITH CANCER. British journal of psychiatry,
Vol.158,
pp. 255-5.
Coombes, R.C.
Wilkinson, J.R.
Bliss, J.M.
Shah, P.
Easton, D.F.
Dowsett, M.
(1991). 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis. Br j cancer,
Vol.64
(2),
pp. 247-250.
show abstract
We have examined the role of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) in the prevention of mammary tumourigenesis in experiments involving 170 rats. We first demonstrated a prophylactic effect of 4-OHA (50 mg/week) in reducing tumour incidence over a 30 week period compared to controls (P = 0.04). We repeated the experiment to determine optimum dose and duration of therapy. Although 4-OHA again prevented tumour development (P less than 0.0005), there was no difference between the standard (50 mg/week) dose and the higher dose (100 mg/week). Rats were randomised at 30 weeks to either stop or to continue prophylactic therapy; marginal benefit in tumour free survival in continuing therapy was observed (P = 0.03). We conclude that 4-OHA is an effective agent in preventing carcinogen-induced mammary tumours in rats and further studies of the role of oestrogen synthesis inhibitors in the prevention of human mammary tumours may be indicated..
LAKHANI, S.
SELBY, P.
BLISS, J.M.
PERREN, T.J.
GORE, M.E.
MCELWAIN, T.J.
(1990). CHEMOTHERAPY FOR MALIGNANT-MELANOMA - COMBINATIONS AND HIGH-DOSES PRODUCE MORE RESPONSES WITHOUT SURVIVAL BENEFIT. British journal of cancer,
Vol.61
(2),
pp. 330-5.
full text
Price, P.
Hogan, S.J.
Bliss, J.M.
Horwich, A.
(1990). The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II Prognostic significance in patients treated by chemotherapy. Eur j cancer,
Vol.26
(4),
pp. 453-457.
show abstract
Tumour growth rates have been measured in metastatic non-seminomatous germ cell testicular tumours (NSGCTT) by estimating the rate of rise of tumour marker production (TMP). TMP was calculated for the time between orchidectomy and the start of chemotherapy in a group of 58 patients with metastatic NSGCTT treated with BEP combination chemotherapy (bleomycin, etoposide and cisplatin). Calculation of TMP (iu/l/day) took account of the continuing clearance of marker from the serum. TMP increased with time in 51 patients and this rise generally appeared to be exponential. The rate of this increase was expressed as the marker production doubling time (MPDT) and is a measure of the tumour growth rate. MPDT varied from 0.5 to greater than 80 days (45 cases) for AFP + ve patients and from 1.8 to greater than 80 days (34 cases) for HCG + ve patients. Patients who failed BEP first line therapy had shorter MPDTs than those who responded (AFP P = 0.08, HCG P = 0.003). It was found that patients with a MPDT less than or equal to 4 days were more likely to fail treatment than those who had a MPDT greater than 4 days (AFP P = 0.009, HCG P = 0.005). MPDTs were independent of initial serum marker concentration. Patients with small volume disease had longer MPDTs than patients with large volume disease (AFP P = 0.02, HCG P = 0.04). Rapid tumour growth rate reflected by short MPDT carries a poor prognosis in patients with NSGCTT treated by BEP chemotherapy..
Coombes, R.C.
Schein, P.S.
Chilvers, C.E.
Wils, J.
Beretta, G.
Bliss, J.M.
Rutten, A.
Amadori, D.
Cortes-Funes, H.
Villar-Grimalt, A.
(1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer International Collaborative Cancer Group. J clin oncol,
Vol.8
(8),
pp. 1362-1369.
show abstract
Three hundred fifteen patients with operable gastric cancer were randomized to receive fluorouracil, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and mitomycin (FAM) or no adjuvant treatment between September 1981 and July 1984. After excluding ineligible patients, 281 patients are included in this analysis. Treatment was moderately well tolerated by the majority of patients, the common side effects being nausea and vomiting (58%) and alopecia (57%). Three possible treatment-related deaths were seen, all due to cardiac failure. At median follow-up of 68 months, 164 patients have died, 73 in the treated arm and 91 in the control arm. There was no significant difference in disease-free or overall survival between the two arms of the study (P = 0.21). There is some evidence that patients with more advanced carcinoma (T3-T4) derived some benefit from treatment (P = 0.04). The interpretation of this finding must take into account that all subgroups were defined retrospectively, and this could, therefore, be a chance finding. We conclude that adjuvant chemotherapy as given in this trial is not indicated as routine treatment in operable gastric cancer, but that further evaluation in stage T3-T4 patients is warranted..
on behalf of the COMPACT Steering Group Bliss, J.M.
(1990). COMPACT: A computer package for clinical trial management. The amer stat,
Vol.44,
p. 242.
Chilvers, C.E.
Saunders, M.
Bliss, J.M.
Nicholls, J.
Horwich, A.
(1989). Influence of delay in diagnosis on prognosis in testicular teratoma. Br j cancer,
Vol.59
(1),
pp. 126-128.
Hamilton, C.R.
Bliss, J.M.
Horwich, A.
(1989). The late effects of cis-platinum on renal function. Eur j cancer clin oncol,
Vol.25
(2),
pp. 185-189.
show abstract
The combination of bleomycin, etoposide and cis-platinum (BEP) is an effective treatment for germ cell tumours. To help define the role of recently developed non-nephrotoxic analogues of cis-platinum we have analysed the long term renal damage caused by this agent. We report on 22 patients studied 8-60 months following BEP chemotherapy. In the 17 cases with no pre-chemotherapy renal impairment there was a fall in mean glomerular filtration rate from 132 ml/min (95% confidence interval 123, 141) pre-chemotherapy to 103 ml/min (95% confidence interval 94, 113) on late follow up. The overall pattern is one of initial fall of glomerular filtration rate during chemotherapy, and no consistent evidence of late recovery or further deterioration; considerable individual variation is observed..
Shah, P.
van der Meide, P.H.
Borman, T.
Schroeder, N.
Bliss, J.M.
Coombes, R.C.
(1989). Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. Br j cancer,
Vol.59
(2),
pp. 206-209.
show abstract
full text
We have used the nitrosomethylurea-induced rat mammary tumour model to study the effects of parenteral administration of human recombinant tumour necrosis factor (rHu-TNF) and rat gamma interferon (IFN-gamma). An inbred strain of tumour bearing female Ludwig/Wistar/Olac rats were randomised to either treatment or control groups. Two independent studies showed that combined treatment with rHu-TNF and rat IFN-gamma induced significant tumour regression over 4 weeks (P = 0.004, P = 0.005 respectively). Treatment with either rHu-TNF or rat IFN-gamma given individually did not affect the overall rate of tumour growth (P = 0.157 and 0.40 respectively) although an initial reduction in tumour size was observed during the first few days after injection. Measurement of circulating oestradiol levels in groups in which maximum tumour regression was observed showed no statistically significant difference when compared to the control group. Similarly, measurement of oestrogen receptor content showed no statistically significant difference between rHu-TNF-gamma or rat-IFN-gamma treatment or combined treatment of rHu-TNF and IFN-gamma with the control group. We conclude from these observations that combined therapy with rHu-TNF and rat IFN-gamma may prove to be useful new forms of treatment for human breast cancer..
Cooperative Urological Cancer Group,
Member Bliss, J.M.
(1989). Prognostic factors in a T3 bladder cancer trial. Br j canc,
Vol.59,
pp. 441-444.
WHITE, I.D.
HOSKIN, P.J.
HANKS, G.W.
BLISS, J.M.
(1989). MORPHINE AND DRYNESS OF THE MOUTH. British medical journal,
Vol.298
(6682),
pp. 1222-2.
HANSELL, D.M.
COOKE, J.C.
PARSONS, C.A.
EVANS, S.H.
DANCE, D.R.
BLISS, J.M.
ILESLEY, I.
(1988). A QUANTITATIVE-ANALYSIS OF THE SPATIAL RELATIONSHIPS OF GROUPED MICROCALCIFICATIONS DEMONSTRATED ON XEROMAMMOGRAPHY IN BENIGN AND MALIGNANT BREAST DISEASE. British journal of radiology,
Vol.61
(721),
pp. 21-5.
Shearer, R.J.
Chilvers, C.E.
Bloom, H.J.
Bliss, J.M.
Horwich, A.
Babiker, A.
(1988). Adjuvant chemotherapy in T3 carcinoma of the bladder: A prospective trial: Preliminary Report. Br j urol,
Vol.62,
pp. 558-564.
MILLARD, F.C.
BLISS, J.M.
CHILVERS, C.E.
GAZET, J.C.
(1987). ORAL-CONTRACEPTIVES AND SURVIVAL IN BREAST-CANCER. British journal of cancer,
Vol.56
(3),
pp. 377-2.
full text
CARTER, R.L.
BLISS, J.M.
SOO, K.C.
OBRIEN, C.J.
(1987). RADICAL NECK DISSECTIONS FOR SQUAMOUS CARCINOMAS - PATHOLOGICAL FINDINGS AND THEIR CLINICAL IMPLICATIONS WITH PARTICULAR REFERENCE TO TRANSCAPSULAR SPREAD. International journal of radiation oncology biology physics,
Vol.13
(6),
pp. 825-8.
HANKS, G.W.
TWYCROSS, R.G.
BLISS, J.M.
(1987). CONTROLLED RELEASE MORPHINE TABLETS - A DOUBLE-BLIND TRIAL IN PATIENTS WITH ADVANCED CANCER. Anaesthesia,
Vol.42
(8),
pp. 840-5.
Hamilton, C.R.
Horwich, A.
Bliss, J.M.
Peckham, M.J.
(1987). Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother oncol,
Vol.10
(2),
pp. 85-90.
show abstract
Between January 1963 and December 1983, 248 patients with stage I teratoma were managed by the Testicular Tumour Unit of the Royal Marsden Hospital (RMH). Before 1979, these patients were treated with adjuvant irradiation to the abdominal and pelvic lymph nodes (142 patients) to a mid-plane dose of 40 Gy in 20 fractions over 4 weeks. In 1979, a surveillance policy was adopted (106 patients) and relapsing patients treated with chemotherapy. By 2 years post-orchidectomy, seven patients (4.9%) in the irradiated group developed duodenal ulceration compared to none in the surveillance group (p = 0.05). A past medical history of duodenal ulcer was a significant risk factor for ulceration after radiotherapy (p = 0.04) whereas a past history of abdominal surgery was not (p = 0.8). It is concluded that adjuvant radiotherapy for stage I teratoma may increase the risk of peptic ulceration..
SOO, K.
CARTER, R.
OBRIEN, C.
BARR, L.
BLISS, J.
SHAW, H.
(1986). PROGNOSTIC IMPLICATIONS OF PERINEURAL SPREAD IN SQUAMOUS CARCINOMAS OF THE HEAD AND NECK. Laryngoscope,
Vol.96
(10),
pp. 1145-1148.
Abe, O.
Abe, R.
Enomoto, K.
Kikuchi, K.
Koyama, H.
Masuda, H.
Nomura, Y.
Sakai, K.
Sugimachi, K.
Tominaga, T.
Uchino, J.
Yoshida, M.
Haybittle, J.L.
Davies, C.
Harvey, V.J.
Holdaway, T.M.
Kay, R.G.
Mason, B.H.
Forbes, J.F.
Wilcken, N.
Gnant, M.
Jakesz, R.
Ploner, M.
Yosef, H.M.
Focan, C.
Lobelle, J.P.
Peek, U.
Oates, G.D.
Powell, J.
Durand, M.
Mauriac, L.
Di Leo, A.
Dolci, S.
Piccart, M.J.
Masood, M.B.
Parker, D.
Price, J.J.
Hupperets, P.S.
Jackson, S.
Ragaz, J.
Berry, D.
Broadwater, G.
Cirrincione, C.
Muss, H.
Norton, L.
Weiss, R.B.
Abu-Zahra, H.T.
Portnoj, S.M.
Baum, M.
Cuzick, J.
Houghton, J.
Riley, D.
Mansel, R.E.
Gordon, N.H.
Davis, H.L.
Beatrice, A.
Mihura, J.
Naja, A.
Lehingue, Y.
Romestaing, P.
Dubois, J.B.
Delozier, T.
Lesec'h, J.M.
Rambert, P.
Petruzelka, L.
Pribylova, O.
Owen, J.R.
Harbeck, N.
Jänicke, F.
Meisner, G.
Meier, P.
Howell, A.
Ribeiro, G.C.
Swindell, R.
Burrett, J.
Clarke, M.
Collins, R.
Darby, S.
Davies, C.
Elphinstone, P.
Evans, V.
Godwin, J.
Gray, R.
Harwood, C.
Hicks, C.
Jackson, D.
James, S.
MacKinnon, E.
McGale, P.
McHugh, T.
Mead, G.
Morris, P.
Oulds, J.
Peto, R.
Taylor, C.
Wang, Y.
Albano, J.
de Oliveira, C.F.
Gervásio, H.
Gordilho, J.
Johansen, H.
Mouridsen, H.T.
Gelman, R.S.
Harris, J.R.
Henderson, I.C.
Shapiro, C.L.
Christiansen, P.
Ejlertsen, B.
Mouridsen, H.T.
Moller, S.
Overgaard, M.
Carstensen, B.
Palshof, T.
Trampisch, H.J.
Dalesio, O.
de Vries, E.G.
Rodenhuis, S.
van Tinteren, H.
Comis, R.L.
Davidson, N.E.
Gray, R.
Robert, N.
Sledge, G.
Tormey, D.C.
Wood, W.
Cameron, D.
Chetty, U.
Forrest, P.
Jack, W.
Rossbach, J.
Klijn, J.G.
Treurniet-Donker, A.D.
van Putten, W.L.
Costa, A.
Veronesi, U.
Bartelink, H.
Duchateau, L.
Legrand, C.
Sylvester, R.
Catalano, R.
Creech, R.H.
Bonneterre, J.
Fargeot, P.
Fumoleau, P.
Kerbrat, P.
Namer, M.
Jonat, W.
Kaufman, M.
Schumacher, M.
von Minckwitz, G.
Bastert, G.
Rauschecker, H.
Sauer, R.
Sauerbrei, W.
Schauer, A.
Schumacher, M.
de Schyrver, A.
Vakaet, L.
Belfiglio, M.
Nicolucci, A.
Pellegrini, F.
Sacco, M.
Valentini, M.
McArdle, C.S.
Smith, D.C.
Galligioni, E.
Boccardo, F.
Rubagotti, A.
Dent, D.M.
Gudgeon, C.A.
Hacking, A.
Erazo, A.
Medina, J.Y.
Izuo, M.
Morishita, Y.
Takei, H.
Fentiman, I.S.
Hayward, J.L.
Rubens, R.D.
Skilton, D.
Scheurlen, H.
Kaufmann, M.
von Fournier, D.
Dafni, U.
Fountzilas, G.
Klefstrom, P.
Blomqvist, C.
Saarto, T.
Magreiter, R.
Asselain, B.
Salmon, R.J.
Vilcoq, J.R.
Arriagada, R.
Hill, C.
Laplanche, A.
Lê, M.G.
Spielmann, M.
Bruzzi, P.
Montanaro, E.
Rosso, R.
Sertoli, M.R.
Venturini, M.
Amadori, D.
Benraadt, J.
Kooi, M.
van de Velde, A.O.
van Dongen, J.A.
Vermorken, J.B.
Castiglione, M.
Cavalli, F.
Coates, A.
Collins, J.
Forbes, J.
Gelber, R.D.
Goldhirsch, A.
Lindtner, J.
Price, K.N.
Rudenstam, C.M.
Senn, H.J.
Bliss, J.M.
Chilvers, C.E.
Coombes, R.C.
Hall, E.
Marty, M.
Borovik, R.
Brufman, G.
Hayat, H.
Robinson, E.
Wigler, N.
Bonadonna, G.
Camerini, T.
De Palo, G.
Del Vecchio, M.
Formelli, F.
Valagussa, P.
Martoni, A.
Pannuti, F.
Cocconi, G.
Colozza, A.
Camisa, R.
Aogi, K.
Takashima, S.
Abe, O.
Ikeda, T.
Inokuchi, K.
Kikuchi, K.
Sawa, K.
Sonoo, H.
Korzeniowski, S.
Skolyszewski, J.
Ogawa, M.
Yamashita, J.
Bonte, J.
Christiaens, R.
Paridaens, R.
Van den Bogaert, W.
Martin, P.
Romain, S.
Hakes, T.
Hudis, C.A.
Norton, L.
Wittes, R.
Giokas, G.
Kondylis, D.
Lissaios, B.
de la Huerta, R.
Sainz, M.G.
Altemus, R.
Cowan, K.
Danforth, D.
Lichter, A.
Lippman, M.
O'Shaughnessy, J.
Pierce, L.J.
Steinberg, S.
Venzon, D.
Zujewski, J.A.
Paradiso, A.
De Lena, M.
Schittulli, F.
Myles, J.D.
Pater, J.L.
Pritchard, K.I.
Whelan, T.
Nomura, Y.
Anderson, S.
Bass, G.
Brown, A.
Bryant, J.
Costantino, J.
Dignam, J.
Fisher, B.
Redmond, C.
Wieand, S.
Wolmark, N.
Baum, M.
Jackson, I.M.
Palmer, M.K.
Ingle, J.N.
Suman, V.J.
Bengtsson, N.O.
Jonsson, H.
Larsson, L.G.
Lythgoe, J.P.
Swindell, R.
Kissin, M.
Erikstein, B.
Hannisdal, E.
Jacobsen, A.B.
Varhaug, J.E.
Erikstein, B.
Gundersen, S.
Hauer-Jensen, M.
Host, H.
Jacobsen, A.B.
Nissen-Meyer, R.
Blamey, R.W.
Mitchell, A.K.
Morgan, D.A.
Robertson, J.F.
Di Palma, M.
Mathé, G.
Misset, J.L.
Clark, R.M.
Levine, M.
Pritchard, K.I.
Whelan, T.
Morimoto, K.
Sawa, K.
Takatsuka, Y.
Crossley, E.
Harris, A.
Talbot, D.
Taylor, M.
Cocconi, G.
di Blasio, B.
Ivanov, V.
Semiglazov, V.
Brockschmidt, J.
Cooper, M.R.
Ueo, H.
Falkson, C.I.
A'Hern, R.
Ashley, S.
Powles, T.J.
Smith, I.E.
Yarnold, J.R.
Gazet, J.C.
Cocoran, N.
Deshpande, N.
de Martino, L.
Douglas, P.
Hacking, A.
Host, H.
Lindtner, A.
Notter, G.
Bryant, A.J.
Ewing, G.H.
Firth, L.A.
Krushen-Kosloski, J.L.
Nissen-Meyer, R.
Foster, L.
George, W.D.
Stewart, H.J.
Stroner, P.
Malmström, P.
Möller, T.R.
Rydén, S.
Tengrup, I.
Tennvall-Nittby, L.
Carstenssen, J.
Dufmats, M.
Hatschek, T.
Nordenskjöld, B.
Söderberg, M.
Carpenter, J.T.
Albain, K.
Crowley, J.
Green, S.
Martino, S.
Osborne, C.K.
Ravdin, P.M.
Glas, U.
Johansson, U.
Rutqvist, L.E.
Singnomklao, T.
Wallgren, A.
Castiglione, M.
Goldhirsch, A.
Maibach, R.
Senn, H.J.
Thürlimann, B.
Brenner, H.
Hercbergs, A.
Yoshimoto, M.
DeBoer, G.
Paterson, A.H.
Pritchard, K.I.
Meakin, J.W.
Panzarella, T.
Pritchard, K.I.
Shan, Y.
Shao, Y.F.
Wang, X.
Zhao, D.B.
Bahi, J.
Reid, M.
Spittle, M.
Deutsch, G.P.
Senanayake, F.
Kwong, D.L.
Bianco, A.R.
Carlomagno, C.
De Laurentiis, M.
De Placido, S.
Buzdar, A.U.
Smith, T.
Bergh, J.
Holmberg, L.
Liljegren, G.
Nilsson, J.
Seifert, M.
Sevelda, P.
Zielinsky, C.C.
Buchanan, R.B.
Cross, M.
Royle, G.T.
Dunn, J.A.
Hills, R.K.
Lee, M.
Morrison, J.M.
Spooner, D.
Litton, A.
Chlebowski, R.T.
Caffier, H.
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials. Lancet,
Vol.366
(9503),
pp. 2087-20.
Coles, C.
Griffin, C.
Kirby, A.
Titley, J.
Agrawal, R.
Alhasso, A.
Bhattacharya, I.
Brunt, M.
Ciurlionis, L.
Chan, C.
Donovan, E.
Emson, M.
Harnett, A.
Haviland, J.
Hopwood, P.
Jefford, M.
Kaggwa, R.
Sawyer, E.
Syndikus, I.
Tsang, Y.
Wheatley, D.
Wilcox, M.
Yarnold, J.
Bliss, J.
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial. The lancet,
.
full text
Johnston, S.
Puhalla, S.
Wheatley, D.
Ring, A.
Barry, P.
Holcombe, C.
Boileau, J.F.
Provencher, L.
Robidoux, A.
Rimawi, M.
McIntosh, S.A.
Shalaby, I.
Stein, R.C.
Thirlwell, M.
Dolling, D.
Morden, J.
Snowdon, C.
Perry, S.
Cornman, C.
Batten, L.M.
Jeffs, L.K.
Dodson, A.
Martins, V.
Modi, A.
Osborne, C.K.
Pogue-Geile, K.L.
Cheang, M.C.
Wolmark, N.
Julian, T.B.
Fisher, K.
MacKenzie, M.
Wilcox, M.
Huang Bartlett, C.
Koehler, M.
Dowsett, M.
Bliss, J.M.
Jacobs, S.A.
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial. Journal of clinical oncology,
,
pp. JCO.18.01624-JCO.18.01624.
full text
Bliss, J.
Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19). The lancet oncology,
.
full text
Bliss, J.
Porta, N.
Banerji, J.
Larkin, J.
A Phase II Trial of Nilotinib in KIT-driven Advanced Melanoma (NICAM). Cell reports medicine,
.
full text